<SEC-DOCUMENT>0001493152-23-024613.txt : 20230714
<SEC-HEADER>0001493152-23-024613.hdr.sgml : 20230714
<ACCEPTANCE-DATETIME>20230714170719
ACCESSION NUMBER:		0001493152-23-024613
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230714
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230714
DATE AS OF CHANGE:		20230714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRxADE HEALTH, INC
		CENTRAL INDEX KEY:			0001382574
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39199
		FILM NUMBER:		231089744

	BUSINESS ADDRESS:	
		STREET 1:		2420 BRUNELLO TRACE
		CITY:			LUTZ
		STATE:			FL
		ZIP:			33558
		BUSINESS PHONE:		(800) 261 0281

	MAIL ADDRESS:	
		STREET 1:		2420 BRUNELLO TRACE
		CITY:			LUTZ
		STATE:			FL
		ZIP:			33558

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRXADE GROUP, INC.
		DATE OF NAME CHANGE:	20140207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCELLINK INTERNATIONAL INC.
		DATE OF NAME CHANGE:	20081230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bluebird Exploration Co.
		DATE OF NAME CHANGE:	20061204
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:MEDS="http://trxadehealth.com/20230714">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_MEDS_trxadehealth.com_20230714 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20230714_20230714 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001382574 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityCentralIndexKey">0001382574</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="meds-20230714.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-07-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-14</xbrli:startDate>
        <xbrli:endDate>2023-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; text-align: center; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20230714__20230714_zkoHVGMAu517"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(D) OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of report (Date of earliest event reported): <span id="xdx_903_edei--DocumentPeriodEndDate_c20230714__20230714_z9oX5856DOif"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 14, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_904_edei--EntityRegistrantName_c20230714__20230714_zyDE9KHRqBn8"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityRegistrantName">TRxADE
HEALTH, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20230714__20230714_zZ30RvFZ8nI8"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20230714__20230714_zB5Jtvs9rWZh"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityFileNumber">001-39199</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20230714__20230714_zLmn2McCtmP3"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityTaxIdentificationNumber">46-3673928</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20230714__20230714_zh9QEJsxZN5c"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityAddressAddressLine1">2420
    Brunello Trace</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20230714__20230714_zIHTWCFNRsmc"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityAddressCityOrTown">Lutz</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230714__20230714_zVGLZk5Fpyq9"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20230714__20230714_ziyNYAnNKtQ"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:EntityAddressPostalZipCode">33558</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--CityAreaCode_c20230714__20230714_zClQrpK71kU5"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:CityAreaCode">(800)</ix:nonNumeric></span>
<span id="xdx_907_edei--LocalPhoneNumber_c20230714__20230714_znXbcZg8CICk"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:LocalPhoneNumber">261-0281</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<i>see</i> General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--WrittenCommunications_c20230714__20230714_zPeKWK7oGeh3"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt:booleantrue" name="dei:WrittenCommunications">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20230714__20230714_zshb6vsXKgme"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20230714__20230714_z85sIgS5nw2"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20230714__20230714_zfWWI3fQ8Eld"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
                                                                                                                           Symbol(s)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--Security12bTitle_c20230714__20230714_zZ0xbnMRje2g"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:Security12bTitle">Common
    Stock, par value $0.00001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--TradingSymbol_c20230714__20230714_zykFGmAUlQPg"><ix:nonNumeric contextRef="AsOf2023-07-14" name="dei:TradingSymbol">MEDS</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--SecurityExchangeName_c20230714__20230714_zlwagFBtKoNi"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20230714__20230714_zXZ1gIMOH4n9"><ix:nonNumeric contextRef="AsOf2023-07-14" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, on June 30, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;MEDS&#8221;),
entered into an Agreement and Plan of Merger (the &#8220;Original Merger Agreement&#8221;) with Superlatus, Inc., a U.S.-based holding
company of food products and distribution capabilities (&#8220;Superlatus&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2023, the Company and Superlatus entered into an Amended and Restated Agreement and Plan of Merger (the &#8220;A&amp;R Merger
Agreement&#8221;; the transactions contemplated thereby, the &#8220;Merger&#8221;), which amends the merger consideration payable to
the shareholders of Superlatus and adds the issuance of non-transferrable rights to receive shares of common stock of the Company at
no cost to the shareholders of the Company in connection with the Merger. Unless otherwise defined herein, the capitalized terms used
below are defined in the A&amp;R Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the A&amp;R Merger Agreement, as a result of and upon the Effective Time, shareholders of Superlatus shall be entitled
to an aggregate of 30,821,941 shares of the Company stock at $7.30 per share, which will be comprised of (i) 136,441 shares of common
stock of the Company, representing 19.99% of the total issued and outstanding common stock of the Company after the consummation of the
Merger, and (ii) 306,855 shares issued of Company&#8217;s Series B Preferred Stock, par value $0.00001 per share (the &#8220;Series B
Preferred Stock&#8221;), with a conversion ratio of 100 to one.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, effective one (1) business day immediately prior to the Closing Date (the &#8220;MEDS Rights Record Date&#8221;),
the Company shall issue to the shareholders of the Company as of the MEDS Rights Record Date, including the independent directors who
are entitled to certain amount of common stock of the Company in connection with their 2023 annual compensation and regardless of whether
the common stock has been issued or vest before the MEDS Rights Records Date (collectively, the &#8220;MEDS Rights Shareholders&#8221;)
a non-transferrable right to receive one share of common stock of the Company at no cost (the &#8220;MEDS Rights&#8221;), with seven
(7) MEDS Rights issued per share of common stock of the Company held as of the MEDS Rights Record Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the A&amp;R Merger Agreement extends the timeline for delivery of ancillary documents in connection with the Merger, including
the Superlatus Shareholder Support Agreement and Superlatus Lock-Up Agreement, to within 10 days of the entry of the A&amp;R Merger Agreement.
Except as described in this Item 1.01, the terms and provisions of the A&amp;R Merger Agreement are materially consistent with the terms
and provisions of the Original Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the A&amp;R Merger Agreement is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The above description of the terms of the A&amp;R Merger Agreement is qualified in its entirety by reference to such exhibit and by reference
to the description of the Merger in the Company&#8217;s Current Report on 8-K filed June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MEDS
Lock-Up Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
ten (10) business days of the execution and delivery of the A&amp;R Merger Agreement and as a condition and inducement to Superlatus&#8217;s
willingness to enter into the A&amp;R Merger Agreement, certain equity holders of the Company will enter into lock-up agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MEDS
Shareholder Registration Rights Agreement for MEDS Rights</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to the issuance of the MEDS Rights to the MEDS Rights Shareholders in accordance with the A&amp;R Merger Agreement, each
MEDS Rights Shareholder will enter into a Registration Rights Agreement in the form to be agreed upon between the Company and Superlatus
and their counsel, which will include agreement of such MEDS Rights Shareholder not to exercise any MEDS Right until the issuable shares
of common stock for the MEDS Rights are duly registered in accordance with the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;) and other applicable Laws or until receipt of written confirmation from the Company that no such registration is required
and that such MEDS Rights Shareholder shall not transfer such common stock of the Company obtained in connection with such Registration
Rights Agreement until the date that is one (1) year following the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02 Unregistered Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the A&amp;R Merger Agreement, the Company will issue shares of common stock and Series B Preferred Stock at the Effective Time. The
A&amp;R Merger Agreement also provides that the Company will issue the MEDS Rights at MEDS Rights Record Date. Such issuances will be
made in reliance on the exemption from registration pursuant to Section 3(a)(9) or Section 4(a)(2) of the Securities Act, Regulation
D under the Securities Act promulgated thereunder, and corresponding provisions of state securities or &#8220;blue sky&#8221; laws. The
information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The issuances
of the securities will not involve a public offering and will be made without general solicitation or general advertising.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of
common stock or other securities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01. Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2023, the Company issued a press release announcing its entry into the A&amp;R Merger Agreement. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein solely for purposes of this Item 7.01 disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Current Report on Form 8-K furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to liability under that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing. Such information shall not be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such
filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K contains certain statements that may be deemed to be &#8220;forward-looking statements&#8221; within the federal
securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are
not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These
forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the
Company and its industry, beliefs and assumptions. Such forward-looking statements include, but are not limited to, statements regarding
our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements
that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions,
are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; or the negative of these terms or other similar expressions, but the absence of these words does not mean that
a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are
beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating
to the following: agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding,
including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit
arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations
of intellectual property rights of others; one or more conditions to closing of the proposed Merger not being satisfied within the expected
timeframe or at all or that the closing of the proposed Merger does not occur; the outcome of any current legal proceedings or future
legal proceedings that may be instituted against the parties or others, including proceedings related to the Merger documents; the occurrence
of any event, change or other circumstance or condition that could give rise to the termination or abandonment of the Merger; unanticipated
difficulties or expenditures relating to the proposed Merger; potential difficulties in employee retention as a result of the announcement
and pendency of the proposed Merger; whether the combined business of the Company and Superlatus will be successful; and the areas detailed
in the Company&#8217;s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided
by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex2-1.htm">Amended and Restated Agreement and Plan of Merger, dated July 14, 2023 by and between TRxADE Health, Inc. and Superlatus, Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release, dated July 14, 2023</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL for the cover page of this Current Report on Form 8-K</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRxADE
    HEALTH, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Suren Ajjarapu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suren
    Ajjarapu</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    July 14, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5ltpURe2bFi1iFSkivga7SrDNlk38O5K3NLaIy8KyzHwzQvRERktdIcNxXuSwx7qplEMo8IyM5oTeka7WCfhb4EVbx8q49v2BKXkGPTMK5VR5obXetcUygWjcl8N+PAAZJ3ICs40IvnpK5qxLNE6rCpQpYcfUsEan+NUl7NWTDNWvtuqAbDWZBGQYdfIb4kjGsKW7ehBfLeR5KoJeO4HImG7Nt+ZmHdWwqLD2XbZD/xt8ABXWSUQ= -->

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex2-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
2.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT
AND PLAN OF MERGER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
and among</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRXADE
HEALTH, INC.</B>,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOODS
MERGER SUB, INC.</B>, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Superlatus
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of July 14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<FONT STYLE="font-variant: small-caps; font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; font-weight: normal">Table
of Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    1. Definitions and Interpretative Provisions </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Definitional and Interpretative Provisions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    2. Description of Transaction </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Merger</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
    of the Merger</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing;
    Effective Time</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational
    Documents; Directors and Officers</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Rights</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    of Company Equity Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing
    of the Company&rsquo;s Transfer Books</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surrender
    of Company Common Shares</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculation
    of Company Report.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Action</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Consequences</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    3. Representations and Warranties of the Company</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    Organization; Foreign Person Status; Subsidiaries</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational
    Documents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority;
    Binding Nature of Agreement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote
    Required</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Contravention;
    Consents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
    of Changes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
    Property; Title to Assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    Property</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements,
    Contracts and Commitments</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permit;
    Compliance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    Compliance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings; Orders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor
    and Employment Matters.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    Plans.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.18
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.20&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Financial Advisors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.21
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested
    Party Transactions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.22&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    Diligence Period.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.23&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Projections.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.24&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Books
    and Records.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    Disclosure.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.26
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Other Representations or Warranties</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    4. Representations and Warranties of MEDS and Merger Sub </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>43</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    Organization; Subsidiaries</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational
    Documents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority;
    Binding Nature of Agreement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Contravention;
    Consents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Filings; Financial Statements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence
    of Undisclosed Liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contracts
    and Commitments</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance;
    Permits; Restrictions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings; Orders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    and Labor Matters; Benefit Plans</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    with Affiliates</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Financial Advisors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valid
    Issuance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    Approval of Independent Director Consideration</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Other Representations or Warranties</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    5. Certain Covenants of the Parties </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>54</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation
    of MEDS&rsquo;s Business</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation
    of the Company&rsquo;s Business.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
    and Investigation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Solicitation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification
    of Certain Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    6. Additional Agreements of the Parties </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Shareholder Written Consent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts;
    Regulatory Approvals.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Options</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    Benefits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    of Officers and Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legends</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
    and Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    of Certain Agreements and Rights</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    16 Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
    Certificate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Announcements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
    of Merger Sub</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    7. Conditions Precedent to Obligations of Each Party </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>66</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Restraints.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
    Approval</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    8. Additional Conditions Precedent to Obligations of MEDS and Merger Sub </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>66</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accuracy
    of Representations</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    of Covenants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Company Material Adverse Effect</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Lock-Up Agreements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Shareholder Written Consent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sapeinta
    Membership Interest Purchase.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prestige
    Farms Purchase Agreement.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intentionally
    Omitted.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.10&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreements.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.11&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Financing.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    9. Additional Conditions Precedent to Obligations of the Company </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>68</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accuracy
    of Representations</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    of Covenants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    MEDS Material Adverse Effect</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payoff
    Letter[s]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Board of Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Lock-up Agreements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    10. Termination </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>69</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Termination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    11. Miscellaneous Provisions </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>72</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Survival
    of Representations and Warranties</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
    Law; Jurisdiction</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participation
    in Negotiation and Drafting.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Remedies; Specific Performance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Third-Party Beneficiaries</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED AGREEMENT AND PLAN OF MERGER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>This
Amended and Restated Agreement and Plan of Merger </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(this
&ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of July 14, 2023, by and among <B>TRxADE Health, Inc<FONT STYLE="font-variant: small-caps">.</FONT></B>,
a Delaware corporation (&ldquo;<B>MEDS</B>&rdquo;), <B>Foods Merger Sub<FONT STYLE="font-variant: small-caps">,</FONT> Inc.</B>, a Delaware
corporation and wholly owned subsidiary of MEDS (&ldquo;<B>Merger Sub</B>&rdquo;), <B>and Superlatus Inc.</B>, a Delaware corporation
(the &ldquo;<B>Company</B>&rdquo;). Certain capitalized terms used in this Agreement are defined in <U>Section 1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Recitals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;MEDS,
Merger Sub, and the Company entered into that certain Agreement and Plan of Merger (the &ldquo;<B>Original Merger Agreement</B>&rdquo;),
dated as of June 30, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;MEDS,
Merger Sub, and the Company desire to amend and restate the Original Merger Agreement in its entirety on the terms and subject to the
conditions set forth in this Agreement and in accordance with Section 11.2 of the Original Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;MEDS
and the Company intend to effect a merger of Merger Sub with and into the Company (the &ldquo;<B>Merger</B>&rdquo;) in accordance with
this Agreement, the DGCL. Upon consummation of the Merger, Merger Sub will cease to exist, and the Company will become a wholly owned
subsidiary of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&nbsp;The
Parties intend that the Merger will qualify as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code and the
Treasury Regulations, and that this Agreement be, and hereby is, adopted as a &ldquo;plan of reorganization&rdquo; for the purposes of
Section 368 of the Code and Treasury Regulations Sections 1.368-2(g) and 1.368-3 (the &ldquo;<B>Intended Tax Treatment</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.&nbsp;The
MEDS Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of MEDS and its stockholders,
(ii) approved and declared advisable this Agreement, the Transaction Documents and the Contemplated Transactions, including the issuance
of shares of MEDS Common Stock to the stockholders of the Company pursuant to the terms of this Agreement and (iii) determined to recommend,
if deemed necessary by MEDS, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of MEDS
vote to approve this Agreement and thereby approve the Contemplated Transactions and against any competing proposals, including the issuance
of shares of MEDS Common Stock to the equity holders of the Company pursuant to the terms of this Agreement and, if deemed necessary
by MEDS, an amendment to MEDS&rsquo;s certificate of incorporation to effect the Nasdaq Reverse Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.&nbsp;The
Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub
and its sole stockholder, (ii) approved and declared advisable this Agreement, the Transaction Documents and the Contemplated Transactions
and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of
Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.&nbsp;The
Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and
its equity holders, (ii) approved and declared advisable this Agreement, the Transaction Documents and the Contemplated Transactions
and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the equity holders
of the Company vote to adopt this Agreement, the Transaction Documents (including the Asset Purchase Agreement) and thereby approve the
Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.&nbsp;Within
ten (10) Business Days of the execution and delivery of this Agreement and as a condition and inducement to MEDS&rsquo;s willingness
to enter into this Agreement, each of the officers, directors and 5% or greater stockholders (together with their Affiliates) of the
Company listed on <U>Section A</U> of the Company Disclosure Schedule (solely in their capacity as equity holders of the Company) are
executing support agreements in favour of MEDS in substantially the form and substance agreeable to MEDS and the Company (the &ldquo;<B>Company
Shareholder Support Agreement</B>&rdquo;), pursuant to which such Persons have, subject to the terms and conditions set forth therein,
agreed to vote all of their Company Common Shares in favour of the adoption of this Agreement, the Transaction Documents and thereby
approve the Contemplated Transactions and against any competing proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.&nbsp;Within
ten (10) Business Days of the execution and delivery of this Agreement and as a condition and inducement to MEDS&rsquo;s willingness
to enter into this Agreement (to the extent deemed applicable and necessary by MEDS), all of the equity holders of the Company listed
on <U>Section A</U> of the Company Disclosure Schedule are executing lock-up agreements (each a &ldquo;<B>Company Lock-Up Agreement</B>,&rdquo;
and collectively, the &ldquo;<B>Company Lock-Up Agreements</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.&nbsp;Within
ten (10) Business Days of the execution and delivery of this Agreement and as a condition and inducement to the Company&rsquo;s willingness
to enter into this Agreement (to the extent deemed applicable and necessary by the Company), all of the equity holders of the MEDS listed
on <U>Section A</U> of the MEDS Disclosure Schedule are executing lock-up agreements (each a &ldquo;<B>MEDS Lock-Up Agreement</B>,&rdquo;
and collectively, the &ldquo;<B>MEDS Lock-Up Agreements</B>&rdquo;). To the extent permissible by applicable Law and at the earliest
date practicable following the Closing Date, MEDS will release such MEDS Lock-Up Agreements as necessary to release up to three (3) million
shares of MEDS Common Stock held by MEDS shareholders who are not &ldquo;affiliates&rdquo; of MEDS as defined in the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.&nbsp;As
a condition and inducement to the Company&rsquo;s willingness to enter into this Agreement, Suren Ajjarapu and Prashant Patel (the &ldquo;<B>Principal
Stockholders</B>&rdquo;) have executed an agreement with MEDS dated June 28, 2023 (the &ldquo;<B>Stock Swap Agreement</B>&rdquo;), pursuant
to which, at the Closing and immediately following the Merger, MEDS shall sell, convey, transfer, assign and deliver to the Principal
Stockholders and the Principal Stockholders shall purchase and accept from MEDS, all of the issued and outstanding Equity Interests of
the MEDS Subsidiaries in exchange for all of the shares of MEDS Common Stock held by the Principal Stockholders (such transaction, the
&ldquo;<B>Stock Swap</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.&nbsp;It
is expected that the holders of Company Common Shares sufficient to adopt and approve this Agreement, the Transaction Documents and the
Contemplated Transactions as required under applicable Law and the Company&rsquo;s Organizational Documents will execute and deliver
an action by written consent adopting this Agreement, in form and substance acceptable to MEDS, in order to obtain the Required Company
Shareholder Vote (each, a &ldquo;<B>Company Shareholder Written Consent</B>&rdquo; and collectively, the &ldquo;<B>Company Shareholder
Written Consents</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties, intending to be legally bound, agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1. <U>Definitions and Interpretative Provisions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.1 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;For
purposes of the Agreement (including this <U>Section 1</U>):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Acceptable
Confidentiality Agreement</B>&rdquo; means a confidentiality agreement containing terms not materially less restrictive in the aggregate
to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any
standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality
agreement with MEDS relating to a potential Acquisition Proposal shall not be required to enter into a new or revised confidentiality
agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Acquisition
Inquiry</B>&rdquo; means with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry,
indication of interest or request for information made or submitted by the Company, on the one hand, or MEDS, on the other hand, to the
other Party) that could reasonably be expected to lead to an Acquisition Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Acquisition
Proposal</B>&rdquo; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made
or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of MEDS or any of its Affiliates,
on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Acquisition
Transaction</B>&rdquo; means any transaction or series of related transactions involving: (a) any merger, consolidation, amalgamation,
share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer,
exchange offer or other similar transaction: (i) in which a Party is a constituent Entity, (ii) in which a Person or &ldquo;group&rdquo;
(as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record
ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any
of its Subsidiaries or (iii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding
securities of any class of voting securities of such Party or any of its Subsidiaries; or (b) any sale, lease, exchange, transfer, license,
acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book
value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole, other than the sale, divestiture and/or
winding down of the MEDS Legacy Business or the sale, license or other disposition of any or all of the MEDS Legacy Assets by MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
shall have the meaning given to such term in Rule 145 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affordable
Care Act</B>&rdquo; means the Patient Protection and Affordable Care Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Aggregate
Valuation</B>&rdquo; means the sum of (i) the Company Valuation, <I><U>plus</U></I> (ii) the MEDS Valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Allocation
Certificate</B>&rdquo; shall have the meaning set forth in <U>Section 6.11</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Balance
Sheet Date</B>&rdquo; means December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business
Data</B>&rdquo; means all business information and data, including Personal Information (whether of employees, contractors, consultants,
customers, consumers, or other persons and whether in electronic or any other form or medium) that is accessed, collected, used, stored,
shared, distributed, transferred, disclosed, destroyed, disposed of or otherwise processed by any of the Business Systems or otherwise
in the course of the conduct of the business of the Company or any Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business
Day</B>&rdquo; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business
Systems</B>&rdquo; means all Software, computer hardware (whether general or special purpose), electronic data processors, databases,
communications, telecommunications, networks, interfaces, platforms, servers, peripherals, and computer systems, including any outsourced
systems and processes, and any Software and systems provided via the cloud or &ldquo;as a service&rdquo;, that are owned or used in the
conduct of the business of the Company or any Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Certificate
of Merger</B>&rdquo; shall have the meaning set forth in <U>Section 2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing</B>&rdquo;
shall have the meaning set forth in <U>Section 2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing
Date</B>&rdquo; shall have the meaning set forth in <U>Section 2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>COBRA</B>&rdquo;
means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section 4980B of the Code and Part 6 of Title I of
ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Code</B>&rdquo;
means the Internal Revenue Code of 1986, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Combined
Companies</B>&rdquo; means Sapientia, Inc., Prestige Farms, Inc., and direct and indirect subsidiaries and/or affiliates acquired by
the Company before Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Allocation Percentage</B>&rdquo; means the quotient (rounded to four decimal places) determined by <I><U>dividing</U></I> (i) the Company
Valuation <I><U>by</U></I> (ii) the Aggregate Valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Board</B>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Board Adverse Recommendation Change</B>&rdquo; shall have the meaning set forth in <U>Section 6.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Board Recommendation</B>&rdquo; shall have the meaning set forth in <U>Section 6.1(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Capitalization Representations</B>&rdquo; means the representations and warranties of the Company set forth in <U>Sections 3.6(a)</U>
and <U>3.6(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Company
Common Shares&rdquo; </B>means the &ldquo;Common Shares&rdquo; as defined in the Company&rsquo;s Certificate of Incorporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Equity Plans</B>&rdquo; means any equity incentive plan of the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Equity Securities</B>&rdquo; means any holder of equity in the Company, including but not limited to shares, options, or warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Equity Value</B>&rdquo; means $225,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Fundamental Representations</B>&rdquo; means the representations and warranties of the Company set forth in <U>Sections 3.2</U>, <U>3.2</U>,
<U>3.3</U>, <U>3.4</U> and <U>3.21</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
IP Rights</B>&rdquo; means all Intellectual Property owned, licensed, or controlled by the Company or its Subsidiaries that is necessary
for, or used or held for use in, the operation of the business of the Company and its Subsidiaries as presently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
IP Rights Agreement</B>&rdquo; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential
information provided under confidentiality agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Material Adverse Effect</B>&rdquo; means any Effect that, considered together with all other Effects that have occurred prior to the
date of determination of the occurrence of a Company Material Adverse Effect, has or would be expected to have a material adverse effect
on the business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole;
<U>provided, however,</U> that Effects arising or resulting from the following shall not be taken into account in determining whether
there has been a Company Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions,
(b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement,
(c) any natural disaster, calamity or epidemics, pandemics (including COVID-19, any COVID-19 Measures, and any precautionary or emergency
measures, recommendations, protocols or orders taken or issued by any Person in response to COVID-19) or other force majeure events,
or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening
of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d) any change
in GAAP or applicable Law or the interpretation thereof, or (e) general economic or political conditions or conditions generally affecting
the industry in which the Company and its Subsidiaries operate; except in each case with respect to <U>clauses (c)</U>, <U>(d)</U> and
<U>(e)</U>, to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly
situated companies in the industry in which the Company and its Subsidiaries operate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Merger Shares</B>&rdquo; means the product determined by <I><U>multiplying</U></I> (i) the Post-Closing MEDS Shares <I><U>by</U></I>
(ii) the Company Allocation Percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Options</B>&rdquo; means options or other rights to purchase Company Common Shares issued by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Registered IP</B>&rdquo; means all Company IP Rights that are owned by the Company that are registered, filed or issued under the authority
of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications
and registrations for any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Shareholder Support Agreements</B>&rdquo; shall have the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Shareholder Written Consent</B>&rdquo; shall have the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Stock Certificate</B>&rdquo; means a valid certificate representing any Company Common Shares outstanding immediately prior to the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Unaudited Interim Balance Sheet</B>&rdquo; means the estimated unaudited statement of assets, liabilities and partner&rsquo;s capital
of the Company for the three-month period ended on March 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Valuation</B>&rdquo; means the value of the Company and the Combined Companies as set forth in the Company Valuation Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Confidentiality
Agreement</B>&rdquo; means the confidentiality agreement between the Company and MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Consent</B>&rdquo;
means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Contemplated
Transactions</B>&rdquo; means the Merger, the Stock Swap and the other transactions contemplated by this Agreement, including the Nasdaq
Reverse Split (to the extent applicable and deemed necessary by MEDS).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Contract</B>&rdquo;
means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage,
license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or
any of its assets are bound or affected under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>DGCL</B>&rdquo;
means the General Corporation Law of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Disabling
Devices</B>&rdquo; means Software viruses, time bombs, logic bombs, trojan horses, trap doors, back doors, or other computer instructions,
intentional devices or techniques that are designed to threaten, infect, assault, vandalize, defraud, disrupt, damage, disable, maliciously
encumber, hack into, incapacitate, infiltrate or slow or shut down a computer system or any component of such computer system, including
any such device affecting system security or compromising or disclosing user data in an unauthorized manner, other than those incorporated
by the Company or the applicable third party intentionally to protect Company Registered IP from misuse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Due
Diligence Period</B>&rdquo; shall have the meaning set forth in <U>Section 3.22.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effect</B>&rdquo;
means any effect, change, event, circumstance, or development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effective
Time</B>&rdquo; shall have the meaning set forth in <U>Section 2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Employee
Plan</B>&rdquo; means (a) an &ldquo;employee benefit plan&rdquo; within the meaning of Section 3(3) of ERISA whether or not subject to
ERISA; (b) other plan, program, policy or arrangement, whether or not reduced to writing, providing for stock options, stock appreciation
rights, restricted stock, phantom stock, stock purchases, or any other equity-based compensation, bonuses (including any annual bonuses,
retention bonuses, referral bonuses, performance bonuses, etc.) or other incentives, salary continuation pay, severance pay, or any other
termination pay, deferred compensation, employment, compensation, commission or other variable compensation, , change in control or transaction
bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing
benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits,
and all other employee benefit plans, agreements, and arrangements, not described in (a) above; and (c) all other plans, programs, policies
or arrangements providing compensation to current or former employees, consultants and non-employee directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Encumbrance</B>&rdquo;
means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude,
adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction
or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security
or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any
restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>End
Date</B>&rdquo; shall have the meaning set forth in <U>Section 10.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Enforceability
Exceptions</B>&rdquo; means the (a) laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b)
rules of law governing specific performance, injunctive relief and other equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Entity</B>&rdquo;
means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited
liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or
joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Environmental
Law</B>&rdquo; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment
(including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to
emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Equity
Interests</B>&rdquo; means (a) in the case of a corporation, any and all shares (however designated) of capital stock, (b) in the case
of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated)
of capital stock, (c) in the case of a partnership or limited liability company, any and all partnership or membership interests (whether
general or limited) or units (whether common or preferred), (d) in any case, any other interest or participation that confers on a person
the right to receive a share of the profits and losses of, or distributions of assets of, the issuing person, and (e) in any case, any
right to acquire any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ERISA</B>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended, and all of the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ERISA
Affiliate</B>&rdquo; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity
or part of the same &ldquo;controlled group&rdquo; as such Entity under Sections 414(b),(c),(m) or (o) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FDA</B>&rdquo;
means the U.S. Food and Drug Administration (or any successor agency thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FDCA</B>&rdquo;
means the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.) and the associated rules, regulations and guidance
documents promulgated thereunder, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>GAAP</B>&rdquo;
means the United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Governmental
Authority</B>&rdquo; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature, (b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or quasi-governmental
authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry,
fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Taxing
Authority) or (d) self-regulatory organization (including Nasdaq).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Governmental
Authorization</B>&rdquo; means any: (a) permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance,
registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental
Authority or pursuant to any Law or (b) right under any Contract with any Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Governmental
Funded IP</B>&rdquo; shall have the meaning set forth in Section 3.10(m).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Hazardous
Materials</B>&rdquo; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable
or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject
to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and
petroleum products or by-products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Healthcare
Laws</B>&rdquo; means any and all Laws promulgated thereunder relating to patient care, human health and safety, or other health regulatory
matters applicable to the business of the Company including, as amended from time to time, (i) the FDCA and the PHSA; (ii) any and all
Laws pertaining to the research (including preclinical, nonclinical, and clinical research or studies), development, testing, production,
manufacture, transfer, storing, distribution, importation, exportation, use, handling, quality, approval or authorization, packaging,
labeling, marketing, pricing, third party reimbursement, promotion or sale of biological products, other cellular and tissue-based products
regulated solely under PHSA &sect; 361, or product candidates, including Laws governing license requirements for any of the foregoing
activities; (iii) all self-referral or fraud and abuse Laws, including the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)),
the Stark Anti-Self-Referral Law (42 U.S.C. &sect; 1395nn), the civil False Claims Act (31 U.S.C. &sect; 3729 et seq.), the criminal
False Claims Act (18 U.S.C.&sect; 287); the administrative False Claims Law (42 U.S.C. &sect;&sect; 1320a-7, 1320a-7a, and 1320a-7b),
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. No. 108-173)), and all similar self-referral or fraud
and abuse laws promulgated by any Governmental Authority, the 21st Century Cures Act (Pub. L. 114-255), or Section 543 of the PHSA; (iv)
the Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &sect; 1320d
- d-8), the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &sect; 17935), and any other state
or federal Law the purpose of which is to protect the privacy and security of individually-identifiable patient information or protected
health information; (v) Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), and the Patient
Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, TRICARE
(10 U.S.C. &sect; 1071 et seq.) or other Governmental Authority health care or payment programs; (vi) the Sunshine/Open Payments Law
(42 U.S.C. &sect; 1320a-7h) and all similar Laws related the reporting of manufacturer payments or transfers of value to health care
professionals; (vii) quality, safety certification and accreditation standards and requirements; (viii) the billing, coding or submission
of claims or collection of accounts receivable or refund of overpayments; (ix) the Prescription Drug Marketing Act of 1987, in each case
including the associated rules and regulations promulgated thereunder and all of their foreign equivalents; and (x) all other requirements
of Law applicable to the operations of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>HSR
Act</B>&rdquo; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IND</B>&rdquo;
means an investigational new drug application (as defined at 21 C.F.R. &sect; 312.3 and more fully described in 21 C.F.R. &sect; 312.20
et seq.) or equivalent application, and all amendments thereto, filed with the FDA in the United States or the applicable Governmental
Authority in a country or group of countries outside the United States (including any supra-national agency such as in the European Union),
including all documents, data, submissions, filings and other information concerning an investigational product (or an investigational
use of an approved product) which are necessary for interstate shipment and administration of the product in clinical investigations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&ldquo;<B>Independent
Director Consideration</B>&rdquo; means the issuance of 22,222 shares of MEDS Common Stock to Donald Fell, 22,222 shares of MEDS Common
Stock to Michael Peterson, and 23,856 shares of MEDS Common Stock to Jeffrey Newell in connection with their 2023 annual compensation
and as a bonus for their service approved by the Board of MEDS on June 9, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&ldquo;<B>Independent
Directors</B>&rdquo; means Donald Fell, Jeffrey Newell, and Michael Peterson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Intellectual
Property</B>&rdquo; means: (a) United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals,
substitutions, divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations,
term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention
disclosures and inventions (collectively, &ldquo;<B>Patents</B>&rdquo;), (b) trademarks, service marks, trade names, domain names, corporate
names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration
thereof and goodwill associated therewith, (c) copyrights, including registrations and applications for registration thereof, (d) software,
including all source code, object code and related documentation, (e) formulae, customer lists, trade secrets, know-how, confidential
information and other proprietary rights and intellectual property, whether patentable or not, and (f) all United States and foreign
rights arising under or associated with any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IRS</B>&rdquo;
means the United States Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Key
Employee</B>&rdquo; means (i) an executive officer of MEDS or the Company; and (ii) any employee of MEDS or the Company that reports
directly to the MEDS Board or the Company Board or to an executive officer of MEDS or the Company, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Knowledge</B>&rdquo;
means, with respect to any Person, the actual knowledge after reasonable inquiry of such Person or any senior-level executive employee
or director of such Person who has or would reasonably be expected to have such knowledge after reasonable inquiry of such employee or
director&rsquo;s direct reports. Any Person that is an Entity shall have Knowledge if any executive officer or director of such Person
as of the date such knowledge is imputed has or should reasonably be expected to have Knowledge of such fact or other matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Law</B>&rdquo;
means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common
law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the
Financial Industry Regulatory Authority).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Leased
Real Property</B>&rdquo; means the real property leased by the Company or Subsidiaries as tenant, together with, to the extent leased
by the Company or Subsidiaries, all buildings and other structures, facilities or improvements located thereon and all easements, licenses,
rights and appurtenances of the Company or Subsidiaries relating to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Legal
Proceeding</B>&rdquo; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative
or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before,
or otherwise involving, any court or other Governmental Authority or any arbitrator or arbitration panel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Legal
Requirement</B>&rdquo; means United States, foreign, domestic, federal, territorial, state, provincial, local or municipal laws, codes,
statutes, common law, ordinances, rules, regulations, decrees, writs, injunctions, judgments, directives, rulings and or orders adopted
or promulgated by any Governmental Entity or any treaty or other requirement, policies, and guidelines having the force of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Allocation Percentage</B>&rdquo; means the quotient (rounded to four decimal places) determined by <I><U>dividing</U></I> (i) the MEDS
Valuation <I><U>by</U></I> (ii) the Aggregate Valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Associate</B>&rdquo; means any current employee, independent contractor, officer or director of MEDS or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Balance Sheet</B>&rdquo; means the audited balance sheet of MEDS as of December 31, 2022, included in MEDS&rsquo;s Report on Form 10-K
for the year ended December 31, 2022, as filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Board</B>&rdquo; means the board of directors of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Capitalization Representations</B>&rdquo; means the representations and warranties of MEDS and Merger Sub set forth in <U>Sections 4.5(a)
</U>and <U>4.6(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Common Stock</B>&rdquo; means the common stock, $0.00001 par value per share, of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Contract</B>&rdquo; means any Contract: (a) to which MEDS is a party, (b) by which MEDS or any MEDS IP Rights or any other asset of MEDS
is or may become bound or under which MEDS has, or may become subject to, any obligation or (c) under which MEDS has or may acquire any
right or interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Covered Person</B>&rdquo; means, with respect to MEDS as an &ldquo;issuer&rdquo; for purposes of Rule 506 promulgated under the Securities
Act, any Person listed in the first paragraph of Rule 506(d)(1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Employee Plan</B>&rdquo; means any Employee Plan that MEDS or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes
to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or
(iv) may reasonably be expected to have any Liability, or (v) utilizes to provide benefits to or otherwise cover any current or former
employee, officer, director or other service provider of MEDS or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Equity Value</B>&rdquo; means $40,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Fundamental Representations</B>&rdquo; means the representations and warranties of MEDS and Merger Sub set forth in <U>Sections 4.1(a)</U>,
<U>4.1(b)</U>, <U>4.3</U>, and <U>4.21</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
IP Rights</B>&rdquo; means all Intellectual Property owned, licensed or controlled by MEDS that is necessary for, or used or held for
use in, the operation of the business of MEDS as presently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
IP Rights Agreement</B>&rdquo; means any Contract governing, related or pertaining to any MEDS IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Legacy Business</B>&rdquo; means the business of MEDS as conducted at any time prior to the date of this Agreement, including but not
limited to business related to the assets listed on Section 1.1 of the MEDS Disclosure Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Legacy Transaction</B>&rdquo; shall have the meaning set forth in <U>Section 5.1(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Material Adverse Effect</B>&rdquo; means any Effect that, considered together with all other Effects that have occurred prior to the
date of determination of the occurrence of the MEDS Material Adverse Effect, has or would reasonably be expected to have a material adverse
effect on the business, financial condition, assets, liabilities or results of operations of MEDS or any of its Subsidiaries, taken as
a whole; provided, however, that Effects arising or resulting from the following shall not be taken into account in determining whether
there has been a MEDS Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions,
(b) any change in the stock price or trading volume of MEDS Common Stock (it being understood, however, that any Effect causing or contributing
to any change in stock price or trading volume of MEDS Common Stock may be taken into account in determining whether a MEDS Material
Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking of any action, or the failure
to take any action, by MEDS that is required to comply with the terms of this Agreement, (d) any natural disaster, calamity or epidemics,
pandemics (including COVID-19, any COVID-19 Measures, and any precautionary or emergency measures, recommendations, protocols or orders
taken or issued by any Person in response to COVID-19) or other force majeure events, or any act or threat of terrorism or war, any armed
hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or
any governmental or other response or reaction to any of the foregoing, (e) any change in GAAP or applicable Law or the interpretation
thereof or (f) general economic or political conditions or conditions generally affecting the industries in which MEDS or any of its
Subsidiaries operates; except, in each case with respect to clauses (d), (e) and (f), to the extent materially and disproportionately
affecting MEDS and any its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which
MEDS or any of its Subsidiaries operates. Notwithstanding the above, a delisting of MEDS Common Stock on Nasdaq shall constitute a MEDS
Material Adverse Effect, provided that the Company has not refused or unreasonably delayed or conditioned its consent to reasonable actions
by MEDS to maintain the listing of MEDS Common Stock on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Net Cash</B>&rdquo; means unrestricted free cash or cash equivalents plus (i) prepaid expenses expected to provide benefit to the combined
company (if any), <I><U>minus</U></I> (ii) total short &amp; long term liabilities accrued at Closing pursuant to GAAP, <I><U>minus</U></I>
(iii) fees and expenses incurred with respect to the Contemplated Transactions (including attorneys&rsquo; fees and investment banking
fees, lease termination costs and other expenses associated with the wind-down of legacy operations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Options</B>&rdquo; means options or other rights to purchase shares of MEDS Common Stock granted by MEDS, including pursuant to any MEDS
Stock Plan, as an &ldquo;inducement&rdquo; award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Outstanding Shares</B>&rdquo; means, subject to <U>Section 2.6(a)</U>, the total number of shares of MEDS Common Stock outstanding immediately
prior to the Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication the issuance of shares
of MEDS Common Stock in respect of all MEDS Options, warrants or other rights to receive shares, whether conditional or unconditional,
that will be outstanding as of immediately prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Registered IP</B>&rdquo; means all MEDS IP Rights that are owned or exclusively licensed by MEDS that are registered, filed or issued
under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks
and all applications for any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Rights</B>&rdquo; shall have the meaning set forth in <U>Section 2.5. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Rights Record Date</B>&rdquo; shall have the meaning set forth in <U>Section 2.5.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MEDS
Rights Shareholders</B>&rdquo; shall have the meaning set forth in <U>Section 2.5.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Merger
Sub Board</B>&rdquo; means the board of directors of Merger Sub.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Multiemployer
Plan</B>&rdquo; means a &ldquo;multiemployer plan,&rdquo; as defined in Section 3(37) or 4001(a)(3) of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Multiple
Employer Plan</B>&rdquo; means a &ldquo;multiple employer plan&rdquo; within the meaning of Section 413(c) of the Code or Section 3(40)
of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Multiple
Employer Welfare Arrangement</B>&rdquo; means a &ldquo;multiple employer welfare arrangement&rdquo; within the meaning of Section 3(40)
of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Nasdaq</B>&rdquo;
means the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Nasdaq
Reverse Split</B>&rdquo; means a reverse stock split of all outstanding shares of MEDS Common Stock effected by MEDS for the purpose
of maintaining compliance with Nasdaq listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Notice
Period</B>&rdquo; shall have the meaning set forth in <U>Section 6.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Order</B>&rdquo;
means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate
integrity agreement, resolution agreement, or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court
or Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Ordinary
Course of Business</B>&rdquo; means, in the case of each of the Company and MEDS, such actions taken in the ordinary course of its normal
operations and consistent with its past practices; <U>provided</U>, <U>however</U>, that during the Pre-Closing Period, the Ordinary
Course of Business of MEDS shall also include actions required to effect and effecting, in one or more transactions, the sale, divestiture,
licensing or winding down of the MEDS Legacy Business or the sale, license or other disposition of any or all of the MEDS Legacy Assets,
including the Stock Swap and the entry into the Stock Swap Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Organizational
Documents</B>&rdquo; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or
incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company,
operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization
of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such
Person, in each case, as amended or supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Party</B>&rdquo;
or &ldquo;<B>Parties</B>&rdquo; means the Company, Merger Sub and MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Permitted
Alternative Agreement</B>&rdquo; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that
constitutes a Superior Offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Permitted
Encumbrance</B>&rdquo; means (a) any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested
in good faith and for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the MEDS Unaudited Interim
Balance Sheet, as applicable, in accordance with GAAP, (b) minor liens that have arisen in the Ordinary Course of Business and that do
not (in any case or in the aggregate) detract from the value of the assets subject thereto or impair the operations of the Company or
MEDS, as applicable, (c) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements, (d)
deposits or pledges made in connection with, or to secure payment of, workers&rsquo; compensation, unemployment insurance or similar
programs mandated by Law, (e) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor,
materials or supplies and (f) liens arising under applicable securities Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
means any individual, Entity or Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Personal
Information</B>&rdquo; means data and information concerning an identifiable natural person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>PHSA</B>&rdquo;
means the Public Health Service Act (42 U.S.C. &sect;&sect; 201 et seq.) and the associated rules, regulations and guidance documents
promulgated thereunder, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Post-Closing
MEDS Shares</B>&rdquo; mean the quotient determined by <I><U>dividing</U></I> (i) the MEDS Outstanding Shares <I><U>by</U></I> (ii) the
MEDS Allocation Percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pre-Closing
Period</B>&rdquo; shall have the meaning set forth in <U>Section 5.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Privacy
Laws</B>&rdquo; mean, collectively, (i) all applicable Laws relating to data privacy, data protection, data security, trans-border data
flow, data loss, data theft, or breach notification with respect to the collection, handling, use, processing, maintenance, storage,
disclosure or transfer of Personal Information enacted, adopted, promulgated or applied by any Governmental Authority, including the
applicable legally binding requirements set forth in applicable regulations and agreements containing consent orders published by regulatory
authorities of competent jurisdiction such as, as applicable, the U.S. Federal Trade Commission, U.S. Federal Communications Commission,
and state data protection authorities, including but not limited to HIPAA; (ii) the internal privacy policy of the Company and any public
statements that the Company has made regarding its privacy policies and practices; (iii) third party privacy policies with which the
Company has been or is contractually obligated to comply; and (iv) any applicable rules of any applicable self-regulatory organizations
in which the Company is or has been a member and/or with which the Company is or has been contractually obligated to comply relating
to data privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification with respect to
the collection, handling, use, processing, maintenance, storage, disclosure or transfer of Personal Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Privacy
Policies</B>&rdquo; means written policies and procedures, satisfying the requirements of applicable Privacy Laws, concerning the privacy,
security, collection and use of Personal Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Products</B>&rdquo;
means any products, product candidates or services, researched, developed, manufactured, labeled, out-licensed, sold, marketed, promoted,
imported or exported, distributed or otherwise made available, as applicable, by or on behalf of the Company or any Subsidiary as of
the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Regulatory
Permits</B>&rdquo; means all Company Permits that are required by applicable Healthcare Laws and that are required and granted by FDA
or any comparable Governmental Authority, including INDs, establishment registrations or permits and cellular and tissue-based product
listings, manufacturing approvals and authorizations, ethical reviews, and their national or foreign equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Representatives</B>&rdquo;
means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Satisfactory
Fairness Opinion</B>&rdquo; means a fairness opinion that states that the Contemplated Transactions are fair to the holders of MEDS Common
Stock from a financial point of view.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Sarbanes-Oxley
Act</B>&rdquo; means the Sarbanes-Oxley Act of 2002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC</B>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Software</B>&rdquo;
means all computer software (in object code or source code format), and related documentation and materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record at
any time before Closing, (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person
to elect at least a majority of the members of such entity&rsquo;s board of directors or other governing body or (b) at least 50% of
the outstanding equity, voting, beneficial or financial interests in such Entity. Notwithstanding the foregoing, &ldquo;Subsidiary&rdquo;
when referring to the Company&rsquo;s Subsidiaries shall expressly include the Combined Companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Superior
Offer</B>&rdquo; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition
Transaction being treated as references to 50% for these purposes) that (a) was not obtained or made as a direct or indirect result of
a breach of (or in violation of) the Agreement and (b) is on terms and conditions that the MEDS Board or the Company Board, as applicable,
determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing
terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following
consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to MEDS&rsquo;s
stockholders or the Company&rsquo;s equity holders, as applicable, than the terms of the Contemplated Transactions and is not subject
to any financing conditions (and if financing is required, such financing is then fully committed to the third party).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax</B>&rdquo;
means any federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax,
value-added tax, surtax, estimated tax, unemployment tax, national health insurance tax, excise tax, ad valorem tax, transfer tax, stamp
tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, customs duty, alternative or add-on minimum or other
tax or similar charge in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including
any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable
to the nonpayment thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax
Return</B>&rdquo; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule,
notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing,
filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment,
collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law
relating to any Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Taxing
Authority</B>&rdquo; means, with respect to any Tax, the Governmental Authority or other authority competent to impose such Tax or responsible
for the administration and/or collection of such Tax or enforcement of any law in relation to Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transaction
Documents</B>&rdquo; means this Agreement, the Stock Swap Agreement, and each other exhibit, certificate, document, instrument or agreement
executed in connection with this Agreement and the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transaction
Expenses</B>&rdquo; means, with respect to a Party, the aggregate amount (without duplication) of all costs, fees and expenses incurred
by such Party or any of its Subsidiaries (including Merger Sub), or for which such Party or any of its Subsidiaries are liable in connection
with the Merger and the negotiation, preparation and execution of this Agreement or any other agreement, document, instrument, filing,
certificate, schedule, exhibit, letter or other document prepared or executed in connection with the Contemplated Transactions, including
(a) any fees and expenses of legal counsel and accountants, the maximum amount of fees and expenses payable to financial advisors, investment
bankers, brokers, consultants, tax advisors, transfer agents, proxy solicitor and other advisors of such Party; and (b) any bonus, retention
payments, severance, change-in-control payments or similar payment obligations (including payments with &ldquo;single-trigger&rdquo;
provisions triggered in connection with the Contemplated Transactions) that become due or payable to any director, officer, employee
or consultant in connection with the consummation of the Contemplated Transactions, together with any payroll Taxes associated therewith;
<U>provided</U>, that, Transaction Expenses shall not include any Costs associated with the obtainment of directors and officers insurance
pursuant to <U>Section 3.19</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transfer
Taxes</B>&rdquo; shall have the meaning set forth in Section 6.8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Treasury
Regulations</B>&rdquo; means the United States Treasury regulations promulgated under the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Virtual
Data Room</B>&rdquo; means the virtual data room established by the Company, access to which was given to MEDS in connection with its
due diligence investigation of the Company relating to the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each of the following terms is defined in the Section set forth opposite such term:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Term</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">409A
    Plan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17(j)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization
    Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Merger</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing
    Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Disclosure Schedule</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Financials</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Lock-Up Agreements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Material Contract</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Shareholder Support Agreement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Shareholder Written Consents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Equity Plans</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Permits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Term</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Valuation Report</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8(b)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D&amp;O
    Indemnified Parties</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug/Device
    Regulatory Agency</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    Time</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
    Permits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    Holder Notice</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2(b)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    Agent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDCA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended
    Tax Treatment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
    Policies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9(b)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    Documents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9(b)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    2014 Plan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6(c)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    2019 Plan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6(c)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Board Recommendation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3(b)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Disclosure Schedule</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Grant Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6(f)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Lockup Agreement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Material Contract</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Net Cash Calculation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Net Cash Schedule</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    SEC Documents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7(a)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Term</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS
    Stock Plans</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6(c)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger
    Consideration</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5(a)(ii)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger
    Sub</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHSA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plans</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy
    Policies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy
    Statement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1(a)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
    Company Shareholder Vote</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Swap</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Swap Agreement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surviving
    Corporation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
<U>Other Definitional and Interpretative Provisions</U>. The words &ldquo;hereof,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo;
and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this
Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation
hereof. References to Sections, Exhibits and Schedules are to Sections, Exhibits and Schedules of this Agreement unless otherwise specified.
Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement.
Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall
include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall
include masculine and feminine gender. Whenever the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; or &ldquo;including&rdquo; are
used in this Agreement, they shall be deemed to be followed by the words &ldquo;without limitation,&rdquo; whether or not they are in
fact followed by those words or words of like import. The word &ldquo;or&rdquo; is not exclusive. &ldquo;Writing,&rdquo; &ldquo;written&rdquo;
and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References
to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with
the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any
statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof,
substituted, from time to time. References to &ldquo;$&rdquo; and &ldquo;dollars&rdquo; are to the currency of the United States. All
accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless
otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through
and including, respectively. All references to &ldquo;days&rdquo; shall be to calendar days unless otherwise indicated as a &ldquo;Business
Day.&rdquo; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement
(including for purposes of &ldquo;Business Day&rdquo; and for hours in a day or Business Day), the time at which a thing, occurrence
or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of
construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or
interpretation of this Agreement. The Parties agree that the Company Disclosure Schedule or MEDS Disclosure Schedule shall be arranged
in sections and subsections corresponding to the numbered and lettered sections and subsections contained in <U>Section 3</U> or <U>Section
4</U>, respectively. The disclosures in any section or subsection of the Company Disclosure Schedule or the MEDS Disclosure Schedule
shall only qualify other sections and subsections in <U>Section 3</U> or <U>Section 4</U>, respectively, to the extent it is readily
apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The words &ldquo;delivered&rdquo;
or &ldquo;made available&rdquo; mean, with respect to any documentation, (a) that prior to 5:00 p.m. (New York City time) on the date
that is two days prior to the date of this Agreement, a copy of such material has been posted to and made available by a Party to the
other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated
Transactions or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic
mail or in hard copy form prior to the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2. <U>Description of Transaction</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">2.1 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Merger</U>. Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be merged
with and into the Company, and the separate existence of Merger Sub shall cease. The Company will continue as the surviving corporation
in the Merger (the &ldquo;<B>Surviving Corporation</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Effects of the Merger</U>. The Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL.
As a result of the Merger, the Company will become a wholly owned subsidiary of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 <U>Closing;
Effective Time</U>. Unless this Agreement is earlier terminated pursuant to the provisions of <U>Section 10.1</U>, and subject to
the satisfaction or waiver of the conditions set forth in <U>Section 6</U>, <U>Section 7</U> and <U>Section 8</U>, the consummation
of the Merger (the &ldquo;<B>Closing</B>&rdquo;) shall take place remotely, on the second Business Day following the satisfaction or
waiver of the last to be satisfied or waived of the conditions set forth in <U>Section 7</U>, <U>Section 8</U> and <U>Section 9</U>,
other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of
each of such conditions, or at such other time, date and place as MEDS and the Company may mutually agree in writing. The date on
which the Closing actually takes place is referred to as the &ldquo;<B>Closing Date</B>.&rdquo; At the Closing, the Parties shall
cause the Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of
merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance as agreed to by the
Parties (the &ldquo;<B>Certificate of Merger</B>&rdquo;). The Merger shall become effective at the time of the filing of such
Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such
Certificate of Merger with the consent of MEDS and the Company (the time as of which the Merger becomes effective being referred to
as the &ldquo;<B>Effective Time</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">2.4 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organizational
Documents; Directors and Officers.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;the
certificate of incorporation of the Surviving Corporation shall be amended and restated in the Merger to read as set forth on <U>Exhibit
A</U> to the Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;the
certificate of incorporation of MEDS shall be identical to the certificate of incorporation of MEDS immediately prior to the Effective
Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; provided, however, that at the Effective
Time, MEDS shall file an amendment to its certificate of incorporation to change the name of MEDS to a name to be agreed upon by MEDS
and the Company and effect the Nasdaq Reverse Split (to the extent applicable and necessary);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;the
bylaws of the Surviving Corporation shall be identical to the bylaws of Merger Sub as in effect immediately prior to the Effective Time,
until thereafter amended as provided by the DGCL and such bylaws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;the
directors and officers of MEDS, each to hold office in accordance with the certificate of incorporation and bylaws of MEDS; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;the
manager of the Surviving Corporation office, in accordance with the certificate of incorporation and bylaws of the Surviving Corporation,
shall be MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 <U>MEDS
Rights</U>. Effective one (1) Business Day immediately prior to the Closing Date (such date, the &ldquo;<B>MEDS Rights Record
Date</B>&rdquo;), MEDS shall issue to the shareholders of MEDS as determined as of the MEDS Rights Record Date including the
Independent Directors in connection with the Independent Director Consideration whether or not the Independent Director
Consideration has been issued or vested before the MEDS Rights Records Date (collectively, the &ldquo;<B>MEDS Rights
Shareholders</B>&rdquo;) a non-transferrable right to receive one share of MEDS Common Stock at no cost (the &ldquo;<B>MEDS
Rights</B>&rdquo;), with seven (7) MEDS Rights issued per share of MEDS Common Stock held as of the MEDS Rights Record Date. The
MEDS Rights will be issued to the MEDS Rights Shareholders upon the condition that each MEDS Rights Shareholder countersigns and
delivers to MEDS a Shareholder Registration Rights Agreement in the form to be agreed upon between MEDS and the Company and their
counsel, which will include agreement of such MEDS Rights Shareholder not to exercise any MEDS Right until the issuable shares of
MEDS Common Stock for the MEDS Rights are duly registered in accordance with the Exchange Act and other applicable Laws (in which
case MEDS shall file the applicable registration statement as soon as reasonably practicable after the filing of MEDS&rsquo;
Quarterly Report on Form 10-Q as of the date of the end of first fiscal quarter following the Closing Date) or until receipt of
written confirmation from MEDS that no such registration is required and that such MEDS Rights Shareholder shall not transfer such
MEDS Common Stock obtained in connection with the MEDS Shareholders Registration Rights Agreement until the date that is one (1)
year following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">2.6 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion
of Company Equity Securities.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
At the Effective Time, by virtue of the Merger and without any further action on the part of MEDS, Merger Sub, the Company or any
equity holder of the Company or MEDS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any Company Common Shares held as treasury stock immediately prior to the Effective Time shall be canceled and retired and shall
cease to exist, and no consideration shall be delivered in exchange therefor; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
collectively, the Company&rsquo;s shareholders shall be entitled to an aggregate of 30,821,941 shares of MEDS Common Stock at $7.30
per share, which is comprised of (i) 136,441 shares of MEDS Common Stock, representing 19.99% of the total issued and outstanding
MEDS Common Stock at Closing, and (ii) 306,855 shares issued as a new class of MEDS non-voting convertible preferred stock with a
conversion ratio of 100 (the &ldquo;<B>Merger Consideration</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If any Company Common Shares outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option
or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then
the shares of MEDS Common Stock issued in exchange for such Company Common Shares will to the same extent be unvested and subject to
the same repurchase option or risk of forfeiture, and such shares of MEDS Common Stock shall accordingly be marked with appropriate
legends. The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, MEDS is
entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other
agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No fractional shares of MEDS Common Stock shall be issued in connection with the Merger, and no certificates or scrip for any such
fractional shares shall be issued, with no cash being paid for any fractional share eliminated by such rounding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All MEDS Options outstanding immediately prior to the Effective Time under the Company Equity Plans (if any) shall be treated in
accordance with <U>Section 6.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Each share of common stock, $0.01 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time
shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.01 par value
per share, of the Surviving Corporation. Each stock certificate of Merger Sub evidencing ownership of any such shares shall, as of
the Effective Time, evidence ownership of such shares of common stock of the Surviving Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If, between the date of this Agreement and the Effective Time, the outstanding Company Common Shares or MEDS Common Stock shall have
been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend,
subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not
previously been taken into account in calculating the Company Merger Shares), combination or exchange of shares or other like
change, the Company Merger Shares shall, to the extent necessary, be equitably adjusted to reflect such change to the extent
necessary to provide the holders of Company Common Shares and MEDS Common Stock with the same economic effect as contemplated by
this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of
shares or other like change; <U>provided</U>, <U>however</U>, that nothing herein will be construed to permit the Company or MEDS to
take any action with respect to Company Common Shares or MEDS Common Stock, respectively, that is prohibited or not expressly
permitted by the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
 <U>Closing of the Company&rsquo;s Transfer Books</U>. At the Effective Time: (a) all Company Capital Stock outstanding immediately prior
to the Effective Time shall be treated in accordance with <U>Section 2.6(a)</U>, and all holders of certificates representing Company
Common Shares that were outstanding immediately prior to the Effective Time shall cease to have any rights as equity holders of the Company
and (b) the stock transfer books of the Company shall be closed with respect to all Company Common Shares outstanding immediately prior
to the Effective Time. No further transfer of any such Company Common Shares shall be made on such stock transfer books after the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">2.8 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Surrender
of Company Common Shares.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, MEDS and the Company shall jointly select a reputable bank, transfer agent or trust company to act
as exchange agent in the Merger (the &ldquo;<B>Exchange Agent</B>&rdquo;). At the Effective Time, MEDS shall deposit with the
Exchange Agent evidence of book-entry shares representing the shares of MEDS Common Stock issuable pursuant to <U>Section 2.6(a)</U>
in exchange for Company Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Promptly after the Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of
Company Common Shares that were converted into the right to receive a portion of the Merger Consideration: (i) a letter of
transmittal in customary form and containing such provisions as MEDS may specify (including a provision confirming that delivery of
Company Stock Certificates shall be effected, and risk of loss and title to Company Stock Certificates shall pass, only upon
delivery of such Company Stock Certificates, if applicable, to the Exchange Agent) and (ii) instructions for effecting the surrender
of Company Stock Certificates, if applicable, in exchange for book-entry shares of MEDS Common Stock. Upon surrender of a Company
Stock Certificate to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents
as may be required by the Exchange Agent or MEDS: (A) the holder of such Company Stock Certificate shall be entitled to receive in
exchange therefor book-entry shares representing their portion of the Merger Consideration (in a number of whole shares of MEDS
Common Stock) that such holder has the right to receive pursuant to the provisions of <U>Section 2.6(a)</U> and (B) the Company
Stock Certificate so surrendered shall be canceled. Until surrendered as contemplated by this <U>Section 2.8(b)</U>, each Company
Stock Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive book-entry shares of
MEDS Common Stock representing their portion of the Merger Consideration. If any Company Stock Certificate shall have been lost,
stolen or destroyed, MEDS may, in its discretion and as a condition precedent to the delivery of any shares of MEDS Common Stock,
require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to
such Company Stock Certificate and post a bond indemnifying MEDS against any claim suffered by MEDS related to the lost, stolen or
destroyed Company Stock Certificate or any MEDS Common Stock issued in exchange therefor as MEDS may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No dividends or other distributions declared or made with respect to MEDS Common Stock with a record date after the Effective Time
shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of MEDS Common Stock that such
holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate, if applicable, or
provides an affidavit of loss or destruction in lieu thereof in accordance with this <U>Section 2.8</U> (at which time such holder
shall be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to receive all such dividends
and distributions, without interest).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Any shares of MEDS Common Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates
as of the date that is 180 days after the Closing Date shall be delivered to MEDS upon demand, and any holders of Company Stock
Certificates who have not theretofore surrendered their Company Stock Certificates in accordance with this <U>Section 2.8</U> shall
thereafter look only to MEDS for satisfaction of their claims for MEDS Common Stock and any dividends or distributions with respect
to shares of MEDS Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
No Party shall be liable to any holder of any Company Stock Certificate or to any other Person with respect to any shares of MEDS
Common Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant
to any applicable abandoned property Law, escheat Law or similar Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9
<U>Calculation of Company Report</U>. No later than fourteen (14) days after the date of this Agreement, the Company will deliver to
MEDS a report (the &ldquo;<B>Company Valuation Report</B>&rdquo;) setting forth, in reasonable detail, the Company Valuation as of immediately
prior to the Closing prepared by The Mentor Group and certified by the Company Board. The Company shall make available to MEDS, as requested
by MEDS, the work papers and back-up materials used or useful in preparing the Company Valuation Report and, if requested by MEDS, the
Company&rsquo;s accountants and counsel upon notice from MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">2.10 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
Action</U>. If, at any time after the Effective Time, any further action is determined by the Surviving Corporation to be necessary
or desirable to carry out the purposes of this Agreement, the Transaction Documents, the Contemplated Transactions or to vest the
Surviving Corporation with full right, title and possession of and to all rights and property of the Company, then the officers and
directors of the Surviving Corporation shall be fully authorized, and shall use their and its best efforts (in the name of the
Company, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">2.11 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tax
Consequences</U>. Subject to the expiration of the Due Diligence Period, the Parties acknowledge and agree that, for U.S. federal (and
applicable state and local) income tax purposes, the Merger is intended to qualify as a reorganization within the meaning of Section
368(a) of the Code. The Parties adopt this Agreement as a &ldquo;plan of reorganization&rdquo; within the meaning of Treasury Regulations
Sections 1.368-2(g) and 1.368-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12 <U>
Withholding</U>. Each of the Exchange Agent, MEDS and the Surviving Corporation shall be entitled to deduct and withhold from any
consideration deliverable pursuant to this Agreement such amounts as are required to be deducted or withheld from such consideration
under the Code or under any other applicable Law. To the extent such amounts are so deducted or withheld and remitted to the
appropriate Taxing Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person
to whom such amounts would otherwise have been paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3. <U>Representations and Warranties of the Company.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to <U>Section 3</U>, except as set forth in the written disclosure schedule delivered by the Company to MEDS (the &ldquo;<B>Company Disclosure
Schedule</B>&rdquo;), the Company represents and warrants to MEDS and Merger Sub as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.1 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Due
Organization; Foreign Person Status; Subsidiaries</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;The
Company and each Subsidiary is a limited liability company or other organization duly incorporated or formed, validly existing and in
good standing under the laws of the jurisdiction of its incorporation or formation and has the requisite corporate or limited liability
company power and authority and all necessary governmental approvals to own, lease and operate its properties and to carry on its business
as it is now being conducted. The Company and each Subsidiary is duly qualified or licensed as a foreign organization to do business,
and is in good standing, in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of
its business makes such qualification or licensing necessary, except for such failures to be so qualified or licensed and in good standing
that would not individually or in the aggregate expected to have a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;The
Company is not a &ldquo;foreign person&rdquo; or a &ldquo;foreign entity,&rdquo; as defined in Section 721 of the Defense Production
Act of 1950, as amended, including all implementing regulations thereof (the &ldquo;<B>DPA</B>&rdquo;). The Company is not controlled
by a &ldquo;foreign person,&rdquo; as defined in the DPA. The Company does not permit any foreign person affiliated with the Company,
whether affiliated as a limited partner or otherwise, to obtain through the Company any of the following with respect to the Company:
(i) access to any &ldquo;material nonpublic technical information&rdquo; (as defined in the DPA) in the possession of the Company; (ii)
membership or observer rights on the Board of Directors or equivalent governing body of the Company or the right to nominate an individual
to a position on the Board of Directors or equivalent governing body of the Company; (iii) any involvement, other than through the voting
of shares, in the substantive decision-making of the Company regarding (x) the use, development, acquisition, or release of any &ldquo;critical
technology&rdquo; (as defined in the DPA), (y) the use, development, acquisition, safekeeping, or release of &ldquo;sensitive personal
data&rdquo; (as defined in the DPA) of U.S. citizens maintained or collected by the Company, or (z) the management, operation, manufacture,
or supply of &ldquo;covered investment critical infrastructure&rdquo; (as defined in the DPA); or (iv) &ldquo;control&rdquo; of the Company
(as defined in the DPA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.2 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organizational
Documents</U>. The Company has prior to the date of this Agreement made available to MEDS in the Virtual Data Room a complete and
correct copy of Organizational Documents and the organizational documents of each Subsidiary, each as amended to date. Such
organizational documents are in full force and effect. Neither the Company nor any Subsidiary is in violation of any of the
provisions of its organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.3 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authority;
Binding Nature of Agreement</U>. The Company has all necessary power and authority to enter into and to perform its obligations under
this Agreement and to consummate the Contemplated Transactions. The Company Board has (i) determined that the Contemplated Transactions
are fair to, advisable and in the best interests of the Company and its equity holders, (ii) approved and declared advisable this Agreement
and the Contemplated Transactions and (iii) equity holders to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the equity holders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This
Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by MEDS and
Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its
terms, subject to the Enforceability Exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.4 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vote
Required</U>. The affirmative vote of the holders of all of the Company Common Shares each outstanding on the record date for the Company
Shareholder Written Consent and entitled to vote thereon, voting as a single class (the &ldquo;<B>Required Company Shareholder Vote</B>&rdquo;),
is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and the
other Transaction Documents and approve the Contemplated Transactions. No interest in the Company is subject to any appraisal or dissenters
rights in connection with the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.5 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Contravention;
Consents.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;Subject
to compliance with the HSR Act and any foreign antitrust Law, obtaining the Required Company Shareholder Vote and the filing of the Certificate
of Merger required by the DGCL, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation
of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;contravene,
conflict with or result in a violation of any of the provisions of the Company&rsquo;s Organizational Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;contravene,
conflict with or result in a violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated
Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned
or used by the Company, is subject;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;contravene,
conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke,
withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;contravene,
conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or
give any Person the right to: (A) declare a default or exercise any remedy under any Company Material Contract, (B) any payment, rebate,
chargeback, penalty or change in delivery schedule under any Company Material Contract, (C) accelerate the maturity or performance of
any Company Material Contract or (D) cancel, terminate or modify any term of any Company Material Contract, except in the case of any
nonmaterial breach, default, penalty or modification; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;result
in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted
Encumbrances).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;Except
for (i) the Required Company Shareholder Vote, (ii) the filing of the Certificate of Merger with the Secretary of State of the State
of Delaware pursuant to the DGCL, (iii) any required filings under the HSR Act and any foreign antitrust Law, and (iv) such consents,
waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state
securities laws, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent
from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated
Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;The
Company Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained
in Section 203 of the DGCL, to the extent applicable to the Company, are, and will be, inapplicable to the execution, delivery and performance
of this Agreement and the Company Shareholder Support Agreements and to the consummation of the Contemplated Transactions. No other state
takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Shareholder Support Agreements
or any of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6&nbsp;<U>Capitalization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Section
3.6(a)</U> of the Company Disclosure Schedule sets forth a true and complete list of all the Equity Interests issued or outstanding in
the Company, and there are no Equity Interests issued or outstanding in the Company except as set forth thereon. On the Closing Date,
each owner of Company Equity Securities is an &ldquo;accredited investor&rdquo; as defined in Rule 501 of Regulation D promulgated under
the Securities Act. All such Equity Interests are held by the holders thereof free and clear of all liens, options, rights of first refusal
and limitations on the Company&rsquo;s voting or transfer rights other than transfer restrictions under applicable securities Laws and
Organizational Documents. All such Equity Interests are validly issued, fully paid and non-assessable and have been issued and granted
in compliance in all respects with (i) applicable securities Laws and other applicable Law and (ii) all preemptive rights and other requirements
set forth in applicable contracts to which the Company is a party and Organizational Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;A
true and complete list of all the Subsidiaries, together with the jurisdiction of incorporation of each Subsidiary and the percentage
of the outstanding Equity Interests of each Subsidiary owned by the Company and each other Subsidiary, is set forth in <U>Section 3.6(b)
</U>of the Company Disclosure Schedule, and there are no Equity Interests issued or outstanding in any Subsidiary except as set forth
thereon. All such Equity Interests are validly issued, fully paid and non-assessable have been issued and granted in compliance in all
respects with (i) applicable securities Laws and other applicable Law and (ii) all preemptive rights and other requirements set forth
in applicable contracts to which the Company is a party and Organizational Documents. Each outstanding Equity Interest of each Subsidiary
is owned 100% by the Company or another Subsidiary free and clear of all Liens, options, rights of first refusal and limitations on the
Company&rsquo;s or any Subsidiary&rsquo;s voting or transfer rights other than transfer restrictions under applicable securities Laws
and their respective organizational documents. The Company does not directly or indirectly own, and has never owned, any Equity Interest
in, or any interest convertible into or exchangeable or exercisable for any Equity Interest in, any other corporation, partnership, joint
venture or business association or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;Except
as set forth in <U>Section 3.6(c)</U> of the Company Disclosure Schedule, there are no options, warrants, preemptive rights, calls, convertible
securities, conversion rights or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued
Equity Interests of the Company or any Subsidiary or obligating the Company or any Subsidiary to issue or sell any shares of Equity Interests
of, or other equity or voting interests in, or any securities convertible into or exchangeable or exercisable for Equity Interests in,
the Company or any Subsidiary. Neither the Company nor any Subsidiary is a party to, or otherwise bound by, and neither the Company nor
any Subsidiary has granted, any equity appreciation rights, participations, phantom equity, restricted shares, restricted share units,
performance shares, contingent value rights or similar securities or rights that are derivative of, or provide economic benefits based,
directly or indirectly, on the value or price of, any Equity Interests in the Company or any Subsidiary. There are no voting trusts,
voting agreements, proxies, shareholder agreements or other agreements to which the Company or any Subsidiary is a party, or to the Company&rsquo;s
knowledge, among any holder of Company Common Shares or any other Equity Interests of the Company or any Subsidiary to which the Company
or any Subsidiary is not a party, with respect to the voting or transfer of the Company Common Shares or any of the Equity Interests
or other securities of the Company. The Company does not own any Equity Interests in any person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;There
are no outstanding contractual obligations of the Company or any Subsidiary to repurchase, redeem or otherwise acquire any Equity Interests
of the Company or any Subsidiary or to provide funds to or make any investment (in the form of a loan, capital contribution or otherwise)
in any person other than a Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<U>Section
3.6(e)</U> of the Company Disclosure Schedule sets forth the following information with respect to each outstanding unexercised Company
Option: (i) the name of the Company Option holder; (ii) the Company Equity Plan (if any) pursuant to which such Company Option was granted;
(iii) the number of Company Common Shares subject to such Company Option; (iv) the exercise price of such Company Option; (v) the date
on which such Company Option was granted; (vi) the number of Company Common Shares subject to the Company Option that are vested and
exercisable; and (vii) the date on which the Company Option expires. The Company has made available to MEDS in the Virtual Data Room
accurate and complete copies of each Company Equity Plan (if any) pursuant to which the Company has granted the Company Options that
are currently outstanding and the form of all award agreements evidencing such Company Options and specifying the vesting schedule for
such Company Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;<U>Section
3.6(f)</U> of the Company Disclosure Schedule sets forth the following information with respect to each outstanding Equity Interest granted
under a Company Equity Plan (if any) (other than the Equity Interests set forth in <U>Section 4.03(e)</U> and <U>4.03(f)</U> of the Company
Disclosure Schedule): (i) the name of the Equity Interest holder; (ii) the Company Equity Plan pursuant to which such Equity Interest
was granted; (iii) the number of Company Common Shares subject to such Equity Interest; (iv) the exercise price or hurdle price of such
Equity Interest (if applicable); (v) the date on which such Equity Interest was granted; (vi) the number of Company Common Shares subject
to the Equity Interest that are vested; (vii) the vesting schedule for such Equity Interest, and (viii) the date on which the Equity
Interest expires. The Company has made available to MEDS in the Virtual Data Room accurate and complete copies of each Company Equity
Plan pursuant to which the Company has granted Equity Interests that are currently outstanding and the form of all award agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.7 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial
Statements</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;The
Company has made available to MEDS in the Virtual Data Room true and complete copies of (i) the consolidated audited balance sheet of
the Company and its Subsidiaries as of December 31, 2021 and December 31, 2022, and the related audited consolidated statements of operations,
cash flows and changes in equity holders&rsquo; equity of the Company and its Subsidiaries for each of the years then ended, and the
unaudited balance sheet of the Company and its Subsidiaries as of for the three months ended March 31, 2023 and (ii) the related audited
consolidated statements of operations, cash flows and changes in equity holders&rsquo; equity of the Company and its Subsidiaries for
the three months then ended (collectively, the &ldquo;<B>Company Financials</B>&rdquo;), which are attached as <U>Section 3.7(a)</U>
of the Company Disclosure Schedule. The Company Financials described in clause (i) above (x) were prepared in accordance with GAAP and
(y) fairly present, in all respects, the financial position of the Company and its Subsidiaries as of the respective dates thereof and
the results of operations and cash flows of the Company and its Subsidiaries for the periods covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;Except
as and to the extent set forth on the Company Financials as of the Balance Sheet Date, the Company does not have any other liabilities
or obligations of any nature (whether accrued, absolute, contingent or otherwise), except for: (i) liabilities that were incurred in
the Ordinary Course of Business since the Balance Sheet Date (and in any event do not relate to breach of contract, tort or noncompliance
with Law) or (ii) such other liabilities and obligations which are not, individually or in the aggregate, be expected to have a Company
Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;Except
as set forth on <U>Section 3.7(c)</U> of the Company Disclosure Schedule, the Company and the Subsidiaries do not have any (i) indebtedness
for borrowed money or indebtedness issued in substitution or exchange for borrowed money, or (ii) indebtedness evidenced by any note,
bond, debenture or other debt security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;Since
January 1, 2020, (i) neither the Company nor any of its Subsidiaries nor any director, officer, employee, auditor, accountant or Representative
of the Company or any Subsidiary, has received or otherwise had or obtained knowledge of any complaint, allegation, assertion or claim,
whether written or, to the Knowledge of the Company, oral, regarding the accounting or auditing practices, procedures, methodologies
or methods of the Company or any of its Subsidiaries or their respective internal accounting controls, including any such complaint,
allegation, assertion or claim that the Company or any of its Subsidiaries has engaged in questionable accounting or auditing practices
and (ii) there have been no internal investigations regarding accounting or revenue recognition discussed with, reviewed by or initiated
at the direction of the chief executive officer, chief financial officer, general counsel, the Company Board or any committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<U>Absence of Changes</U>. Since January 1, 2020, and on and prior to the date of this Agreement, except as set forth on <U>Section 3.8
</U>of the Company Disclosure Schedule or as expressly contemplated by this Agreement, (a) the Company and the Subsidiaries have conducted
their respective businesses in all respects in the Ordinary Course of Business, (b) the Company and the Subsidiaries have not sold, assigned,
transferred, permitted to lapse, abandoned, or otherwise disposed of any right, title, or interest in or to any of their respective assets
(including Company IP Rights) other than revocable non-exclusive licenses (or sublicenses) of Company IP Rights granted in the ordinary
course of business, (c) there has not been a Company Material Adverse Effect and (d) none of the Company or any Subsidiary has taken
any action that, if taken after the date of this Agreement, would constitute a breach of any of the covenants set forth in <U>Section
5.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.9 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Real
Property; Title to Assets.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;The
Company and its Subsidiaries do not own, and have never owned, any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Section
3.9(b)</U> of the Company Disclosure Schedule lists the street address (and, if applicable, the suite numbers(s)) of each parcel of Leased
Real Property, and sets forth a list of each lease, sublease, and license pursuant to which the Company or any Subsidiary leases, subleases
or licenses any real property (each, a &ldquo;<B>Lease</B>&rdquo;), with the name of each other party thereto and the date of each Lease
in connection therewith, and each amendment thereto (collectively, the &ldquo;<B>Lease Documents</B>&rdquo;). True, correct and complete
copies of all Lease Documents have been made available to MEDS in the Virtual Data Room. Except as set forth in <U>Section 3.9(b)</U>
of the Company Disclosure Schedule, (i) there are no leases, subleases, sublicenses, concessions or other contracts granting to any person
other than the applicable Company or Subsidiaries specified as the tenant in the applicable Lease Document the right to use or occupy
all or any portion of the Leased Real Property, (ii) all such Leases are in full force and effect, are valid and enforceable in accordance
with their respective terms, subject to the Enforceability Exceptions, and there is not, under any of such Leases, any existing default
or event of default (or event which, with notice or lapse of time, or both, would constitute a default) by the Company or any Subsidiary
or, to the Company&rsquo;s knowledge, by the other party to such Leases, and (iii) there are no disputes with respect to any Lease Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;There
are no contractual or legal restrictions that preclude or restrict the ability of the Company or any Subsidiary to use any Leased Real
Property for the purposes for which it is currently being, or is intended to be, used, except as would not be expected to have a Company
Material Adverse Effect. The Leased Real Property, and the improvements thereon, are in compliance in all respects with all applicable
Laws, in good repair and in good condition (ordinary wear and tear excepted), and there are no patent or latent defects or adverse physical
conditions other than those that would not be expected to have a Company Material Adverse Effect. In the past three years, there has
not been any interruption in the delivery of adequate service of any utilities required in the operation of the business of the Company
or any Subsidiary currently conducted on the Leased Real Property and neither the Company nor any Subsidiary has experienced any disruptions
to its operations arising out of any recurring loss of electrical power, flooding, limitations to access to public sewer and water or
restrictions on septic service at the Leased Real Property, except as would not be expected to have a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;Each
of the Company and the Subsidiaries has legal and valid title to, or, in the case of Leased Real Property and assets, valid leasehold
or subleasehold interests in, all of its properties and assets, tangible and intangible, real, personal and mixed, used or held for use
in its business, free and clear of all liens other than Permitted Encumbrances, except as would not be expected to have a Company Material
Adverse Effect. The Company Leased Real Property constitutes all of the real property interests owned, used or held for use in the conduct
of the business of the Company and the Subsidiaries consistent with past practice and is sufficient in all respects for the continued
conduct and operation of such business, consistent with past practice and as presently proposed to be conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;The
assets owned by the Company and the Subsidiaries (including without limitation the Leased Real Property) are all of the assets used by
the Company and the Subsidiaries with respect to the business of the Company and the Subsidiaries as conducted in the ordinary course
of business, and such assets comprise all of the assets and rights necessary for the ownership and operation of the assets of the Company
and the Subsidiaries and to carry out the business of the Company and the Subsidiaries substantially in the same manner as of the date
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.10 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual
Property.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Section
3.10(a)</U> of the Company Disclosure Schedule sets forth a true and complete list of all (i) Company Registered IP, and (ii) Company
IP Rights that are licensed to the Company or any of the Subsidiaries, specifying as to each such item, as applicable, (w) the record
owner of such item, (x) the jurisdictions in which such item has been issued, registered or filed, (y) the issuance, registration or
application date, as applicable, for such item, and (z) the issuance, registration or application number, as applicable, for such item.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;All
fees and filings necessary as of the date of this Agreement to obtain or maintain any application or registration, issuance or grant
of any Company Registered IP and, to the Company&rsquo;s knowledge, Company IP Rights, have been timely submitted to the relevant intellectual
property office or Governmental Authority and Internet domain name registrars or social media platforms, as applicable. No item of the
Company Registered IP or, to the Company&rsquo;s knowledge, Company IP Rights has been unintentionally abandoned or cancelled. Except
as set forth in <U>Section 3.10(b)</U> of the Company Disclosure Schedules, as of the date of this Agreement, the Company Registered
IP and, to the Company&rsquo;s knowledge, Company IP Rights are not the subject of any pending Legal Proceedings, including litigation,
interference, re-examination, <I>inter parties</I> review, reissue, opposition, nullity or cancellation proceedings , or any other similar
challenges worldwide, and, to the Company&rsquo;s knowledge, no such Legal Proceedings are threatened by any Governmental Authority or
any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;Except
as set forth in <U>Section 3.10(c)</U> of the Company Disclosure Schedules, the Company and/or the Subsidiaries exclusively own all right,
title and interest in and to all Company Registered IP and owned Company IP Rights, free and clear of all liens (other than Permitted
Encumbrances) and hold all right, title and interest in and to all of the Company&rsquo;s or the applicable Subsidiary&rsquo;s rights
under all licensed Company IP Rights free and clear of any lien (other than Permitted Encumbrances). For all patents included in the
Company Registered IP, each inventor listed on the patent has assigned his or her rights to the Company or the relevant Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;The
Company Registered IP and the Company IP Rights constitute all of the Intellectual Property rights that are used in, held for use, or
necessary to enable the Company and its Subsidiaries to conduct the Company&rsquo;s and Subsidiaries&rsquo; business as currently conducted
or as contemplated to be conducted as of the date hereof. All Company Registered IP is subsisting, and, to the knowledge of the Company,
valid, and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;Except
as set forth on <U>Section 3.10(e)</U> of the Company Disclosure Schedule, all Persons who independently or jointly contributed to or
otherwise participated in the authorship, invention, creation, improvement, modification or development of any Company Registered IP
or owned Company IP Rights have assigned to the Company or the relevant Subsidiary, as applicable, all of their rights, title, and interest
in and to such Company Registered IP or owned Company IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;The
Company and the Subsidiaries have taken all steps to timely obtain, maintain, protect, and enforce the Company Registered IP and owned
Company IP Rights, and to safeguard and maintain the secrecy of any trade secrets, confidential know-how and other confidential information
owned by or licensed to the Company and the Subsidiaries, including, but not limited to, placing any employee, worker, independent contractor,
officer or other representative of the Company having access to any of the foregoing under sufficient written confidentiality terms.
Without limiting the foregoing, the Company and the Subsidiaries have not disclosed any trade secrets, confidential know-how or confidential
information to any other Person unless such disclosure was under an appropriate written non-disclosure agreement containing appropriate
limitations on use, reproduction and disclosure or was otherwise made subject to an appropriate duty of confidence. Except as set forth
in <U>Section 3.10(f)</U> of the Company Disclosure Schedule, there has been no violation or unauthorized access to or disclosure of
any trade secrets, confidential know-how or confidential information of or in the possession of the Company or any of the Subsidiaries,
or of any written obligations with respect to such, except as would not be expected to have a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;None
of the Company Registered IP, owned Company IP Rights or, to the Company&rsquo;s knowledge, licensed Company IP Rights is subject to
any outstanding writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree entered, issued
or rendered by any Governmental Authority that restricts in any manner the use, sale, transfer, licensing or exploitation thereof by
the Company and the Subsidiaries or affects the validity, use or enforceability of any such Company Registered IP or Company IP Rights.
The consummation of the Contemplated Transactions will not alter, encumber, impair or extinguish any Company Registered IP or owned Company
IP Rights or the Company&rsquo;s or any applicable Subsidiary&rsquo;s rights under any Company IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;The
operation of the business of the Company and the Subsidiaries (including the Products) has not and does not infringe, misappropriate
or violate any Intellectual Property rights of any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;In
the past three (3) years, there has been no Legal Proceeding pending against the Company or any of the Subsidiaries nor has the Company
or any of the Subsidiaries received any written communications (i) alleging that the Company or any of the Subsidiaries has infringed,
misappropriated or otherwise violated any Intellectual Property rights of any other Person, (ii) challenging the validity, enforceability,
use or exclusive ownership of any Company Registered IP or owned Company IP Rights, or (iii) inviting the Company or any of the Subsidiaries
to take a license under any patent or any other Intellectual Property, or consider the applicability of any patents or any other Intellectual
Property to any products or services of the Company or any of the Subsidiaries or to the conduct of the Company&rsquo;s business, except
as set forth in <U>Section 3.10(i)</U> of the Company Disclosure Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;No
Person is infringing, misappropriating or otherwise violating any Company Registered IP or Company IP Rights. Except as set forth in
<U>Section 3.10(j)</U> of the Company Disclosure Schedule, for the past three (3) years, neither the Company nor any of the Subsidiaries
has threatened or made any claim against any Person alleging any infringement, misappropriation or other violation of any Company Registered
IP or Company IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;The
Company and Subsidiaries have a valid and enforceable license to use all licensed Company IP Rights applicable to each such entity. Company
and each applicable Subsidiary has performed all obligations imposed on it in the agreements and contracts concerning licensed Company
IP Rights, has made all payments required to date under such agreements and contracts, and is not, nor, to the knowledge of the Company
and Subsidiaries, is any other party thereto, in breach or default thereunder, nor, to the knowledge of the Company and Subsidiaries,
has any event occurred that with notice or lapse of time or both would constitute a default thereunder. The consummation of any of the
transactions contemplated by this Agreement will not result in the breach, modification, cancellation, termination, suspension of, or
acceleration of any payments with respect to, nor require any third-party consent, permission or authorization regarding, any contract
or agreement providing for the license or other use of Company Registered IP or Company IP Rights. Following the Closing, the Company
and Subsidiaries shall be permitted to exercise all of Company or the applicable Subsidiaries&rsquo; rights under such agreements and
contracts to the same extent that the Company and Subsidiaries would have been able to exercise had the transactions contemplated by
this Agreement not occurred, without the payment of any additional amounts or consideration other than ongoing fees, royalties or payments
which the Company or Subsidiaries would otherwise be required to pay in the absence of such transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;The
Company and the Subsidiaries own, or have obtained, possess and are in compliance with valid licenses to use, all of the Software present
on the computers and other software-enabled electronic devices that they own or lease or that are otherwise under the control of the
Company and the Subsidiaries and used by them in connection with the Company&rsquo;s and the Subsidiaries&rsquo; business, except as
is not and would not be expected to have a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;<U>Section
3.10(m)</U> of the Company Disclosure Schedule contains a true and complete list of any and all Company Registered IP and Company IP
Rights that were created, developed or reduced to practice, or is being created, developed or reduced to practice, (i) pursuant to, or
in connection with, any agreement with any Governmental Authority or Governmental Authority-affiliated entity, or university, college
or other educational institution, or (ii) using any funding or facilities of any Governmental Authority or Governmental Authority-affiliated
entity, or university, college or other educational institution (collectively, &ldquo;<B>Government Funded IP</B>&rdquo;). Except as
is not and would not be expected to have a Company Material Adverse Effect, the Company and the Subsidiaries, and to the Company&rsquo;s
knowledge, the applicable licensors of licensed Company IP Rights, have taken any and all actions necessary to obtain, secure, maintain,
enforce and protect the Company&rsquo;s or any applicable Subsidiary&rsquo;s right, title and interest in, to and under all Government
Funded IP, and the Company and the Subsidiaries, and to the Company&rsquo;s knowledge the applicable licensors of Company IP Rights,
have complied with any and all any Intellectual Property rights disclosure and/or licensing obligations under any applicable contract
referenced in clause (i) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;The
Company and the Subsidiaries maintain disaster recovery, business continuity and risk assessment plans, procedures and facilities, including
by implementing systems and procedures. To the Company&rsquo;s knowledge, since January 1, 2019, there has not been any failure with
respect to any of the Business Systems that has not been remedied or replaced in all respects. The Company and each of the Subsidiaries
have purchased a sufficient number of licenses for the operation of their Business Systems that constitute Company IP Rights as currently
conducted or as contemplated to be conducted as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;The
Company and each of the Subsidiaries currently and since January 1, 2019, comply with and have complied with (i) all Privacy Laws applicable
to the Company or a Subsidiary, (ii) any applicable publicly posted privacy policies of the Company and/or the Subsidiary, respectively,
concerning the collection, dissemination, storage or use of Personal Information, including any policies or disclosures posted to websites
or other media maintained or published by the Company or a Subsidiary, (iii) PCI DSS, and (iv) all contractual commitments that the Company
or any Subsidiary has entered into or is otherwise bound with respect to privacy and/or data security; (collectively, the &ldquo;<B>Data
Security Requirements</B>&rdquo;). The Company and the Subsidiaries have each implemented physical, technical, organizational and administrative
data security safeguards designed to protect the security and integrity of the Business Systems constituting Company Registered IP and
any Business Data, including where applicable, implementing industry standard procedures designed to prevent unauthorized access and
the introduction of Disabling Devices, and the taking and storing on-site and off-site of back-up copies of critical data. To the Company&rsquo;s
knowledge, there is no Disabling Device in any of the Business Systems constituting Company Registered IP. Since January 1, 2019, neither
the Company nor any of the Subsidiaries has (a) experienced any data security breaches, unauthorized access or use of any of the Business
Systems constituting Company Registered IP, or unauthorized acquisition, destruction, damage, disclosure, loss, corruption, alteration
or use of any Business Data or (b) received written notice of any audits, proceedings or investigations by any Governmental Authority
or any customer, or received any claims or complaints regarding the collection, dissemination, storage or use of Personal Information,
or the violation of any applicable Privacy Laws, and, to the Company&rsquo;s knowledge, there is no basis for the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;Except
as would not be expected to have a Company Material Adverse Effect, the Company and/or one of the Subsidiaries (i) owns or possesses
all right, title and interest in and to the Business Data constituting Company Registered IP free and clear of any restrictions other
than those imposed by applicable Data Security Requirements, or (ii) has the right, as applicable, to use, exploit, publish, reproduce,
distribute, license, sell, and create derivative works of the Business Data, in whole or in part, in the manner in which the Company
and the Subsidiaries receive and use such Business Data prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;Except
as would not create a Company Material Adverse Effect, all past and current employees and independent contractors of the Company and
the Subsidiaries that provide services for the Company and are or were directly involved in the development of Company Registered IP
have executed commercially reasonable confidentiality agreements with Company or the Subsidiaries (as applicable) to maintain in confidence
all confidential information acquired or contributed by them in the course of their employment or engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;To
the Company&rsquo;s knowledge, there are no defects or technical concerns or problems, in each case that are current, unresolved and
material, in any of the Company Registered IP or owned Company IP Rights currently under development which are not of the type that are
capable of being remediated in the ordinary course of business without delaying the Company&rsquo;s or the Subsidiaries&rsquo; commercialization
timeline as currently planned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.11 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Agreements,
Contracts and Commitments.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Section
3.11(a)</U> of the Company Disclosure Schedule lists, as of the date of this Agreement, the following types of contracts and agreements
to which the Company or any Subsidiary is a party or by which any of their respective assets is bound (each, a &ldquo;<B>Company Material
Contract</B>&rdquo; and collectively, the &ldquo;<B>Company Material Contracts</B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;each
contract and agreement with consideration paid or payable to the Company or any of the Subsidiaries of more than $250,000, in the aggregate,
over the past 12 months;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;each
contract and agreement with suppliers to the Company or any Subsidiary, including those relating to the design, research, development,
testing, manufacture, labeling, marketing, promotion, sale or distribution of products of the Company or any Subsidiary, for expenditures
paid or payable by the Company or any Subsidiary requiring payment obligation of an amount equal to or greater than $250,000 over any
12-month period;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;each
contract requiring payment by or to the Company after the date of this Agreement in excess of $250,000 pursuant to its express terms
relating to (A) any agreement involving provision of services or products with respect to any pre-clinical development activities of
the Company or (B) any alliance, joint venture, cooperation, development or other agreement currently in force under which the Company
has continuing obligations to develop any product, technology or service, or any agreement pursuant to which the Company has continuing
obligations to develop any Intellectual Property rights that will not be owned, in whole or in part, by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;all
management contracts (excluding contracts for employment) and contracts with other workers and consultants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;all
contracts or agreements involving the payment of royalties or other amounts calculated based upon the revenues or income of the Company
or any Subsidiary or income or revenues related to any product of the Company or any Subsidiary to which the Company or any Subsidiary
is a party pursuant to which the Company has paid an amount equal to or greater than $250,000 over any 12-month period;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;all
contracts and agreements evidencing indebtedness for borrowed money in an amount greater than $250,000, and any pledge agreements, security
agreements or other collateral agreements in which the Company or any Subsidiary granted to any person a security interest in or lien
on any of the property or assets of the Company or any Subsidiary, and all agreements or instruments guarantying the debts or other obligations
of any person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&nbsp;all
partnership, joint venture or similar agreements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)&nbsp;all
contracts and agreements with any Governmental Authority to which the Company or any Subsidiary is a party, other than any permits;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)&nbsp;any
contract relating to the acquisition or disposition of any business or asset (whether by merger, sale of stock, sale of assets or otherwise)
under which the Company or any of its affiliates has or will have obligations with respect to an &ldquo;earn out,&rdquo; contingent purchase
price or similar contingent payment obligation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;all
contracts and agreements that limit, or purport to limit, the ability of the Company or any Subsidiary to compete in any line of business
or with any person or entity or in any geographic area or during any period of time, excluding customary confidentiality agreements and
agreements that contain customary confidentiality clauses;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)&nbsp;all
Leases, and all leases or master leases of personal property, likely to result in annual payments of $250,000 or more in a 12-month period;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)&nbsp;all
contracts involving use of, or grant of any rights to or in, any Company-Licensed IP by or to the Company or any Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)&nbsp;contracts
which involve the license or grant of rights to Company Registered IP by the Company or any Subsidiary Company other than (A) contracts
with customers on the Company&rsquo;s standard form of customer agreement, copies of which have been made available in the Virtual Data
Room, (B) limited licenses to confidential information under non-disclosure and confidentiality agreements entered into in the ordinary
course of business, (C) agreements with employees, independent contractors or consultants on the Company&rsquo;s standard form of invention
assignment and proprietary information agreement or consultant agreement (copies of which have been made available to MEDS), and (D)
other non-exclusive non-material licenses to Company Registered IP granted in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)&nbsp;all
contracts for the development of Company Registered IP for the benefit of the Company, other than employment or consulting agreements
entered into on the form of such agreement made available in the Virtual Data Room, without modification;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)&nbsp;all
contracts under which any broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission
in connection with the Contemplated Transactions, or which has a fee tail still in effect, based upon arrangements made by or on behalf
of the Company or any Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)&nbsp;all
contracts that provide for the settlement of any Legal Proceeding that contains any ongoing obligation on the Company or the Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)&nbsp;all
contracts between the Company and any holders of more than 2% of the Company Common Shares (assuming the full conversion or exercise
of all Company Common Shares held by such person) that relate to such holder&rsquo;s ownership of Company Common Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)
all contracts or agreements under which the Company has agreed to purchase goods or services from a vendor, supplier or other person
on a preferred supplier or &ldquo;most favored supplier&rdquo; basis; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)
all agreements for the development of Company Registered IP for the benefit of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) each Company Material Contract is a legal, valid and binding obligation of the Company or the Subsidiaries and, to the knowledge
of the Company, the other parties thereto, and neither the Company nor any Subsidiary is in breach or violation of, or default
under, any Company Material Contract nor has any Company Material Contract been canceled by the other party; (i) to the
Company&rsquo;s knowledge, no other party is in breach or violation of, or default under, any Company Material Contract; and (ii)
the Company and the Subsidiaries have not received any written, or to the knowledge of the Company, oral claim of default under any
such Company Material Contract, except for any such conflicts, violations, breaches, defaults or other occurrences which would not
be expected to result in a Company Material Adverse Effect. No party to a Company Material Contract has given written notice of or,
to the knowledge of the Company, threatened (A) any potential exercise of termination rights with respect to any Material Contract
or (B) any non-renewal or modification of any Company Material Contract. The Company has furnished or made available to MEDS in the
Virtual Data Room true and complete copies of all Company Material Contracts, including any amendments thereto that are material in
nature to the extent Company has a copy of such Company Material Contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.12 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Permit;
Compliance</U>. Except as set forth in <U>Section 3.12</U> of the Company Disclosure Schedule, each of the Company and the Subsidiaries
is in possession of all franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, consents, certificates,
approvals, registrations and orders of any Governmental Authority necessary for each of the Company or the Subsidiaries to own, lease
and operate its properties or to carry on its business as it is now being conducted (the &ldquo;<B><U>Company Permits</U></B>&rdquo;),
except where the failure to have such Company Permits would not be expected to have a Company Material Adverse Effect. No suspension
or cancellation of any of the Company Permits is pending or, to the Knowledge of the Company, threatened in writing. Except as set forth
in <U>Section 3.12</U> of the Company Disclosure Schedule, neither the Company nor any Subsidiary is in conflict with, or in default,
breach or violation of, (a) any Law applicable to the Company or any Subsidiary or by which any property or asset of the Company or any
Subsidiary is bound or affected, or (b) any Company Permit, except, in each case, for any such conflicts, defaults, breaches or violations
that would not have or would not be expected to have a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.13 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory
Compliance.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Section
3.13(a)</U> of the Company Disclosure Schedule sets forth, as of the date of this Agreement, a true and complete list of all the Company&rsquo;s
and Subsidiaries&rsquo; Products along with a description of each Product, its current stage of development or commercialization and
domestic and foreign regulatory statuses, as applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Section
3.13(b)</U> of the Company Disclosure Schedules sets forth, as of the date of this Agreement, a true and complete list of all Regulatory
Permits held by the Company and Subsidiaries, which are the only Regulatory Permits that are necessary for the Company and Subsidiaries
to conduct their business. The Company and Subsidiaries are in compliance in all respects with all Regulatory Permits. No Governmental
Authority has indicated in writing that it is considering limiting, suspending or revoking any Regulatory Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;As
of the date of this Agreement, there is (and since January 1, 2018, there has been) no Proceeding against the Company or Subsidiaries
related to compliance with Healthcare Laws and no such Proceedings have been threatened in writing. The Company and Subsidiaries have
not received (i) any written notice from FDA or any other Governmental Authority regarding any regulatory action against the Company
or Subsidiaries or any Product, including any notice of violation or adverse findings, any regulatory, untitled or warning letters, FDA
Form 483 notices of inspectional observations, &ldquo;dear doctor&rdquo; letters, safety communications or enforcement notices, or (ii)
any other written correspondence or notice setting forth allegedly objectionable observations or alleged violations of applicable Healthcare
Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;Except
as set forth on <U>Section 3.13(d)</U> of the Company Disclosure Schedule, and to the Knowledge of the Company, all Products are (and
since January 1, 2018, have been), whether by the Company or a third party, researched, developed, tested, investigated, produced, manufactured,
transferred, prepared, packaged, labeled, imported, exported, promoted, commercialized, marketed, sold, registered, stored and distributed
in compliance in all respects with all applicable Healthcare Laws, including those requirements relating to the FDA&rsquo;s good laboratory
practices, good clinical practices, good tissue practices, good manufacturing practices, investigational use, protection of human study
subjects, pre-market approval and applications to market a new product, establishment registration and product listing, safety and adverse
reaction reporting, labeling and deviation reporting and the respective counterparts thereof promulgated by Governmental Authorities
in countries outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;All
preclinical studies and clinical trials conducted by or on behalf of the Company or Subsidiaries or involving any Products are being,
and have been since January 1, 2018, conducted in all respects in accordance with all applicable clinical trial protocols, informed consents
and Healthcare Laws, including the FDA&rsquo;s standards for good laboratory practices and good clinical practices and the respective
counterparts thereof promulgated by Governmental Authorities in countries outside the United States. No preclinical study or clinical
trial conducted by or on behalf of the Company or Subsidiaries has been terminated or suspended prior to completion, and none of the
FDA or any other applicable Governmental Authority, clinical investigator that has participated or is participating in or institutional
review board or independent ethics committee that has or has had jurisdiction over, a preclinical study or clinical trial conducted by
or on behalf of the Company or any Subsidiary has commenced, or, to the Company&rsquo;s Knowledge, threatened to commence, any action
to place a clinical hold order on, or otherwise terminate or suspend or refuse to commence, any proposed or ongoing study or trial conducted
or proposed to be conducted by or on behalf of the Company or any Subsidiary. Further, no clinical investigator, researcher or clinical
staff participating in any clinical trial conducted by or, to the Knowledge of the Company, on behalf of the Company or any Subsidiary
has been disqualified from participating in trials involving any Product, and to the Knowledge of the Company, no such administrative
action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;All
manufacturing operations conducted by for the benefit of, the Company or its Subsidiaries in connection with any Product, since January
1, 2018, have been and are being conducted in compliance in all respects with applicable Healthcare Laws, including the FDA&rsquo;s standards
for good manufacturing practices and good tissue practices and the respective counterparts thereof promulgated by Governmental Authorities
in countries outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;No
Products have been seized, withdrawn, recalled, detained or subject to a suspension, other than in the ordinary course of business, of
research, development, testing, clinical investigation, manufacturing or distribution. As of the date of this Agreement, no Legal Proceedings
in the United States or any other jurisdiction seeking the withdrawal, recall, revocation, suspension, import detention or seizure of
any Product are pending or, to the Company&rsquo;s Knowledge, have been threatened in writing against the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;The
Company and each of its employees, agents, contractors, officers, and directors are, and has at all times been, in compliance with all
applicable Healthcare Laws. No Person has filed or has threatened to file against the Company any claim under any federal or state whistleblower
statute regarding the Company&rsquo;s non-compliance with applicable Healthcare Laws. Neither the Company nor any of its directors, managers,
officers, employees, agents, individual independent contractors, or third parties involved in the research or development of Products,
including licensors, clinical trial investigators, coordinators, or monitors (i) have been excluded from participation, suspended, or
debarred from any state or federal healthcare program (including Medicare or Medicaid) and/or any other healthcare program or reimbursement
agreement or (ii) have received notice, written or oral, from the FDA, any other Governmental Authority and/or any Person with respect
to debarment, disqualification, restriction, or violation of any Healthcare Law or (iii) entered into any agreement or settlement with
any Governmental Authority for any alleged non-compliance with, or violation of, any Healthcare Law. Neither the Company nor its Subsidiaries,
any of their officers, directors, employees, agents, or third parties or contractors involved in the research or development of Products
have been convicted of any crime or engaged in any conduct for which (A) debarment is mandated or permitted by 21 U.S.C. &sect; 335a
or (B) such Person could be excluded from participating in the federal healthcare programs under Section 1128 of the Social Security
Act or any similar Law. No officer, director, contractor, employee, or agent of the Company or Subsidiaries has (i) made any untrue statement
of fact or fraudulent statement to the FDA or any other Governmental Authority; (ii) failed to disclose a fact required to be disclosed
to the FDA or any other Governmental Authority; (iii) received written notice of or been subject to any enforcement action involving
the FDA or other Governmental Authority, including any suspension, consent decree, notice of criminal investigation, indictment, sentencing
memorandum, plea agreement, court order or target or no target letter that would result in a Material Adverse Effect and none of the
foregoing are pending or threatened; or (iv) committed an act, made a statement, failed to make a statement or caused another Person
to commit an act, to make a statement, or fail to make a statement that would be expected to provide the basis for the FDA or any other
Governmental Authority to refuse to grant a Regulatory Permit for any Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;Except
as set forth on <U>Section 3.13(i)</U> of the Company Disclosure Schedule, since January 1, 2019, all reports (including complaints,
adverse events or reactions, deviations, and any other annual or incident-specific reports required by FDA or any Governmental Authority),
documents, Regulatory Permits and notices required to be filed, maintained or furnished to the FDA or any other Governmental Authority
by the Company involving Products have been so filed, maintained or furnished, except as is not and would not be expected to be, individually
or in the aggregate, material to the Company or Subsidiaries, taken as a whole. All such reports (including complaints, adverse events
or reactions, deviation, and any other annual or incident-specific reports required by FDA or any Governmental Authority), documents,
Regulatory Permits and notices were complete and accurate in all respects on the date filed (or were corrected or supplemented by a subsequent
filing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;There
have been no Legal Proceedings, and no such Legal Proceedings are pending or threatened in writing against the Company or any Subsidiary
related to product liability for the Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;Except
as set forth on <U>Section 3.13(k)</U> of the Company Disclosure Schedule, the Company and Subsidiaries and their Representatives, and
any other Persons acting for or on behalf of any of the foregoing, are and have been at all times in compliance in all respects with
all applicable Healthcare Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.14 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal
Proceedings; Orders</U>. There is no Legal Proceeding pending or, to the Knowledge of the Company, threatened against the Company or
any Subsidiary, or any property or asset of the Company or any Subsidiary. Neither the Company nor any Subsidiary nor any property or
asset of the Company or any Subsidiary is, subject to any continuing order of, consent decree, settlement agreement or other similar
written agreement with, or, continuing investigation by, any Governmental Authority, or any order, writ, judgment, injunction, decree,
determination or award of any Governmental Authority, except for any such order, writ, judgement, injunction, decree, determination or
award that would not be expected to be to the Company and the Subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.15 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tax
Matters</U>. Except as set forth in <U>Section 3.15</U> of the Company Disclosure Schedules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;All
U.S. federal income and all other Tax Returns required to be filed by or with respect to the Company have been duly and timely filed
(taking into account any extension of time to file), and each such Tax Return is true, correct and complete in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;All
U.S. federal income and all other Taxes owed by the Company or for which the Company may otherwise be liable (whether or not shown on
any Tax Return) have been paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;There
is no claim against the Company for any Taxes, and no assessment, deficiency or adjustment has been asserted, proposed or threatened
in writing by any Taxing Authority with respect to any Taxes or Tax Returns of or with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;No
audit, examination, investigation, litigation or other administrative or judicial proceeding in respect of income or other Taxes or Tax
matters is pending, being conducted or has been threatened in writing with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;The
Company has not received written notice of any claim from a Taxing Authority in a jurisdiction in which the Company does not file Tax
Returns stating that the Company is or may be subject to Tax in such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;The
Company has not waived any statute of limitations with respect to Taxes or agreed to any extension of time with respect to a Tax assessment
or deficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;There
are no liens or encumbrances for Taxes upon any of the assets of the Company except for Permitted Encumbrances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;The
Company is not a party to, is bound by or has an obligation under any Tax sharing agreement, Tax indemnification agreement, Tax allocation
agreement or similar contract or arrangement (including any agreement, contract or arrangement providing for the sharing or ceding of
credits or losses) or has a potential liability or obligation to any person as a result of or pursuant to any such agreement, contract
or arrangement, in each case, other than an agreement, contract or arrangement the primary purpose of which does not relate to Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;The
Company has not been a member of an affiliated group filing a consolidated, combined or unitary U.S. federal, state, local or non-U.S.
income Tax Return (other than a group of which the Company was the common parent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company has no liability for the Taxes of any person under Treasury Regulations Section 1.1502-6 (or any similar provision of
state, local or non-U.S. law), as a transferee or successor, by contract or otherwise, in each case, other than an agreement,
contract or arrangement the primary purpose of which does not relate to Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The Company does not have any request for a ruling in respect of Taxes pending with any Taxing Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company has not engaged in or entered into a &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulation Section
1.6011-4(b)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The Company has made available to MEDS true, correct and complete copies of all income Tax Returns filed by the Company for the two
most recent taxable years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
For U.S. federal income tax purposes, the Company is, and has been since its formation, classified as either a partnership or a
disregarded entity. The Company has made a valid election under Section 754 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any Tax
period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting made prior to the
Closing under Section 481(c) of the Code (or any corresponding or similar provision of state, local or non-U.S. income tax law);
(ii) &ldquo;closing agreement&rdquo; as described in Section 7121 of the Code (or any corresponding or similar provision of state,
local or non-U.S. income tax law) executed prior to the Closing; (iii) installment sale or open transaction disposition made prior
to the Closing; or (iv) prepaid amount or deferred revenue received prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
The Company has not (i) deferred, extended or delayed the payment of the employer&rsquo;s share of any &ldquo;applicable employment
taxes&rdquo; under Section 2302 of the CARES Act, (ii) failed to properly comply with and duly account for all credits received
under Sections 7001 through 7005 of the Families First Coronavirus Response Act (Public Law 116-127) and Section 2301 of the CARES
Act and related guidance thereunder, (iii) deferred any payroll tax obligations (including those imposed by Section 3101(a) and 3201
of the Code) (for example, by failure to timely withhold, deposit or remit such amounts in accordance with the applicable provisions
of the Code and the Treasury Regulations promulgated thereunder) pursuant to or in connection with the Payroll Tax Executive Order,
and (iv) sought, or intends to seek, a covered loan under Section 7(a)(36) of the Small Business Act (15 U.S.C. 636(a)), as added by
Section 1102 of the CARES Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
The Company has not applied for nor received any Employee Retention Tax Credits under Section 2301 of the CARES Act or Code Section
3134.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
To the knowledge of the Company, there are no facts, circumstances or plans that, either alone or in combination, could be expected
to prevent the Transactions from qualifying for the Intended Tax Treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16&nbsp; <U>Labor
and Employment Matters.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Section
3.16(a)</U> of the Company Disclosure Schedule sets forth a true, correct and complete list of all employees of the Company or any
Subsidiary as of the date hereof, including any employee who is on a leave of absence of any nature, authorized or unauthorized, and
sets forth for each such individual the following: (i) name and employing entity; (ii) title or position and location of employment;
(iii) hire date; (iv) current annualized base salary or (if paid on an hourly basis) hourly rate of pay, and (for U.S. employees)
status as exempt or non-exempt under the Fair Labor Standards Act; (v) commission, bonus or other incentive-based compensation
eligibility, and all other compensation for which he or she is eligible; and (vi) for those employees outside of the United States,
the period of required notice, if any, prior to termination of their employment if such notice period is longer than the statutory
minimum under applicable local Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except as set forth in <U>Section 3.16(b)</U> of the Company Disclosure Schedule, as of the date of this Agreement, no employee of
the Company or any Subsidiary is represented by a labor union, works council, trade union, or similar representative of employees
and neither the Company nor any Subsidiary is a party to, subject to, or bound by a collective bargaining agreement, collective
agreement or any other contract or agreement with a labor union, works council, trade union, or similar representative of employees.
As of the date of this Agreement and during the two-year period immediately prior to such date, there are no and were no strikes,
lockouts or work stoppages existing or, to the Company&rsquo;s knowledge, threatened, with respect to any employees or the Company
or any Subsidiaries or any other individuals who have provided services with respect to the Company or any Subsidiaries. As of the
date of this Agreement and during the two-year period immediately prior to such date, there have been no union certification or
representation petitions or demands with respect to the Company or any Subsidiaries or any of their employees and, to the
Company&rsquo;s knowledge, no union or labor organizing campaign or similar effort is pending or threatened with respect to the
Company, any Subsidiaries, or any of their employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as set forth in <U>Section 3.16(c)</U> of the Company Disclosure Schedule, as of the date of this Agreement, there are no
Actions pending or, to the knowledge of the Company, threatened against the Company or any Subsidiary by any of their respective
current or former employees, workers or independent contractors, except for any such Actions that would not be expected to have a
Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except as set forth in <U>Section 3.16(d)</U> of the Company Disclosure Schedule, the Company and the Subsidiaries are and have been
since January 1, 2019, in compliance in all respects with all applicable Laws relating to labor and employment, including all such
laws regarding employment practices, employment discrimination, terms and conditions of employment, redundancies, mass layoffs and
plant closings, information and consultation, furloughs, immigration, meal and rest breaks, working time, pay equity, workers&rsquo;
compensation, family and medical leave and all other employee leave, holiday pay, recordkeeping, classification of employees,
workers and independent contractors, wages and hours, pay checks and pay stubs, employee seating, anti-harassment and
anti-retaliation (including all such Laws relating to the prompt and thorough investigation and remediation of any complaints) and
occupational safety and health requirements, and neither the Company nor any Subsidiary is liable for any arrears of wages,
penalties or other sums for failure to comply with any of the foregoing, except for any such non-compliance that would not be
expected to have a Company Material Adverse Effect. Each employee of the Company and each Subsidiary and any worker and other
individual who has provided services with respect to the Company or any Subsidiary has been paid (and as of the Closing will have
been paid) all wages, bonuses, compensation and other sums owed and due to such individual as of such date in all
respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
To the knowledge of the Company, no employee of the Company or any Subsidiary has provided or is providing information to any law
enforcement agency regarding the commission or possible commission of any crime or the violation or possible violation of any
applicable Law. None of the Company, any Subsidiary or, to the knowledge of the Company, any officer, employee, contractor,
subcontractor or agent of the Company or any Subsidiary has discharged, demoted, suspended, threatened, harassed or in any other
manner discriminated against an employee of the Company or any Subsidiary in the terms and conditions of employment because of any
act of such employee described in 18 U.S.C. sec. 1514A(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17 <U>Employee
Plans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Section
3.17(a)</U> of the Company Disclosure Schedule includes a true and correct list of, as of the date of this Agreement, all Plans (as
defined below), including all forms of offer letter and agreement pursuant to which all individuals who are employed or engaged as
employees, workers, or independent contractors by the Company or any Subsidiary and no such individual is employed or engaged on
terms that differ to a extent from such forms of offer letter or agreement. <U>Section 3.17(a)</U> of the Company Disclosure
Schedule sets forth a true and correct list of any employment or similar agreement with any senior executive of the Company. For
purposes of this Agreement, &ldquo;<B>Plans</B>&rdquo; shall mean all Employee Plans that are maintained, contributed to, required
to be contributed to, or sponsored by the Company or any Subsidiary for the benefit of any current or former employee, officer,
director, worker, consultant and/or other service provider, or under which the Company or any Subsidiary or ERISA Affiliate has or
could be expected to incur any Liability (contingent or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
With respect to each Plan, the Company has made available to MEDS, as applicable (i) a true and complete copy of the current plan
document and all amendments thereto (or summary of the Plan if unwritten) and each insurance contract, trust agreement or other
funding agreement or arrangement (including all amendments thereto), (ii) copies of the most recent scheme booklet, summary plan
description and any summaries of modifications, (iii) a copy of the three most recently filed IRS Form 5500 annual report and
accompanying schedules (or, if not yet filed, the most recent draft thereof) or other most recent annual or other reports filed with
any Governmental Authority and all schedules thereto, (iv) copies of the most recently received IRS determination, opinion or
advisory letter for each such Plan, and (v)copies of non-discrimination and other compliance testing for each of the past three
years, (vi) copies of annual safe-harbor, automatic enrollment, and any other required notices for the current and prior two years,
(vii) copies of any filings under the IRS&rsquo; Employee Plans Compliance Resolution System or the DOL&rsquo;s Voluntary Fiduciary
Compliance Program within the prior three years and (viii) any non-routine correspondence from any Governmental Authority with
respect to any Plan within the past three (3) years. Neither the Company nor any Subsidiary has any commitment to modify, change or
terminate any Plan, other than with respect to a modification, change or termination required by ERISA or the Code, or other
applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
None of the Company or any ERISA Affiliate contributes to or has any obligation to contribute to, or has at any time within six
years prior to the Closing Date contributed to or had an obligation to contribute to, and no Plan is, (i) a Multiemployer Plan, (ii)
a plan subject to Section 412 of the Code, Section 302 of ERISA and/or Title IV of ERISA, (iii) a Multiple Employer Plan, (iv) a
&ldquo;multiple employer welfare arrangement&rdquo; within the meaning of Section 3(40) of ERISA, or (v) a &ldquo;voluntary
employees&rsquo; beneficiary association&rdquo; within the meaning of Section 509(c)(9) of the Code or other funding arrangement for
the provision of welfare benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except as set forth on <U>Section 3.17(d)</U> of the Company Disclosure Schedule , neither the Company nor any Subsidiary is nor
will be obligated, whether under any Plan or otherwise, to pay separation, severance, redundancy, termination or similar benefits to
any person as a result of the execution of this Agreement, or the consummation of the Contemplated Transactions (either alone or
combination with any other event), nor will any such events accelerate the time of payment, funding or vesting, or increase the
amount, of any benefit or other compensation due to any individual. Neither the execution of this Agreement, nor the consummation of
the Contemplated Transactions (either alone or combination with any other event), will (i) result in imposition of the tax imposed
under Sections 280G and 4999 of the Code, whether or not some other subsequent action or event would be required to cause such
payment, acceleration or provision to be triggered, or (ii) result in a Tax gross-up or similar payment to any individual for any
Tax or interest that may be due under any Section of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
None of the Plans provide, nor does the Company or any Subsidiary have any obligation to provide, retiree medical to any current or
former employee, officer, director or consultant of the Company or any Subsidiary after termination of employment or service except
as may be required under Section 4980B of the Code and Parts 6 and 7 of Title I of ERISA and the regulations thereunder or any
analogous state Law (and at the sole cost of such former employee, officer, director or consultant).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Each Plan is and has been within the past six (6) years in compliance, in all respects, in accordance with its terms and the
requirements of all applicable Laws including, without limitation, ERISA, the Patient Protection and Affordable Care Act of 2010 and
the Code. The Company and the Subsidiaries have performed, in all respects, all obligations required to be performed by them under,
are not in any respect in default under or in violation of, and have no knowledge of any default or violation in any respect by any
party to, any Plan. No Action is pending or, to the knowledge of the Company, threatened with respect to any Plan or the assets of
any Plan (other than claims for benefits in the ordinary course) and, to the knowledge of the Company, no fact or event exists that
could be expected to give rise to any such Action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Each Plan that is intended to be qualified under Section 401(a) of the Code or Section 401(k) of the Code has (i) timely received a
favorable determination letter from the IRS covering all of the provisions applicable to the Plan for which determination letters
are currently available that the Plan is so qualified and each trust established in connection with such Plan is exempt from federal
income Taxation under Section 501(a) of the Code or (ii) is entitled to rely on a favorable opinion letter from the IRS, and, to the
knowledge of the Company, no fact or event has occurred since the date of such determination or opinion letter or letters from the
IRS that would adversely affect the qualified status of any such Plans or the exempt status of any such trust.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
There has not been, nor is there expected to be, any &ldquo;prohibited transaction&rdquo; (within the meaning of Section 406 of
ERISA or Section 4975 of the Code) or any &ldquo;reportable event&rdquo; (within the meaning of Section 4043 of ERISA) with respect
to any Plan that could be expected to result in liability to the Company or any of the Subsidiaries. To the knowledge of the
Company, there have been no acts or omissions by the Company or any ERISA Affiliate that have given or could be expected to give
rise to any fines, penalties, Taxes or related charges under Sections 502 or 4071 of ERISA or Section 511 or Chapter 43 of the Code
for which the Company or any ERISA Affiliate may be liable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
All contributions, premiums or payments required to be made with respect to any Plan pursuant to their terms and provisions or
pursuant to applicable Law have been timely made to the extent due or properly accrued on the consolidated financial statements of
the Company and the Subsidiaries to the extent required by, and in accordance with, GAAP, except as would not result in liability to
the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Each Plan that could be a &ldquo;nonqualified deferred compensation&rdquo; arrangement under Section 409A of the Code has been
administered and operated in compliance with the provisions of Section 409A of the Code and the Treasury Regulations promulgated
thereunder. No service provider is entitled to a Tax gross-up or similar payment for any Tax or interest that may be due under
Section 409A or 4999 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.18 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Environmental
Matters</U>. (a) Neither the Company nor any of the Subsidiaries has violated since January 1, 2019, nor are they in violation of, applicable
Environmental Law or Environmental Permits; (b) to the knowledge of the Company, none of the properties currently or formerly owned,
leased or operated by the Company or any Subsidiary (including, without limitation, soils and surface and ground waters) are contaminated
with, or have had a release of, any Hazardous Materials at or affecting such properties which requires reporting, investigation, remediation,
monitoring or other response action by the Company or any Subsidiary pursuant to applicable Environmental Laws, or which could give rise
to a liability of the Company or any Subsidiary under Environmental Laws; (c) to the Company&rsquo;s knowledge, none of the Company or
any of the Subsidiaries is actually, potentially or allegedly liable pursuant to applicable Environmental Laws for any off-site contamination
by Hazardous Materials; (d) each of the Company and each Subsidiary has all permits, licenses and other authorizations required of the
Company under applicable Environmental Law (&ldquo;<B>Environmental Permits</B>&rdquo;); (e) each of the Company and each Subsidiary,
and their Products, are in compliance with Environmental Laws and Environmental Permits in all respects; (f) neither the Company nor
any Subsidiary is the subject of any pending or threatened action alleging any violation or, or liability under, Environmental Laws,
except in each case as would not have a Company Material Adverse Effect; (g) neither the Company nor any of the Subsidiaries has entered
into any consent decree, settlement agreement, or order pursuant to any Environmental Law, nor is a party to any judgment, decree or
judicial or administrative order pursuant to any applicable Environmental Law; and (h) to the knowledge of the Company, no site or property
to or at which the Company or any of the Subsidiaries directly or indirectly (through a sub-contractor) transported or disposed, or arranged
for the transportation or disposal, of a Hazardous Materials is currently undergoing investigation, remediation or other response action
under applicable Environmental Law. The Company has provided all environmental site assessments, reports, studies or other evaluations
in its possession or constructive control relating to any properties currently or formerly owned, leased or operated by the Company or
any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.19 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Section
3.19(a)</U> of the Company Disclosure Schedule sets forth, with respect to each insurance policy under which the Company or any
Subsidiary is an insured (the &ldquo;<B>Insurance Policies</B>&rdquo;), a named insured or otherwise the principal beneficiary of
coverage as of the date of this Agreement (i) the names of the insurer, the principal insured and each named insured, (ii) the
policy number, (iii) the period, scope and amount of coverage and (iv) the premium most recently charged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
With respect to each such Insurance Policy, except as would not be expected to result in a Company Material Adverse Effect: (i) the
policy is legal, valid, binding and enforceable in accordance with its terms (subject to the Enforceability Exceptions) and, except
for policies that have expired under their terms in the ordinary course, is in full force and effect; (ii) neither the Company nor
any Subsidiary is in breach or default (including any such breach or default with respect to the payment of premiums or the giving
of notice), and no event has occurred which, with notice or the lapse of time, would constitute such a breach or default, or permit
termination or modification, under the policy; and (iii) to the knowledge of the Company, no insurer on the policy has been declared
insolvent or placed in receivership, conservatorship or liquidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.20 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Financial Advisors</U>. Except as set forth on <U>Section 3.20</U> of the Company Disclosure Schedule, no broker, finder or investment
banker is entitled to any brokerage fee, finder&rsquo;s fee, opinion fee, success fee, transaction fee or other fee or commission in
connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.21 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Interested
Party Transactions</U>. Except as set forth in <U>Section 3.21</U> of the Company Disclosure Schedule and for employment relationships
and the payment of compensation, benefits and expense reimbursements and advances in the ordinary course of the Company&rsquo;s business
(all of which are set forth in the Company Disclosure Schedule), no director, officer or other affiliate of the Company or any Subsidiary
has or has had, directly or indirectly (a) an economic interest in any person that has furnished or sold, or furnishes or sells, services
or Products that the Company or any Subsidiary furnishes or sells, or proposes to furnish or sell; (b) an economic interest in any person
that purchases from or sells or furnishes to, the Company or any Subsidiary, any goods or services; (c) a beneficial interest in any
Company Material Contract; or (d) any contractual or other arrangement with the Company or any Subsidiary, other than customary indemnity
arrangements. The Company and the Subsidiaries have not, since January 1, 2019, (i) extended or maintained credit, arranged for the extension
of credit or renewed an extension of credit in the form of a personal loan to or for any director or executive officer (or equivalent
thereof) of the Company, or (ii) modified any term of any such extension or maintenance of credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.22 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Due
Diligence Period. </U>The Company hereby acknowledges and agrees that MEDS shall have until the date that is sixty (60) days after
the execution and delivery of this Agreement, unless terminated sooner by the Parties, to perform such investigations, examinations,
and diligence as MEDS deems necessary or desirable to determine whether the Agreement is acceptable to MEDS (the &ldquo;<B>Due
Diligence Period</B>&rdquo;). The Company agrees to provide that it will provide to MEDS all documentation or agreements in form and
substance reasonably acceptable to MEDS and its counsel. If, for any reason or for no reason in MEDS&rsquo;s sole and absolute
discretion, that MEDS does not wish to consummate the Agreement, then MEDS shall have the right to terminate this Agreement by
giving written notice to the Company on or before the conclusion of the Due Diligence Period. If MEDS terminates the Merger in
accordance with <U>Section 3.22</U>, all rights and obligations of the parties under this Agreement shall expire (except to the
extent that any such rights and obligations survive the termination of this Agreement pursuant to the terms of this Agreement), and
this Agreement shall become null and void. If MEDS does not terminate this Agreement in accordance with this <U>Section 3.22</U> on
or before the termination of the Due Diligence Period. Buyer shall have no further right to terminate this Agreement pursuant to
this <U>Section 3.22</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.23 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial
Projections. </U>The Company hereby acknowledges and agrees that the financial projections related to the Company and the Combined
Companies are true, accurate, and correct as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.24 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Books
and Records. </U>The books and record books of the Company, all of which have been made available to MEDS on or before the Due
Diligence Period, are complete and correct and have been maintained in accordance with sound business practices. The Company agrees
to provide any additional information reasonably requested by MEDS or its counsel related to this <U>Section 3.24</U>.The Company
represents that the books of the Company contain accurate and complete records of all meetings, and actions taken by written consent
of, the stockholders, the board of directors and any committees of the board of directors of the Company, and no meeting, or action
taken by written consent, of any such stockholders, board of directors or committee has been held for which minutes have not been
prepared and are not contained in such minute books. At the Closing, all of those books and records will be in the possession of the
post-closing Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.25 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Full
Disclosure. </U>No representation or warranty by the Company in this Agreement and no statement contained in the Company Disclosure
Schedules or any certificate or other document furnished or to be furnished to MEDS pursuant to this Agreement contains any untrue
statement of a fact, or omits to state a fact necessary to make the statements contained therein, in light of the circumstances in
which they are made, not misleading. The Company agrees that it has an ongoing duty to supplement the Company Disclosure Schedules.
Notwithstanding the foregoing, the Company&rsquo;s duty to update the Company Disclosure Schedules shall not affect or limit
MEDS&rsquo;s termination rights set forth in <U>Section 3.22 </U>nor shall this <U>Section 3.25</U> be construed to waive or excuse
the Company&rsquo;s obligations under Section <U>3.1</U>, <U>3.2</U>, <U>3.3</U>, <U>3.4</U>, <U>3.5</U>, <U>3.6</U>, <U>3.7</U>, <U>3.8</U>, <U>3.9</U>, <U>3.10</U>, <U>3.11</U>, <U>3.12</U>, <U>3.13</U>, <U>3.14</U>, <U>3.15</U>, <U>3.16</U>, <U>3.17</U>, <U>3.18</U>, <U>3.19</U>, <U>3.20</U>, <U>3.23</U>,
and <U>3.24</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">3.26 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Other Representations or Warranties</U>. The Company hereby acknowledges and agrees that, except for the representations and
warranties contained in this Agreement, neither MEDS nor any other person on behalf of MEDS makes any express or implied
representation or warranty with respect to MEDS or with respect to any other information provided to the Company, any of its
stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express
representations and warranties of MEDS set forth in <U>Section 4</U> (in each case as qualified and limited by the MEDS Disclosure
Schedule)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the
accuracy or completeness thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4. <U>Representations and Warranties of MEDS and Merger Sub</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
(i) as set forth in the written disclosure schedule delivered by MEDS to the Company before the termination of the Due Diligence Period
(the &ldquo;<B>MEDS Disclosure Schedule</B>&rdquo;), (ii) as disclosed in the MEDS SEC Documents filed with the SEC prior to the date
hereof and publicly available on the SEC&rsquo;s Electronic Data Gathering Analysis and Retrieval system, MEDS and Merger Sub represent
and warrant to the Company as follows, or provided to the Company during the Due Diligence Period:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.1 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Due
Organization; Subsidiaries.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each of MEDS and its Subsidiaries (including Merger Sub) is a corporation or limited liability company duly incorporated or formed,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization and has all necessary
corporate or limited liability company power and authority (i) to conduct its business in the manner in which its business is
currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are
currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound. Since the date of
its formation, Merger Sub has not engaged in any activities other than in connection with or as contemplated by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each of MEDS and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in
such jurisdiction), under the laws of all jurisdictions where the nature of its business in the manner in which its business is
currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified
individually or in the aggregate would not be reasonably expected to have a MEDS Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as set forth on <U>Section 4.1(c)</U> of the MEDS Disclosure Schedule, MEDS has no Subsidiaries other than Merger Sub and
MEDS does not own any capital stock of, or any equity ownership or profit-sharing interest of any nature in, or control directly or
indirectly, any other Entity other than Merger Sub. MEDS is not and has not otherwise been, directly or indirectly, a party to,
member of or participant in any partnership, joint venture or similar business entity. MEDS has not agreed and is not obligated to
make, nor is MEDS bound by any Contract under which it may become obligated to make, any future investment in or capital
contribution to any other Entity. MEDS has not, at any time, been a general partner of, and has not otherwise been liable for any of
the debts or other obligations of, any general partnership, limited partnership or other Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.2 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organizational
Documents</U>. Within ten (10) days of the execution and delivery of this Agreement, MEDS will deliver to the Company accurate and complete
copies of MEDS&rsquo;s Organizational Documents. MEDS is not in breach or violation of its Organizational Documents in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.3 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authority;
Binding Nature of Agreement</U>. Each of MEDS and Merger Sub has all necessary corporate power and authority to enter into and to perform
its obligations under this Agreement and to consummate the Contemplated Transactions. The MEDS Board (at meetings duly called and held)
has (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of MEDS and its stockholders,
(b) approved and declared advisable this Agreement, the other Transaction Documents and the Contemplated Transactions, including the
issuance of shares of MEDS Common Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c) determined
to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of MEDS vote to approve
the Contemplated Transactions, including the Stock Swap. The Merger Sub Board (by unanimous written consent) has: (x) determined that
the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (y) deemed advisable
and approved this Agreement and the Contemplated Transactions and (z) determined to recommend, upon the terms and subject to the conditions
set forth in this Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.
This Agreement has been duly executed and delivered by MEDS and Merger Sub and, assuming the due authorization, execution and delivery
by the Company, constitutes the legal, valid and binding obligation of MEDS and Merger Sub, enforceable against each of MEDS and Merger
Sub in accordance with its terms, subject to the Enforceability Exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.4 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Contravention;
Consents.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to compliance with the HSR Act and any foreign antitrust Law, and the filing of the Certificate of Merger required by the
DGCL, neither (x) the execution, delivery or performance of this Agreement by MEDS or Merger Sub, nor (y) the consummation of the
Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of MEDS or its
Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to
challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which MEDS or
its Subsidiaries or any of the assets owned or used by MEDS or its Subsidiaries, is subject;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental
Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by MEDS
or its Subsidiaries or that otherwise relates to the business of MEDS, or any of the assets owned, leased or used by
MEDS;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any MEDS Material
Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any MEDS Material Contract, (B) any
material payment, rebate, chargeback, penalty or change in delivery schedule under any such MEDS Material Contract, (C) accelerate
the maturity or performance of any MEDS Material Contract or (D) cancel, terminate or modify any term of any MEDS Material Contract,
except in the case of any nonmaterial breach, default, penalty or modification; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by MEDS or its Subsidiaries
(except for Permitted Encumbrances).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except for (i) any Consent set forth on <U>Section 4.4</U> of the MEDS Disclosure Schedule under any MEDS Contract, (ii) the filing
of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL (iii) any required filings
under the HSR Act and any foreign antitrust Law and (iv) such consents, waivers, approvals, orders, authorizations, registrations,
declarations and filings as may be required under applicable federal and state securities laws, neither MEDS nor any of its
Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in
connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated
Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The MEDS Board and the Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to
business combinations contained in Section 203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance
of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies
or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.5 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capitalization.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The authorized capital stock of MEDS consists of (i) 682,500 shares of MEDS Common Stock. Within ten (10) days of the execution and
delivery of this Agreement, MEDS shall deliver the number of shares have been issued and are outstanding as of June 29, 2023 (the
&ldquo;<B>Capitalization Date</B>&rdquo;) to the Company and (ii) no shares of preferred stock, par value $0.00001 per share, of
which no shares have been issued and are outstanding as of the Capitalization Date. MEDS does not hold any shares of its capital
stock in its treasury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
All of the outstanding shares of MEDS Common Stock have been duly authorized and validly issued, and are fully paid and
nonassessable and are free of any Encumbrances (other than Permitted Encumbrances). None of the outstanding shares of MEDS Common
Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right. None of the
outstanding shares of MEDS Common Stock is subject to any right of first refusal in favor of MEDS. Except as contemplated hereby and
by the other Transaction Documents, there is no MEDS Contract relating to the voting or registration of, or restricting any Person
from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares
of MEDS Common Stock. MEDS is not under any obligation, nor is MEDS bound by any Contract pursuant to which it may become obligated,
to repurchase, redeem or otherwise acquire any outstanding shares of MEDS Common Stock or other securities. <U>Section 4.5(b)</U> of
the MEDS Disclosure Schedule accurately and completely describes all repurchase rights held by MEDS with respect to shares of MEDS
Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are
currently exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except for the MEDS 2014 Equity Incentive Plan, as amended (the &ldquo;<B>MEDS 2014 Plan</B>&rdquo;) and the MEDS 2019 Equity
Incentive Plan (the &ldquo;<B>MEDS 2019 Plan</B>&rdquo; and, together with the MEDS 2014 Plan, the &ldquo;<B>MEDS Stock
Plans</B>&rdquo;), and except as set forth on <U>Section 4.5(c)</U> of the MEDS Disclosure Schedule, MEDS does not have any stock
option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. <U>Section
4.5(c)</U> of the MEDS Disclosure Schedule sets forth the following information with respect to each MEDS Option outstanding as of
the date of this Agreement, as applicable: (i) the name of the holder, (ii) the number of shares of MEDS Common Stock subject to
such MEDS Option at the time of grant, (iii) the number of shares of MEDS Common Stock subject to such MEDS Option as of the date of
this Agreement, (iv) the exercise price of such MEDS Option, (v) the date on which such MEDS Option was granted, (vi) the applicable
vesting schedule, including any acceleration provisions and the number of vested and unvested shares as of the date of this
Agreement, (vii) the date on which such MEDS Option expires, (viii) whether such MEDS Option is intended to be an &ldquo;incentive
stock option&rdquo; (as defined in the Code) or a nonqualified stock option, (ix) in the case of a MEDS Option, the plan pursuant to
which such MEDS Option was granted and (x) the number of shares remain available for future issuance pursuant to the MEDS Stock
Plans. MEDS has made available to the Company accurate and complete copies of equity incentive plans pursuant to MEDS has
equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder
approval of the MEDS Stock Plans and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except for the outstanding MEDS Options as set forth on <U>Section 4.5(d)</U> of the MEDS Disclosure Schedule, there is no: (i)
outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital
stock or other securities of MEDS, (ii) outstanding security, instrument or obligation that is or may become convertible into or
exchangeable for any shares of the capital stock or other securities of MEDS, or (iii) stockholder rights plan (or similar plan
commonly referred to as a &ldquo;poison pill&rdquo;) or Contract under which MEDS is or may become obligated to sell or otherwise
issue any shares of its capital stock or any other securities . There are no outstanding or authorized stock appreciation, phantom
stock, profit participation or other similar rights with respect to MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
All outstanding shares of MEDS Common Stock, MEDS Options, and other securities of MEDS have been issued and granted in compliance
with (i) all applicable securities Laws and other applicable Law and (ii) all requirements set forth in applicable
Contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
With respect to MEDS Options granted pursuant to the MEDS Stock Plans, (i) each grant of a MEDS Option was duly authorized no later
than the date on which the grant of such MEDS Option was by its terms to be effective (the &ldquo;<B>MEDS Grant Date</B>&rdquo;) by
all necessary corporate action, including, as applicable, approval by the MEDS Board (or a duly constituted and authorized committee
thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement
governing such grant (if any) was duly executed and delivered by each party thereto, (ii) each MEDS Option grant was made in
accordance with the terms of the MEDS Stock Plan pursuant to which it was granted and all other applicable Law and regulatory rules
or requirements, and (iii) the per share exercise price of each MEDS Option was not less than the fair market value of a share of
MEDS Common Stock on the applicable MEDS Grant Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.6 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC
Filings; Financial Statements.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as set forth on <U>Section 4.7(a)</U> of the MEDS Disclosure Schedule, since January 1, 2022, MEDS has filed or furnished, as
applicable, on a timely basis all material forms, statements, certifications, reports and documents required to be filed or
furnished by it with the SEC under the Exchange Act or the Securities Act (the &ldquo;<B>MEDS SEC Documents</B>&rdquo;). As of the
time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of
such filing), each of the MEDS SEC Documents complied in all material respects with the applicable requirements of the Securities
Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the MEDS SEC Documents contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements
required by (i) Rule 13a-14 under the Exchange Act and (ii) 18 U.S.C. &sect;1350 (Section 906 of the Sarbanes-Oxley Act) relating to
the MEDS SEC Documents (collectively, the &ldquo;<B>Certifications</B>&rdquo;) are accurate and complete and comply as to form and
content with all applicable Laws. As used in this <U>Section 4.6</U>, the term &ldquo;file&rdquo; and variations thereof shall be
broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the
SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements (including any related notes)
contained or incorporated by reference in the MEDS SEC Documents: (i) complied as to form in all material respects with the Securities
Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii) were prepared in
accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements,
as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to
normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless
otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the financial position of
MEDS as of the respective dates thereof and the results of operations and cash flows of MEDS for the periods covered thereby. Other than
as expressly disclosed in the MEDS SEC Documents filed prior to the date hereof, there has been no material change in MEDS&rsquo;s accounting
methods or principles that would be required to be disclosed in MEDS&rsquo;s financial statements in accordance with GAAP. The books
of account and other financial records of MEDS and each of its Subsidiaries are true and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as set forth on <U>Section 4.7(c)</U> of the
MEDS Disclosure Schedule, MEDS maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)
of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable
assurance (i) that MEDS maintains records that in reasonable detail accurately and fairly reflect MEDS&rsquo;s transactions and dispositions
of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)
that receipts and expenditures are made only in accordance with authorizations of management and the MEDS Board and (iv) regarding prevention
or timely detection of the unauthorized acquisition, use or disposition of MEDS&rsquo;s assets that could have a material effect on MEDS&rsquo;s
financial statements. MEDS has evaluated the effectiveness of MEDS&rsquo;s internal control over financial reporting and, to the extent
required by applicable Law, presented in any applicable MEDS SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment
thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered
by such report or amendment based on such evaluation. MEDS has disclosed to MEDS&rsquo;s auditors and the Audit Committee of the MEDS
Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and
material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect
MEDS&rsquo;s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that
involves management or other employees who have a significant role in MEDS&rsquo;s or its Subsidiaries&rsquo; internal control over financial
reporting. Except as disclosed in the MEDS SEC Documents filed prior to the date hereof, MEDS&rsquo;s internal control over financial
reporting is effective and MEDS has not identified any material weaknesses in the design or operation of MEDS&rsquo;s internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.7
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence of Undisclosed Liabilities</U></FONT>. Neither
MEDS nor any of its Subsidiaries has any Liability of a type required to be reflected or reserved for on a balance sheet prepared in
accordance with GAAP, except for: (a) Liabilities disclosed, reflected or reserved against in the MEDS Unaudited Interim Balance Sheet,
(b) normal and recurring current Liabilities that have been incurred by MEDS or its Subsidiaries since the date of the MEDS Unaudited
Interim Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort,
infringement, or violation of Law), (c) Liabilities for performance of obligations of MEDS or any of its Subsidiaries under MEDS Contracts,
(d) Liabilities incurred in connection with the MEDS Legacy Business or the Contemplated Transactions and (e) Liabilities described in
<U>Section 4.8</U> of the MEDS Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.8
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Contracts and Commitments.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section 4.8</U> of the MEDS Disclosure Schedule identifies
each MEDS Contract that is in effect as of the date of this Agreement other than the Securities Purchase Agreement (each, an &ldquo;<B>MEDS
Material Contract</B>&rdquo; and collectively, the &ldquo;<B>MEDS Material Contracts</B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract relating to any material bonus, deferred
compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other Employee Plans or arrangements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(ii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract requiring payments by MEDS after
the date of this Agreement in excess of $75,000 pursuant to its express terms relating to the employment of, or the performance of employment-related
services by, any Person, including any employee, consultant or independent contractor, or Entity providing employment related, consulting
or independent contractor services, not terminable by MEDS on ninety (90) calendar days&rsquo; or less notice without liability, except
to the extent general principles of wrongful termination Law may limit MEDS&rsquo;s, or such successor&rsquo;s ability to terminate employees
at will;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(iii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract relating to any agreement or plan,
including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased, or the
vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction
with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis
of any of the Contemplated Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(iv)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract relating to any agreement of indemnification
or guaranty not entered into in the Ordinary Course of Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(v)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract containing (A) any covenant limiting
the freedom of MEDS or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development,
manufacture, or distribution of the MEDS&rsquo;s products or services (B) any most-favored pricing arrangement, (C) any exclusivity provision
or (D) any non-solicitation provision;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(vi)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract (A) pursuant to which any Person
granted MEDS an exclusive license under any Intellectual Property, or (B) pursuant to which MEDS granted any Person an exclusive license
under any MEDS IP Rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(vii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract relating to capital expenditures
and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without
penalty;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(viii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract relating to the disposition or acquisition
of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of
this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(ix)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract relating to any mortgages, indentures,
loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension
of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of MEDS or any loans or debt obligations
with officers or directors of MEDS;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(x)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract requiring payment by or to the Company
after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying
any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical
or clinical development activities of the Company, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation,
development or other agreement currently in force under which MEDS or any of its Subsidiaries has continuing obligations to develop or
market any product, technology or service, or any agreement pursuant to which MEDS or any of its Subsidiaries has continuing obligations
to develop any Intellectual Property that will not be owned, in whole or in part, by MEDS or such Subsidiary or (D) any Contract to license
any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture
or produce any product, service or technology of MEDS or any of its Subsidiaries or any Contract to sell, distribute or commercialize
any products or service of MEDS or any of its Subsidiaries, in each case, except for MEDS Contracts entered into in the Ordinary Course
of Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xi)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract with any Person, including any financial
advisor, broker, finder, investment banker or other Person, providing advisory services to MEDS in connection with the Contemplated Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each MEDS Contract to which MEDS or any of its Subsidiaries
is a party or by which any of their assets and properties is currently bound, which involves annual obligations of payment by, or annual
payments to, MEDS or such Subsidiary in excess of $100,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xiii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any MEDS Real Estate Lease;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xiv)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other MEDS Contract that is not terminable at will
(with no penalty or payment) by MEDS or any of its Subsidiaries, and (A) which involves payment or receipt by MEDS or such Subsidiary
after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations
after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of MEDS
and its Subsidiaries taken as a whole; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before the termination of the Due Diligence Period,
MEDS will deliver or make available to the Company accurate and complete copies of all MEDS Material Contracts, including all amendments
thereto. There are no MEDS Material Contracts that are not in written form. MEDS has not nor, to MEDS&rsquo;s Knowledge as of the date
of this Agreement, has any other party to a MEDS Material Contract, breached, violated or defaulted under, or received notice that it
breached, violated or defaulted under, any of the terms or conditions of any MEDS Material Contract in such manner as would permit any
other party to cancel or terminate any such MEDS Material Contract, or would permit any other party to seek damages which would reasonably
be expected to have a MEDS Material Adverse Effect. As to MEDS and its Subsidiaries, as of the date of this Agreement, each MEDS Material
Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating,
or has a right pursuant to the terms of any MEDS Material Contract to change, any material amount paid or payable to MEDS under any MEDS
Material Contract or any other material term or provision of any MEDS Material Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.9
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance; Permits; Restrictions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS and each of its Subsidiaries is, and since January
1, 2022, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order, or other
action by any Governmental Authority is pending or, to the Knowledge of MEDS, threatened against MEDS or any of its Subsidiaries. There
is no agreement or Order binding upon MEDS or any of its Subsidiaries which (i) has or would reasonably be expected to have the effect
of prohibiting or materially impairing any business practice of MEDS or any of its Subsidiaries, any acquisition of material property
by MEDS or any of its Subsidiaries or the conduct of business by MEDS or any of its Subsidiaries as currently conducted, (ii) is reasonably
likely to have an adverse effect on MEDS&rsquo;s ability to comply with or perform any covenant or obligation under this Agreement or
(iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated
Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of MEDS and its Subsidiaries holds all required
Governmental Authorizations that are material to the operation of the business of MEDS and Merger Sub as currently conducted (collectively,
the &ldquo;<B>MEDS Permits</B>&rdquo;). Each of MEDS and its Subsidiaries is in material compliance with the terms of the MEDS Permits.
No Legal Proceeding is pending or, to the Knowledge of MEDS, threatened, which seeks to revoke, substantially limit, suspend, or materially
modify any MEDS Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.10
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal Proceedings; Orders.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 112.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as set forth in the MEDS Disclosure Schedule, there is no pending Legal Proceeding and, to the Knowledge of MEDS, no Person has
threatened in writing to commence any Legal Proceeding: (i) that involves MEDS or any of its Subsidiaries or any MEDS Associate (in his
or her capacity as such) or any of the material assets owned or used by MEDS or any of its Subsidiaries or (ii) that challenges, or that
may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 112.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no Order to which MEDS or any of its Subsidiaries,
or any of the material assets owned or used by MEDS or any of its Subsidiaries is subject. To the Knowledge of MEDS, no officer or other
Key Employee of MEDS or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing
any conduct, activity or practice relating to the business of MEDS or any of its Subsidiaries or to any material assets owned or used
by MEDS or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.11
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tax Matters.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of MEDS and each of its Subsidiaries has timely
filed all income Tax Returns and all other material Tax Returns required to be filed under applicable Law. All such Tax Returns were
true, correct and complete in all material respects and have been prepared in material compliance with all applicable Law. Subject to
exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where MEDS or any of its Subsidiaries
does not file Tax Returns that MEDS or any of its Subsidiaries is subject to taxation by that jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All material amounts of Taxes due and owing by MEDS
and each of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid. The unpaid Taxes of MEDS and each of its
Subsidiaries for periods (or portions thereof) ending on or prior to the date of the MEDS Unaudited Interim Balance Sheet do not materially
exceed the accruals for current Taxes set forth on the MEDS Unaudited Interim Balance Sheet. Since the date of the MEDS Unaudited Interim
Balance Sheet, neither MEDS nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of
Business or otherwise inconsistent with past custom and practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of MEDS and each of its Subsidiaries has withheld
and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any
amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no Encumbrances for material Taxes (other
Encumbrances described in clause (a) of the definition of &ldquo;<B>Permitted Encumbrances</B>&rdquo;) upon any of the assets of MEDS
or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No deficiencies for a material amount of Taxes with
respect to MEDS or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have
not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, examinations assessments
or other actions for or relating to any liability in respect of Taxes of MEDS or any of its Subsidiaries. Neither MEDS nor any of its
Subsidiaries has waived any statute of limitations in respect of material Taxes or agreed to any extension of time with respect to a
material Tax assessment or deficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries is a party
to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries has been a
member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is
MEDS). Neither MEDS nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than MEDS or its Subsidiaries)
under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor,
by Contract (other than an Ordinary Course Agreement) or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(h)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries has distributed
stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed
in whole or in part by Section 355 of the Code or Section 361 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries has entered
into any transaction identified as a &ldquo;reportable transaction&rdquo; for purposes of Treasury Regulations Sections 1.6011-4(b)(2)
or 301.6111-2(b)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(j)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries will be required
to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending
after the Closing Date as a result of any: (i) change in, or use of improper, method of accounting for a taxable period ending on or
prior to the Closing Date; (ii) &ldquo;closing agreement&rdquo; as described in Section 7121 of the Code (or any corresponding or similar
provision of state, local or foreign income Tax law) executed on or prior to the Closing Date; (iii) installment sale or open transaction
disposition made on or prior to the Closing Date; (iv) prepaid amount, advance payments or deferred revenue received or accrued on or
prior to the Closing Date other than in respect of such amounts reflected in the MEDS Balance Sheet or received in the Ordinary Course
of Business since the date of the MEDS Balance Sheet; or (v) intercompany transaction or excess loss amount described in Treasury Regulations
under Section 1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(k)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries is aware of
any facts or circumstances or has knowingly taken or agreed to take any action, in each case, that would reasonably be expected to prevent
or impede the Merger from qualifying as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.12
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employee and Labor Matters; Benefit Plans.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section 4.13(a)</U> of the MEDS Disclosure Schedule
sets forth, for each current MEDS Associate who is an employee of MEDS or any of its Subsidiaries, such employee&rsquo;s name, employer,
title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt
from the Fair Labor Standards Act, annual salary and wage rate, most recent annual bonus received and current annual bonus opportunity.
<U>Section 4.17(a)</U> of the MEDS Disclosure Schedule separately sets forth, for each current MEDS Associate who is an individual independent
contractor engaged by MEDS or any of its Subsidiaries, such contractor&rsquo;s name, duties and rate of compensation. No Key Employee
has indicated to MEDS or any of its Subsidiaries that he or she intends to resign or retire as a result of the transactions contemplated
by this Agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The employment of MEDS&rsquo;s employees is terminable
by MEDS at will. MEDS has made available to the Company accurate and complete copies of all employee manuals and handbooks, disclosure
materials, policy statements and other materials relating to the employment of MEDS Associates to the extent currently effective and
material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS is not a party to, bound by the terms of, and does
not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of
its employees, and there are no labor organizations representing or, to the Knowledge of MEDS, purporting to represent or seeking to
represent any employees of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section 4.12(e)</U> of the MEDS Disclosure Schedule
lists all MEDS Employee Plans (other than employment arrangements which are terminable &ldquo;at will&rdquo; without any contractual
obligation on the part of MEDS or any of its Subsidiaries to make any severance, termination, change in control or similar payment and
that are substantively identical to the employment arrangements made available to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each MEDS Employee Plan that is intended to be qualified
under Section 401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from
the IRS. To the Knowledge of MEDS, nothing has occurred that would reasonably be expected to adversely affect the qualified status of
any such MEDS Employee Plan or the exempt status of any related trust.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each MEDS Employee Plan has been established, maintained
and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA
and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge
of MEDS, threatened with respect to any MEDS Employee Plan. All payments and/or contributions required to have been made with respect
to all MEDS Employee Plans either have been made or have been accrued in accordance with the terms of the applicable MEDS Employee Plan
and applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(h)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its ERISA Affiliates maintains,
contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to, or been required to contribute
to (i) any &ldquo;employee benefit plan&rdquo; that is or was subject to Title IV or Section 302 of ERISA or Section 412 of the Code,
(ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section 419 of the Code, (iv) any Multiple Employer
Plan, or (v) any Multiple Employer Welfare Arrangement. Neither MEDS nor any of its ERISA Affiliates has ever incurred any liability
under Title IV of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No MEDS Employee Plan provides for medical or other
welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous
state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. MEDS
does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(j)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No MEDS Employee Plan is subject to any law of a foreign
jurisdiction outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(k)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each MEDS Employee Plan that constitutes in any part
a &ldquo;nonqualified deferred compensation plan&rdquo; (as such term is defined under Section 409A(d)(1) of the Code and the guidance
thereunder) (each, a &ldquo;<B>409A Plan</B>&rdquo;) has been operated and maintained in all material respects in operational and documentary
compliance with the requirements of Section 409A of the Code and the applicable guidance thereunder. No payment to be made under any
409A Plan is or, when made in accordance with the terms of the 409A Plan, will be subject to the penalties of Section 409A(a)(1) of the
Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(l)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS is in material compliance with all applicable federal,
state and local laws, rules and regulations respecting employment, employment practices, terms and conditions of employment, worker classification,
tax withholding, prohibited discrimination, harassment, equal employment, fair employment practices, meal and rest periods, immigration
status, employee safety and health, wages (including overtime wages), compensation, and hours of work, and in each case, with respect
to the employees of MEDS: (i) has withheld and reported all material amounts required by law or by agreement to be withheld and reported
with respect to wages, salaries and other payments to employees, (ii) is not liable for any arrears of wages, severance pay or any Taxes
or any penalty for failure to comply with any of the foregoing and (iii) is not liable for any material payment to any trust or other
fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social
security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business).
There are no actions, suits, claims or administrative matters pending or, to the Knowledge of MEDS, threatened or reasonably anticipated
against MEDS relating to any employee, independent contractor, director, employment agreement or MEDS Employee Plan (other than routine
claims for benefits). To the Knowledge of MEDS, there are no pending or threatened or reasonably anticipated claims or actions against
MEDS, any MEDS trustee or any trustee of any Subsidiary under any workers&rsquo; compensation policy or long-term disability policy.
MEDS is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state, or local agency
or Governmental Authority with respect to employment practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(m)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS has no material liability with respect to any misclassification
within the past four (4) years of (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from
another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. MEDS has not taken any action
which would constitute a &ldquo;plant closing&rdquo; or &ldquo;mass layoff&rdquo; within the meaning of the WARN Act or similar state
or local law, issued any notification of a plant closing or mass layoff required by the WARN Act or similar state or local law (nor has
MEDS been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under WARN or
any similar state or local law that remains unsatisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(n)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has never been, nor has there been any threat
of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar
activity or dispute, affecting MEDS. No event has occurred within the past six months, and no condition or circumstance exists, that
might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage,
lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(o)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MEDS is not, nor has MEDS been, engaged in any unfair
labor practice within the meaning of the National Labor Relations Act. There is no Legal Proceeding, claim, labor dispute or grievance
pending or, to the Knowledge of MEDS, threatened or reasonably anticipated relating to any employment contract, privacy right, labor
dispute, wages and hours, leave of absence, plant closing notification, workers&rsquo; compensation policy, long-term disability policy,
harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any MEDS Associate,
including charges of unfair labor practices or discrimination complaints.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(p)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no contract, agreement, plan or arrangement
to which MEDS or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees for excise taxes paid
pursuant to the Code, including, but not limited to, Section 4999 or Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(q)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither MEDS nor any of its Subsidiaries is a party
to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the
consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) (i) result in the payment
of any &ldquo;parachute payment&rdquo; within the meaning of Section 280G of the Code or (ii) result in, or cause the accelerated vesting,
payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other
service provider of MEDS or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.13
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions with Affiliates.</U> Except as set forth
in the MEDS SEC Documents filed prior to the date of this Agreement, since the date of MEDS&rsquo;s last proxy statement filed in 2022
with the SEC, no event has occurred that would be required to be reported by MEDS pursuant to Item 404 of Regulation S-K promulgated
by the SEC. <U>Section 4.13</U> of the MEDS Disclosure Schedule identifies each Person who is (or who may be deemed to be) an Affiliate
of MEDS as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.14
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Financial Advisors</U>. Except as set forth on
<U>Section 4.14</U> of the MEDS Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&rsquo;s
fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon
arrangements made by or on behalf of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.15
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Valid Issuance</U></FONT>. The MEDS Common Stock
to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.16
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shareholder Approval of Independent Director Consideration</U>.
No later than five months following the Closing Date, MEDS shall obtain approval from the shareholders of MEDS of the Independent Director
Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">4.17
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Other Representations or Warranties</U>. MEDS
hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor
any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation
or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to MEDS, Merger Sub or
stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations
and warranties of the Company set forth in <U>Section 3</U> (in each case as qualified and limited by the Company Disclosure Schedule))
none of MEDS, Merger Sub nor any of their respective Representatives or stockholders, has relied on any such information (including the
accuracy or completeness thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5. <U>Certain Covenants of the Parties.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">5.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Operation of MEDS&rsquo;s Business.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except (i) as expressly contemplated or permitted by
this Agreement, (ii) as set forth on <U>Section 5.1(a)</U> of the MEDS Disclosure Schedule, (iii) as required by applicable Law, (iv)
any action taken or not taken by MEDS or any of its Subsidiaries (including Merger Sub) in good faith to respond to changes in relationships
with officers, employees, agents, independent contractors, suppliers, customers and other business partners, or (v) unless the Company
shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing
on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to <U>Section 10
</U>and the Effective Time (the &ldquo;<B>Pre-Closing Period</B>&rdquo;), MEDS shall use commercially reasonable efforts to conduct its
business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of
all Contracts that constitute MEDS Material Contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except (i) as expressly contemplated or permitted by
this Agreement or the other Transaction Documents, (ii) as set forth in <U>Section 5.1(b)</U> of the MEDS Disclosure Schedule, (iii)
as required by applicable Law, (iv) any action taken or not taken by MEDS or any of its Subsidiaries (including Merger Sub) in good faith
to respond to changes in relationships with officers, employees, agents, independent contractors, suppliers, customers and other business
partners, or (v) with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned),
at all times during the Pre-Closing Period, MEDS shall not:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">declare, accrue, set aside or pay any dividend or make
any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital
stock or other securities (except for shares of MEDS Common Stock from terminated employees, directors or consultants of MEDS);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(ii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell, issue, grant, pledge or otherwise dispose of or
encumber or authorize the issuance of (A) any capital stock or other security (except for MEDS Common Stock) issued upon the valid exercise
or settlement of outstanding MEDS Options or MEDS Warrants, as applicable, (B) any option, warrant or right to acquire any capital stock
or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(iii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except as required to give effect to anything in contemplation
of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business
combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except in connection
with or furtherance of the Contemplated Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(iv)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">form any Subsidiary or acquire any equity interest or
other interest in any other Entity or enter into a joint venture with any other Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(v)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) lend money to any Person, (B) incur or guarantee
any indebtedness for borrowed money, other than in the Ordinary Course of Business, (C) guarantee any debt securities of others or (D)
make any capital expenditure or commitment in excess of $250,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(vi)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other than in the Ordinary Course of Business (A) adopt,
establish or enter into any MEDS Employee Plan, (B) cause or permit any MEDS Employee Plan to be amended other than as required by law
or in order to make amendments for the purposes of Section 409A of the Code, (C) pay any bonus or make any profit-sharing or similar
payment to (except with respect to obligations pursuant to any MEDS Employee Plan), or increase the amount of the wages, salary, commissions,
fringe benefits or other compensation or remuneration payable to, any of its employees, directors or consultants or (D) increase the
severance or change of control benefits offered to any current or new employees, directors or consultants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(vii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into any material transaction outside the Ordinary
Course of Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(viii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire any material asset or sell, lease or otherwise
irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in
the Ordinary Course of Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(ix)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make, change or revoke any material Tax election; file
any material amendment to any Tax Return or adopt or change any material accounting method in respect of Taxes; enter into any material
Tax closing agreement, settle any material Tax claim or assessment, or consent to any extension or waiver of the limitation period applicable
to or relating to any material Tax claim or assessment, other than any such extension or waiver that is obtained in the ordinary course
of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(x)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into, amend or terminate any MEDS Material Contract;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xi)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agree, resolve or commit to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of MEDS prior
to the Effective Time. Prior to the Effective Time, MEDS shall exercise, consistent with the terms and conditions of this Agreement,
complete unilateral control and supervision over its business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding any provision herein to the contrary
(including the foregoing provisions of this <U>Section 5.1)</U> MEDS may engage in the sale, license, transfer, disposition, divestiture
or other monetization transaction (e.g., a royalty transaction) or winding down of the MEDS Legacy Business or the sale, license, transfer,
disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any MEDS Legacy Assets
(each, an &ldquo;<B>MEDS Legacy Transaction</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">5.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Operation of the Company&rsquo;s Business.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
The Company agrees that, between the date of this Agreement and the Effective Time or the earlier termination of this Agreement, except
as (i) expressly contemplated by any other provision of this Agreement or any other Transaction Document, (ii) as set forth in <U>Section
5.2(a)</U> of the Company Disclosure Schedule, and (iii) as required by applicable Law (including as may be requested or compelled by
any Governmental Authority), unless MEDS shall otherwise consent in writing</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Company shall and shall cause the Subsidiaries to, use its best efforts conduct its and their respective businesses in the ordinary
course of business and in a manner consistent with past practice in all material respects; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the Company shall, and shall cause each Subsidiary to, use its best efforts to maintain and preserve intact in all material respects
the business organization, assets, properties and material business relations of the Company and the Subsidiaries taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By way of amplification and not limitation, except as
(i) expressly required by any other provision of this Agreement or any other Transaction Documents, (ii) as set forth in <U>Section 5.2(b)
</U>of the Company Disclosure Schedule, and (iii) as required by applicable Law:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend or otherwise change its certificate of incorporation
or bylaws or equivalent Organizational Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(ii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) issue, sell, pledge, dispose of, grant or encumber,
or authorize the issuance, sale, pledge, disposition, grant or encumbrance of, any Equity Interests of the Company or any Subsidiary,
or any options, warrants, convertible securities or other rights of any kind to acquire any Equity Interests (including, without limitation,
any phantom interest), of the Company or any Subsidiary; or (B) sell any assets of the Company or any Subsidiary that would be expected
to have a Company Material Adverse Effect; <U>provided</U>, <U>however</U>, that the actions described in subsection (A) shall be permissible
to the extent made in the ordinary course of business consistent with past practice and in compliance with the Plans;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(iii)
form any subsidiary or acquire any Equity Interest or other interest in any other entity or enter into a joint venture with any other
entity</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(iv)
declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any
of its Equity Interests (other than tax distributions in accordance with the Company&rsquo;s Organizational Documents, if any)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(v)
reclassify, combine, split, subdivide or redeem, or purchase or otherwise acquire, directly or indirectly, any of its Equity Interests</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(vi)
(A) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or substantially all of the assets or any
other business combination) any material assets or any corporation, partnership, other business organization or any division thereof;
(B) incur any indebtedness for borrowed money or issue any debt securities or assume, guarantee or endorse, or otherwise become responsible
for, the obligations of any person, or make any loans or advances, or intentionally grant any security interest in any of its assets,
other than (1) intercompany indebtedness among the Company and its Subsidiaries or (2) indebtedness that is incurred in the ordinary
course of business consistent with past practice (and, with respect to borrowed money indebtedness, is reasonably necessary to meet any
current obligations of the Company and its Subsidiaries); or (C) merge, consolidate, combine or amalgamate with any person</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(vii)
(A) grant any increase in the compensation, incentives or benefits payable or to become payable to any current or former executive officer,
(B) enter into any new or materially amend any existing, employment, retention, bonus, change in control, severance, redundancy or termination
agreement with any current or former executive officer whose base salary is in excess of $250,000, (C) accelerate or commit to accelerate
the funding, payment, or vesting of any compensation or benefits to any current or former executive officer whose base salary is in excess
of $250,000, (D) establish or become obligated under any collective bargaining agreement, collective agreement, or other contract or
agreement with a labor union, trade union, works council, or other representative of executive officers; (E) hire any new executive officers
whose base salary is in excess of $250,000; <U>provided</U>, <U>however</U>, that the actions described in subsection (A) shall be permissible
to the extent made in the ordinary course of business consistent with past practice (and not to exceed 10% with respect to any such executive
officer)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(viii)
adopt, amend and/or terminate any material Plan except as may be required by applicable Law, is necessary in order to consummate the
Contemplated Transactions, or health and welfare plan renewals in the ordinary course of business</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(ix)
materially amend (other than reasonable and usual amendments in the ordinary course of business), the accounting policies or procedures,
other than as required by GAAP</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(x)
(A) amend any material Tax Return, (B) change any material method of Tax accounting, (C) make (inconsistent with past practice), change
or rescind any material election relating to Taxes (including, for the avoidance of doubt, any election that results in the Company or
any Subsidiary being treated as other than a partnership or a disregarded entity for U.S. federal income tax purposes), or (D) settle
or compromise any material U.S. federal, state, local or non-U.S. Tax audit, assessment, Tax claim or other controversy relating to Taxes</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xi)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into, amend or terminate any Company Material
Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xii)
fail to maintain the Leased Real Property, including the improvements located thereon or used in connection therewith, in substantially
the same condition as of the date of this Agreement, except where the failure to maintain such Leased Real Property would reasonably
be expected to have a Company Material Adverse Effect</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
fail to maintain the existence of, or use reasonable efforts to protect, Company Registered IP to the extent that such action or inaction
would reasonably be expected to have a Company Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)
permit any item of Company Registered IP to lapse or to be abandoned, invalidated, dedicated to the public, or disclaimed, or otherwise
become unenforceable or fail to perform or make any applicable filings, recordings or other similar actions or filings, or fail to pay
all required fees and Taxes required or advisable to maintain and protect its interest in each and every material item of Company Registered
IP to the extent that such action or inaction would reasonably be expected to have a Company Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)
waive, release, assign, settle or compromise any Legal Proceeding, other than waivers, releases, assignments, settlements or compromises
that are solely monetary in nature and do not exceed $500,000 individually or $1,000,000 in the aggregate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)
take any action or knowingly fail to take any action, which action or failure to act would reasonably be expected to prevent or impede
the Contemplated Transactions from qualifying for the Intended Tax Treatment; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(xvii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agree, resolve or commit to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
contained in this Agreement shall give MEDS, directly or indirectly, the right to control or direct the operations of the Company prior
to the Effective Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement,
complete unilateral control and supervision over its business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">5.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Access and Investigation.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the terms of the Confidentiality Agreement,
which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable
notice, MEDS, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such
Party&rsquo;s Representatives to (i) provide the other Party and such other Party&rsquo;s Representatives with reasonable access during
normal business hours to such Party&rsquo;s Representatives, personnel and assets and to all existing books, records, Tax Returns, work
papers and other documents and information relating to such Party and its Subsidiaries, (ii) provide the other Party and such other Party&rsquo;s
Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information
relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such
Party and its Subsidiaries as the other Party may reasonably request and (iii) permit the other Party&rsquo;s officers and other employees
to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of
such Party responsible for such Party&rsquo;s financial statements and the internal controls of such Party to discuss such matters as
the other Party may deem necessary. Any investigation conducted by either MEDS or the Company pursuant to this <U>Section 5.3</U> shall
be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party. Notwithstanding the
foregoing, satisfying such covenants shall in no event be a condition to Closing nor shall the failure to satisfy such covenants prior
to the Closing Date be a breach of this Agreement or constitute a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything herein to the contrary in this
<U>Section 5.3,</U> no access or examination contemplated by this <U>Section 5.3</U> shall be permitted to the extent that it would require
any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law;
<U>provided</U>, that such Party or its Subsidiary (i) shall be entitled to withhold only such information that may not be provided without
causing such violation or waiver, (ii) shall provide to the other Party all related information that may be provided without causing
such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii) shall enter into such
effective and appropriate joint defense agreements or other protective arrangements as may be reasonably requested by the other Party
in order that all such information may be provided to the other Party without causing such violation or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">5.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Solicitation.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of MEDS and the Company agrees that, during the
Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives
to, directly or indirectly (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or
announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that would reasonably be expected to lead to an Acquisition
Proposal or Acquisition Inquiry, (ii) furnish any non-public information regarding such Party to any Person in connection with or in
response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect
to any Acquisition Proposal or Acquisition Inquiry, (iv) approve, endorse or recommend any Acquisition Proposal (subject to <U>Section
6.1</U> and <U>Section 6.3</U>)or (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating
to any Acquisition Transaction; <U>provided</U>, <U>however</U>, that, notwithstanding anything contained in this <U>Section 5.4</U>
and subject to compliance with this <U>Section 5.4</U>, prior to the approval of this Agreement by a Party&rsquo;s equity holders (i.e.,
the Required Company Shareholder Vote, in the case of the Company), such Party may furnish non-public information regarding such Party
and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal
by such Person which such Party&rsquo;s board of directors determines in good faith, after consultation with such Party&rsquo;s financial
advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if (A)
neither such Party nor any Representative of such Party shall have breached this <U>Section 5.4</U> in any material respect, (B) the
board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such
action would reasonably be expected to be inconsistent with the board of directors&rsquo; fiduciary duties under applicable Law, (C)
at least two (2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such
Person, such Party gives the other Party written notice of the identity of such Person and of such Party&rsquo;s intention to furnish
nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable
Confidentiality Agreement and (E) at least two (2) Business Days prior to furnishing any such nonpublic information to such Person, such
Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such
Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any
Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this <U>Section 5.4</U> by such
Party, the taking of such action by such Representative shall be deemed to constitute a breach of this <U>Section 5.4</U> by such Party
for purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any Party or any Representative of such Party receives
an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event
later than one (1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other
Party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting
such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with
respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed
modification thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Party shall immediately cease and cause to be terminated
any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal as of the date of this
Agreement and request the destruction or return of any nonpublic information provided to such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">5.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notification of Certain Matters</U>. During the Pre-Closing
Period, each of the Company, on the one hand, and MEDS, on the other hand, shall promptly notify the other (and, if in writing, furnish
copies of) if any of the following occurs: (a) any notice or other communication is received from any Person alleging that the Consent
of such Person is or may be required in connection with any of the Contemplated Transactions; (b) any Legal Proceeding against or involving
or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party
or, to the Knowledge of such Party, any director, officer or Key Employee of such Party; (c) such Party becomes aware of any inaccuracy
in any representation or warranty made by such Party in this Agreement; or (d) the failure of such Party to comply with any covenant
or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions
set forth in <U>Section 7</U>, <U>Section 8</U> or <U>Section 9</U>, as applicable, impossible or materially less likely. No such notice
shall be deemed to supplement or amend the Company Disclosure Schedule or the MEDS Disclosure Schedule for the purpose of (x) determining
the accuracy of any of the representations and warranties made by the Company or MEDS in this Agreement or (y) determining whether any
condition set forth in <U>Section 7</U>, <U>Section 8</U> or <U>Section 9</U> has been satisfied. Any failure by either Party to provide
notice pursuant to this <U>Section 5.5</U> shall not be deemed to be a breach for purposes of <U>Section 8.2</U> or <U>Section 9.2</U>,
as applicable, unless such failure to provide such notice was knowing and intentional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6. <U>Additional Agreements of the Parties.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company Shareholder Written Consent.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall obtain the approval by written consent
from Company Shareholders sufficient for the Required Company Shareholder Vote in lieu of a meeting pursuant to Section 228 of the DGCL,
for purposes of (i) adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given
thereby is irrevocable and that such equity holder is aware of its rights to demand appraisal for its shares pursuant to Section 262
of the DGCL, a copy of which will be attached thereto, and that such equity holder has received and read a copy of Section 262 of the
DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its equity in
connection with the Merger and thereby waives any rights to receive payment of the fair value of its equity under the DGCL. Under no
circumstances shall the Company assert that any other approval or consent is necessary by its equity holders to approve this Agreement
and the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonably promptly following receipt of the Required
Company Shareholder Vote, the Company shall prepare and mail a notice (the &ldquo;<B>Equity Holder Notice</B>&rdquo;) to every equity
holder of the Company that did not execute the Company Shareholder Written Consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Equity Holder Notice shall (i) be a statement to
the effect that the Company Board determined that the Merger is advisable in accordance with Section 251(b) of the DGCL and in the best
interests of the equity holders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions,
(ii) provide the equity holders of the Company to whom it is sent with notice of the actions taken in the Company Shareholder Written
Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with
Section 228(e) of the DGCL and the organizational documents of the Company and (iii) include a description of the appraisal rights of
the Company&rsquo;s equity holders available under the DGCL, along with such other information as is required thereunder and pursuant
to applicable Law. All materials (including any amendments thereto) submitted to the equity holders of the Company in accordance with
this <U>Section 6.2(c)</U> shall be subject to MEDS&rsquo;s advance review and reasonable approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company agrees that, subject to <U>Section 6.1(d)
</U>(i) the Company Board shall recommend that the Company&rsquo;s equity holders vote to adopt and approve this Agreement and the Contemplated
Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in <U>Section 6.2(a)</U>
(the recommendation of the Company Board that the Company&rsquo;s equity holders vote to adopt and approve this Agreement being referred
to as the &ldquo;<B>Company Board Recommendation</B>&rdquo;) and (ii) the Company Board Recommendation shall not be withdrawn or modified
(and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to MEDS,
and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse
to MEDS or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted
or proposed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything to the contrary contained in
<U>Section 6.1(c)</U> and subject to compliance with <U>Section 5.4</U> and <U>Section 6.1,</U> if at any time prior to approval and
adoption of this Agreement by the Required Company Shareholder Vote, the Company receives a bona fide written Superior Offer, the Company
Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify
the Company Board Recommendation) in a manner adverse to MEDS (collectively, a &ldquo;<B>Company Board Adverse Recommendation Change</B>&rdquo;)
if, but only if, following the receipt of and on account of such Superior Offer, (i) the Company Board determines in good faith, based
on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably
be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has, and has caused its financial advisors
and outside legal counsel to, during the Notice Period, negotiate with MEDS in good faith to make such adjustments to the terms and conditions
of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if after MEDS shall have delivered
to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have
determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the
Company Board Recommendation would be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations
of the terms and conditions of this Agreement); <U>provided</U> that (x) MEDS receives written notice from the Company confirming that
the Company Board has determined to change its recommendation at least four (4) Business Days in advance of the Company Board Adverse
Recommendation Change (the &ldquo;<B>Notice Period</B>&rdquo;), which notice shall include a description in reasonable detail of the
reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with
any party making a potential Superior Offer, (y) during any Notice Period, MEDS shall be entitled to deliver to the Company one or more
counterproposals to such Acquisition Proposal and the Company shall, and shall cause its Representatives to, negotiate with MEDS in good
faith (to the extent MEDS desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable
Acquisition Proposal ceases to constitute a Superior Offer and (z) in the event of any material amendment to any Superior Offer (including
any revision in the amount, form or mix of consideration the Company&rsquo;s equity holders would receive as a result of such potential
Superior Offer), the Company shall be required to provide MEDS with notice of such material amendment and the Notice Period shall be
extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period following such notification during
which the Parties shall comply again with the requirements of this <U>Section 6.1(d)</U> and the Company Board shall not make a Company
Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple
extensions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s obligation to solicit the consent
of its equity holders to sign the Company Shareholder Written Consent in accordance with <U>Section 6.2(a)</U> shall not be limited or
otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal, or
by any Company Board Adverse Recommendation Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Efforts; Regulatory Approvals</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parties shall use reasonable best efforts to consummate
the Contemplated Transactions. Without limiting the generality of the foregoing, each Party (i) shall make all filings and other submissions
(if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions,
(ii) shall use reasonable best efforts to obtain each Consent (if any) required to be obtained (pursuant to any applicable Law or Contract,
or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect,
(iii) shall use reasonable best efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions
and (iv) shall use commercially reasonable best efforts to satisfy the conditions precedent to the consummation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall use commercially reasonable efforts
to contemplate the transactions in connection with the Combined Companies. The Company shall make or cause to be made all filings and
other submissions (if any) and give all notices (if any) required to be made in connection with the transactions to acquire the Combined
Companies (ii) shall use best efforts to obtain each Consent (if any) required to be obtained (pursuant to any applicable Law or Contract,
or otherwise) by such party in connection with the transactions to acquire the Combined Companies, (iii) shall use best efforts to lift
any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv) shall use its best efforts to satisfy the
conditions precedent related to the Combined Companies to the consummation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the generality of the foregoing, each
Party shall use best efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications,
notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental
Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental
Authority. Without limiting the generality of the foregoing, the Parties shall, promptly and no later than five (5) Business Days after
the date of this Agreement, prepare and file, if any, (a) the notification and report forms required to be filed under the HSR Act and
(b) any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to
antitrust or competition matters. The Company and MEDS shall respond, as promptly as is practicable to respond, in compliance with (i)
any inquiries or requests received from the Federal Trade Commission or the Department of Justice for additional information or documentation,
and (ii) any inquiries or requests received from any state attorney general, foreign antitrust or competition authority or other Governmental
Authority in connection with antitrust or competition matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until the Closing or earlier termination of this Agreement,
MEDS and the Company will each: (i) give the other Party prompt notice of the commencement of any investigation, action or Legal Proceeding
by or before any Governmental Authority with respect to this Agreement or any of the other transactions contemplated by this Agreement,
(ii) keep the other Party informed as to the status of any such investigation, action or Legal Proceeding, and (iii) promptly inform
the other Party of any communication to or from the Federal Trade Commission, the Department of Justice or any other Governmental Authority
regarding this Agreement or any of the other transactions contemplated by this Agreement, in each case to the extent permitted under
applicable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MEDS Options</U>. Prior to the Closing, the MEDS
Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that the vesting and
exercisability of each unexpired, unexercised and unvested MEDS Option shall be accelerated in full effective as of immediately prior
to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employee Benefits</U>. MEDS shall comply with the
terms of any employment, severance, retention, change of control, or similar agreement specified on <U>Section 4.12(e)</U> of the MEDS
Disclosure Schedule, subject to the provisions of such agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification of Officers and Directors.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From the Effective Time through the sixth anniversary
of the date on which the Effective Time occurs, each of MEDS and the Surviving Corporation shall indemnify and hold harmless each person
who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of MEDS
or the Company, respectively (the &ldquo;<B>D&amp;O Indemnified Parties</B>&rdquo;), against all claims, losses, liabilities, damages,
judgments, fines and reasonable fees, costs and expenses, including attorneys&rsquo; fees and disbursements (collectively, &ldquo;<B>Costs</B>&rdquo;),
incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative,
arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of MEDS or of the Company,
whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under the DGCL. Each
D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding
or investigation from each of MEDS and the Surviving Corporation, jointly and severally, upon receipt by MEDS or the Surviving Corporation
from the D&amp;O Indemnified Party of a request therefor; <U>provided</U> that any such person to whom expenses are advanced provides
an undertaking to MEDS, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person
is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&rsquo; rights with regards to counsel,
following the Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain GS2Law PLLC, Nelson Mullins Riley
&amp; Scarborough LLP or such other counsel selected by the D&amp;O Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of the certificate of incorporation and
bylaws of MEDS with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers
of MEDS that are presently set forth in the certificate of incorporation and bylaws of MEDS shall not be amended, modified or repealed
for a period of six (6) years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who,
at or prior to the Effective Time, were officers or directors of MEDS, unless such modification is required by applicable Law. The certificate
of incorporation and bylaws of the Surviving Corporation shall contain, and MEDS shall cause the certificate of incorporation and bylaws
of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and
exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws
of MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From and after the Effective Time, (i) the Surviving
Corporation shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately
prior to the Closing pursuant to any indemnification provisions under the Company&rsquo;s Organizational Documents and pursuant to any
indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring
at or prior to the Effective Time and (ii) MEDS shall fulfill and honor in all respects the obligations of MEDS to its D&amp;O Indemnified
Parties as of immediately prior to the Closing pursuant to any indemnification provisions under MEDS&rsquo;s Organizational Documents
and pursuant to any indemnification agreements between MEDS and such D&amp;O Indemnified Parties, with respect to claims arising out
of matters occurring at or prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From and after the Effective Time, MEDS shall maintain
directors&rsquo; and officers&rsquo; liability insurance policies, with an effective date as of the Closing Date, on commercially available
terms and conditions and with coverage limits customary for U.S. public companies similarly situated to MEDS, and obtain as of the Closing
Date &ldquo;tail&rdquo; insurance policies with a claims period of six (6) years from the Effective Time with at least the same coverage
and amounts, and containing terms and conditions that are not less advantageous to the D&amp;O Indemnified Parties of MEDS when compared
to the insurance maintained by MEDS as of the date hereof, in each case with respect to claims arising out of or relating to events which
occurred on or prior to the Effective Time (including in connection with the transactions contemplated by this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From and after the Effective Time, MEDS shall pay all
expenses, including reasonable attorneys&rsquo; fees, that are incurred by the persons referred to in this <U>Section 6.7</U> in connection
with their enforcement of the rights provided to such persons in this <U>Section 6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of this <U>Section 6.7</U> are intended
to be in addition to the rights otherwise available to the current and former officers and directors of MEDS and the Company by Law,
charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified
Parties, their heirs and their Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event MEDS or the Surviving Corporation or any
of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving
corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any
Person, then, and in each such case, proper provision shall be made so that the successors and assigns of MEDS or the Surviving Corporation,
as the case may be, shall succeed to the obligations set forth in this <U>Section 6.7</U>. MEDS shall cause the Surviving Corporation
to perform all of the obligations of the Surviving Corporation under this <U>Section 6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tax Matters.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of MEDS and the Company shall use reasonable best
efforts (and shall cause its Affiliates) to (i) cause the Merger to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section
368(a) of the Code, and (ii) not take any actions, or fail to take any action, which action or failure to act would reasonably be expected
to prevent or impede the Merger from qualifying as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code. The
Parties shall not file any U.S. federal, state or local Tax Return in a manner that is inconsistent with the treatment of the Merger
as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code for U.S. federal, state income and other relevant
Tax purposes, and shall not take any inconsistent position during the course of any audit, litigation or other proceeding with respect
to Taxes, in each case, unless otherwise required by a determination within the meaning of Section 1313(a) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All transfer, documentary, sales, use, stamp, registration,
excise, recording, registration value added and other such similar Taxes and fees (including any penalties and interest) that become
payable in connection with or by reason of the execution of this Agreement and the transactions contemplated hereby (collectively, &ldquo;<B>Transfer
Taxes</B>&rdquo;) shall be divided equally between MEDS and the Company. Unless otherwise required by applicable law, MEDS shall timely
file any Tax Return or other document with respect to such Taxes or fees (and the Company shall reasonably cooperate with respect thereto
as necessary).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.7 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legends</U>.
MEDS shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of MEDS Common
Stock to be received in the Merger by equity holders of the Company who may be considered &ldquo;affiliates&rdquo; of MEDS for
purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue
appropriate stop transfer instructions to the transfer agent for MEDS Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.8
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Officers and Directors</U>. Until successors are
duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and
take all necessary action so that the Persons listed on <U>Section 6.10</U> of the MEDS Disclosure Schedule are elected or appointed,
as applicable, to the positions of officers or directors of MEDS and the Surviving Corporation, as set forth therein, to serve in such
positions effective as of the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.9
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination of Certain Agreements and Rights</U>.
Except as set forth on <U>Section 6.11</U> of the MEDS Disclosure Schedule, each of MEDS and the Company shall cause any stockholder
agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either MEDS
or the Company and any holders of MEDS Common Stock or Company Common Shares, respectively, including any such Contract granting any
Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior
to the Effective Time, without any liability being imposed on the part of MEDS or the Surviving Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.10
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section 16 Matters</U>. Prior to the Effective Time,
MEDS shall take all such steps as may be required to cause any acquisitions of MEDS Common Stock and any options to purchase MEDS Common
Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting
requirements of Section 16(a) of the Exchange Act with respect to MEDS after the Effective Time, to be exempt under Rule 16b-3 promulgated
under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.11
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Allocation Certificate</U>. The Company will prepare
and deliver to MEDS prior to the Closing a certificate signed by the Company Board in a form reasonably acceptable to MEDS setting forth
(as of immediately prior to the Effective Time) (a) each holder of Company Common Shares, (b) such holder&rsquo;s name and address, (c)
the number or percentage and type of Company Common Shares held as of the Closing Date for each such holder and (d) the number of shares
of MEDS Common Stock to be issued to such holder pursuant to this Agreement in respect of the Company Common Shares held by such holder
as of immediately prior to the Effective Time (the &ldquo;<B>Allocation Certificate</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.12
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Public Announcements</U>. Unless otherwise required
by applicable Law (based upon the reasonable advice of counsel), the Company shall not make any public announcements in respect of this
Agreement, the Merger, or the Contemplated Transactions or otherwise communicate with any news media without the prior written consent
of MEDS and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">6.13
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Obligations of Merger Sub</U>. MEDS will take all
action necessary to cause Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions
set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7. <U>Conditions Precedent to Obligations of Each Party.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing
are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior
to the Closing, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">7.1 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Restraints</U>. No temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of
the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Authority of
competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the
Contemplated Transactions illegal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">7.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stockholder Approval</U>. The Company shall have
obtained the Required Company Shareholder Vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">7.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory Matters</U>. All required filings under
the HSR Act shall have been completed and any waiting period applicable to the consummation of the Merger under the HSR Act shall have
expired or been terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
8. <U>Additional Conditions Precedent to Obligations of MEDS and Merger Sub.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of MEDS and Merger Sub to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the
Closing are subject to the satisfaction or the written waiver by MEDS, at or prior to the Closing, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accuracy of Representations</U>. The Company Fundamental
Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct
on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations
and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct
as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this
Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date,
except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate or (y) for those representations
and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct,
subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties
of the Company contained in this Agreement (other than the Company Fundamental Representations and the Company Capitalization Representations)
shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and
correct would not be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company
Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only
as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding
clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and
warranties, any update of or modification to the Company Disclosure Schedule made or purported to have been made after the date of this
Agreement shall be disregarded).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Performance of Covenants</U>. The Company shall have
performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under
this Agreement at or prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Documents</U>. MEDS shall have received the following
documents, each of which shall be in full force and effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a certificate executed by the Chief Executive Officer
of the Company certifying (i) that the conditions set forth in <U>Sections 8.1</U>, <U>8.2</U>, <U>8.4</U> and <U>8.6</U> have been duly
satisfied and (ii) that the information set forth in the Allocation Certificate delivered by the Company in accordance with <U>Section
6.11</U> is true and accurate in all respects as of the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a certificate pursuant to Treasury Regulations Sections
1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section
1.897-2(h), in each case, in form and substance acceptable to MEDS;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Stock Swap Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company Valuation Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory Fairness Opinion; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Allocation Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Company Material Adverse Effect</U>. Since the
date of this Agreement, there shall not have occurred any Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company Lock-Up Agreements</U>. The Company Lock-Up
Agreements will continue to be in full force and effect as of immediately following the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company Shareholder Written Consent</U>. The Company
Shareholder Written Consent executed by the equity holders of the Company shall be in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.7 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sapientia
Membership Interest Purchase</U>. Unless waived by MEDS, the Company shall have closed its membership interest purchase agreement
with Sapientia Technology, LLC, a Delaware limited liability company, including obtaining all customary consents of governing bodies
and equity holders and any applicable third parties, either before or simultaneously with the Closing. The Company shall provide
access to all legal and financial information as requested as requested by MEDS related to this transaction and will not sign any
definitive agreements in connection therewith without the prior approval and input of MEDS and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.8 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Prestige
Farms Purchase Agreement</U>. Unless waived by MEDS, the Company shall have closed its purchase agreement with Prestige Farms, Inc.
including obtaining all customary consents of governing bodies and equity holders and any applicable third parties, either before or
simultaneously with the Closing. The Company shall provide access to all legal and financial information as requested as requested
by MEDS related to this transaction and will not sign any definitive agreements in connection therewith without the prior approval
and input of MEDS and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.9
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intentionally Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.10 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fairness
Opinion</U>. Within ten (10) Business Days of the execution and delivery of this Agreement, MEDS shall have received a fairness
opinion from The Mentor Group in a form acceptable to MEDS in its sole and absolute discretion. The Company shall provide access to
all legal and financial information as requested as requested by MEDS and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">8.11 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consulting
Agreements</U>. The Principal Stockholders each shall have entered into a twelve (12) month consulting agreement, in form and
substance acceptable to MEDS and the Company, with the post-closing Company to be effective immediately following
Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9. <U>Additional Conditions Precedent to Obligations of the Company.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of the Company to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing
are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">9.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accuracy of Representations</U>. Each of the MEDS
Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true
and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such
representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall
be true and correct as of such date). The MEDS Capitalization Representations shall have been true and correct in all respects as of
the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and
as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate or (y) for those
representations and warranties which address matters only as of a particular date (which representations and warranties shall have been
true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations
and warranties of MEDS and Merger Sub contained in this Agreement (other than the MEDS Fundamental Representations and the MEDS Capitalization
Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing
Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to
be true and correct would not reasonably be expected to have a MEDS Material Adverse Effect (without giving effect to any references
therein to any MEDS Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which
address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as
set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy
of such representations and warranties, any update of or modification to the MEDS Disclosure Schedule made or purported to have been
made after the date of this Agreement shall be disregarded).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">9.2 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Performance
of Covenants</U>. MEDS and Merger Sub shall have performed or complied with in all material respects all of their agreements and
covenants required to be performed or complied with by each of them under this Agreement at or prior to the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">9.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Documents</U>. The Company shall have received the
following documents, each of which shall be in full force and effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a certificate executed by an executive officer of MEDS
confirming that the conditions set forth in <U>Sections 9.1</U>, <U>9.2</U> and <U>9.4</U> have been duly satisfied;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">written resignations in forms satisfactory to the Company,
dated as of the Closing Date and effective as of the Closing executed by the officers and directors of MEDS who are not to continue as
officers or directors of MEDS; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Stock Swap Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">9.4 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
MEDS Material Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred any MEDS Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
<U>Payoff Letter[s]</U>. If applicable, the Company shall have received a true and correct copies of each payoff letter addressed to
the Company and MEDS from MEDS debtholders in connection with the repayment by MEDS of any unpaid indebtedness for borrowed money of
MEDS and related fees to MEDS debtholders and termination of the relevant debt instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">9.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MEDS Board of Directors</U>. The Company shall have
been granted the right to appoint or elect, as applicable, no less than 3 board seats on the MEDS Board after Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">9.7
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MEDS Lock-Up Agreements</U>. The MEDS Lock-Up Agreements
will continue to be in full force and effect as of immediately following the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10. <U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">10.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination</U>. This Agreement may be terminated
prior to the Effective Time (whether before or after adoption of this Agreement by the Company&rsquo;s equity holders, unless otherwise
specified below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by mutual written consent of MEDS and the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by either MEDS or the Company if the Merger shall not
have been consummated by August 30, 2023 (subject to possible extension as provided in this <U>Section 10.1(b),</U> the &ldquo;<B>End
Date</B>&rdquo;); <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this <U>Section 10.1(b)</U> shall
not be available to the Company or MEDS if such Party&rsquo;s action or failure to act has been a principal cause of the failure of the
Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by either MEDS or the Company if a court of competent
jurisdiction or Governmental Authority shall have issued a final and nonappealable Order, or shall have taken any other action, having
the effect of permanently restraining, enjoining or otherwise prohibiting any of the Contemplated Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by MEDS if (i) the Company shall not have delivered
to MEDS the Company Valuation Certificate in compliance with <U>Section 2.9</U> that reflects a Company Valuation of at least $225,000,000.00
or (ii) the MEDS Board has not received Satisfactory Fairness Opinion that the Contemplated Transactions are fair to the holders of MEDS
Common Stock from a financial point of view by the date that is fourteen (14) days after the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by MEDS, in its sole and absolute discretion, in accordance
with <U>Section 3.22;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by MEDS if the matters set forth on <U>Section 6.1</U>
of the MEDS Disclosure Schedule have not been resolved by the date that is 60 days after the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the Company, upon a breach of any representation,
warranty, covenant or agreement set forth in this Agreement by MEDS or Merger Sub or if any representation or warranty of MEDS or Merger
Sub shall have become inaccurate, in either case, such that the conditions set forth in <U>Section 9.1</U> or <U>Section 9.2</U> would
not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <U>provided</U>,
that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; <U>provided
further</U>, that if such inaccuracy in MEDS&rsquo;s or Merger Sub&rsquo;s representations and warranties or breach by MEDS or Merger
Sub is curable by MEDS or Merger Sub, then this Agreement shall not be terminable pursuant to this <U>Section 10.1(g)</U> as a result
of such particular breach or inaccuracy until the earlier of (i) the expiration of a 30-day period commencing upon delivery of written
notice from the Company to MEDS of such breach or inaccuracy and its intention to terminate this Agreement pursuant to this <U>Section
10.1(g)</U> and (ii) MEDS or Merger Sub (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following
delivery of written notice from the Company to MEDS of such breach or inaccuracy and its intention to terminate this Agreement pursuant
to this <U>Section 10.1(g)</U> (it being understood that this Agreement shall not be terminable pursuant to this <U>Section 10.1(g)</U>
as a result of such particular breach or inaccuracy if such breach by MEDS or Merger Sub is cured prior to such termination becoming
effective);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(h)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by MEDS, upon a breach of any representation, warranty,
covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become
inaccurate, in either case, such that the conditions set forth in <U>Section 8.1</U> or <U>Section 8.2</U> would not be satisfied as
of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <U>provided</U> that MEDS
is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; <U>provided</U>, <U>further</U>,
that if such inaccuracy in the Company&rsquo;s representations and warranties or breach by the Company is curable by the Company then
this Agreement shall not be terminable pursuant to this <U>Section 10.1(h)</U> as a result of such particular breach or inaccuracy until
the earlier of (i) the expiration of a 30-day period commencing upon delivery of written notice from MEDS to the Company of such breach
or inaccuracy and its intention to terminate this Agreement pursuant to this <U>Section 10.1(h)</U> and (ii) the Company ceasing to exercise
commercially reasonable efforts to cure such breach following delivery of written notice from MEDS to the Company of such breach or inaccuracy
and its intention to terminate this Agreement pursuant to this <U>Section 10.1(h)</U> (it being understood that this Agreement shall
not be terminable pursuant to this <U>Section 10.1(h)</U> as a result of such particular breach or inaccuracy if such breach by the Company
is cured prior to such termination becoming effective); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by MEDS and following compliance with all of the requirements
set forth in the proviso to this <U>Section 10.1(i)</U>, upon the MEDS Board authorizing MEDS to enter into a Permitted Alternative Agreement;
<U>provided</U>, <U>however</U>, that MEDS shall not enter into any Permitted Alternative Agreement unless: (i) the Company shall have
received written notice from MEDS of MEDS&rsquo;s intention to enter into such Permitted Alternative Agreement at least four (4) Business
Days in advance, with such notice describing in reasonable detail the reasons for such intention as well as the material terms and conditions
of such Permitted Alternative Agreement, including the identity of the counterparty together with copies of the then current draft of
such Permitted Alternative Agreement and any other related principal transaction documents, (ii) MEDS shall have complied in all material
respects with its obligations under <U>Section 5.4</U> and <U>Section 6.3</U>, (iii) the MEDS Board shall have determined in good faith,
after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would be inconsistent
with its fiduciary obligations under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Party desiring to terminate this Agreement pursuant to this <U>Section 10.1</U> (other than pursuant to <U>Section 3.22</U> and <U>Section
10.1(a)</U>) shall give a written notice of such termination to the other Party specifying the provisions hereof pursuant to which such
termination is made and the basis therefor described in reasonable detail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">10.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect of Termination</U>. In the event of the termination
of this Agreement as provided in <U>Section 10.1,</U> this Agreement shall be of no further force or effect; <U>provided</U>, <U>however</U>,
that (a) this <U>Section 10.2</U>, <U>Section 10.3</U>, and <U>Section 11</U> shall survive the termination of this Agreement and shall
remain in full force and effect and (b) the termination of this Agreement and the provisions of <U>Section 10.3</U> shall not relieve
any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or
other provision contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">10.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as set forth in this <U>Section 10.3</U> all
fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such
expenses, whether or not the Merger is consummated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Agreement is terminated by the Company pursuant
to <U>Section 10.1(h)</U>, MEDS shall reimburse the Company for all reasonable out-of-pocket fees and expenses incurred by the Company
in connection with this Agreement and the Contemplated Transactions, up to a maximum of $200,000, by wire transfer of same-day funds
within ten (10) Business Days following the date on which the Company submits to MEDS true and correct copies of reasonable documentation
supporting such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Agreement is terminated by MEDS pursuant to
<U>Section 10.1(f)</U>, the Company shall reimburse MEDS for all out-of-pocket fees and expenses incurred by MEDS in connection with
this Agreement and the Contemplated Transactions, up to a maximum of $200,000, by wire transfer of same-day funds within ten (10) Business
Days following the date on which MEDS submits to the Company true and correct copies of reasonable documentation supporting such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If either Party fails to pay when due any amount payable
by it under this <U>Section 10.3</U>, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including
reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by
the other Party of its rights under this <U>Section 10.3</U> and (ii) such Party shall pay to the other Party interest on such overdue
amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue
amount is actually paid to the other Party in full) at a rate per annum equal to the &ldquo;prime rate&rdquo; (as announced by Bank of
America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parties agree that, subject to <U>Section 10.2</U>,
the payment of the fees and expenses set forth in this <U>Section 10.3</U> shall be the sole and exclusive remedy of each Party following
a termination of this Agreement under the circumstances described in this <U>Section 10.3</U>, it being understood that in no event shall
either MEDS or the Company be required to pay the individual fees or damages payable pursuant to this <U>Section 10.3</U> on more than
one occasion. Subject to <U>Section 10.2</U>, following the payment of the fees and expenses set forth in this <U>Section 10.3</U> by
a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the
termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated
Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim,
action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner,
member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other representative of such Party) in connection with
or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure
of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from
any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement
or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions
to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this <U>Section 10.3</U> are an integral part
of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement and (z) any amount payable
pursuant to this <U>Section 10.3</U> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the
Parties in the circumstances in which such amount is payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
11. <U>Miscellaneous Provisions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.1
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Survival of Representations and Warranties</U>.
The representations and warranties of the Company, MEDS and Merger Sub contained in this Agreement or any certificate or instrument delivered
pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time
and this <U>Section 11</U> shall survive the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.2
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment</U>. This Agreement may be amended with
the approval of the respective boards of directors of the Company, Merger Sub and MEDS at any time; <U>provided</U>, <U>however</U>,
that after any such approval of this Agreement by a Party&rsquo;s equity holders, no amendment shall be made which by Law requires further
approval of such equity holders without the further approval of such equity holders. This Agreement may not be amended except by an instrument
in writing signed on behalf of each of the Company, Merger Sub and MEDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.3
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any provision hereof may be waived by the waiving Party
solely on such Party&rsquo;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any
power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege
or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise
of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege
or remedy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Party shall be deemed to have waived any claim arising
out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right,
privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver
shall not be applicable or have any effect except in the specific instance in which it is given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.4
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Entire Agreement; Counterparts; Exchanges by Electronic
Transmission or Facsimile</U>. This Agreement and the other Transaction Documents and schedules, exhibits, certificates, instruments
and agreements referred to in this Agreement or any other Transaction Document constitute the entire agreement and supersede all prior
agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and
thereof; <U>provided</U>, <U>however</U>, that the Confidentiality Agreement shall not be superseded and shall remain in full force and
effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise)
by all Parties by facsimile or electronic transmission in .PDF format shall be sufficient to bind the Parties to the terms and conditions
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.5
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Applicable Law; Jurisdiction</U>. This Agreement
shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise
govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating
to this Agreement or any of the Contemplated Transactions, each of the Parties (a) irrevocably and unconditionally consents and submits
to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have
subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware,
(b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause
(a) of this <U>Section 11.5</U>, (c) waives any objection to laying venue in any such action or proceeding in such courts, (d) waives
any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process
upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section 11.7</U> of this
Agreement and (f) irrevocably and unconditionally waives the right to trial by jury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.6
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Assignability</U>. This Agreement shall be binding
upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns;
<U>provided</U>, <U>however</U>, neither this Agreement nor any of the Company&rsquo;s rights or obligations hereunder may be assigned
or delegated without the prior written consent of MEDS, and any attempted assignment or delegation of this Agreement or any of such rights
or obligations by the Company without MEDS&rsquo;s prior written consent shall be void and of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.7
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>. All notices and other communications
hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a) one (1) Business Day after being
sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b) upon delivery in the
case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic
confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the
intended recipient as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to MEDS or Merger Sub:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRxADE
Health, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2420
Brunello Trace<BR>
Lutz, Florida 33558</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Suren Ajjarapu</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
suren@trxade.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nelson
Mullins Riley &amp; Scarborough LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
Constitution Ave, NW, Suite 900</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
DC 20001</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Andy Tucker</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
<U>andy.tucker@nelsonmullins.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superlatus,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">445
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Timothy Alford</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
tasuperlatusfoods.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GS2Law,
PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20803
Biscayne Blvd</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4th
Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aventura,
FL 33180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Yosef Shwedel, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
ys@gs2law.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.8
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cooperation</U>. Each Party agrees to cooperate fully
with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other
actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent
and purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.9 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Participation
in Negotiation and Drafting</U>. Each Party acknowledges and agrees that they have participated in the negotiation and drafting of,
and carefully considered and read each of the terms of this Agreement and understands all of its covenants. Accordingly, neither
party shall be entitled to any drafting or interpretation presumption in their favor with respect to this Agreement or any of the
other Transaction Documents. Each Party executed this Agreement as their free act and deed. Any presumption of law which provides
that an agreement be construed against the drafter is waived by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.10
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>. Any term or provision of this Agreement
that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining
terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or
in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement
is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision,
to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that
comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable
as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace
such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible,
the economic, business and other purposes of such invalid or unenforceable term or provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.11
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Remedies; Specific Performance</U>. Except
as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive
of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude
the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not
be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their
specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise
breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement
and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this
being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety
or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not
oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate
remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">11.12
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Third-Party Beneficiaries</U>. Nothing in this
Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties
to the extent of their respective rights pursuant to <U>Section 6.5</U>) any right, benefit or remedy of any nature whatsoever under
or by reason of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Remainder
of page intentionally left blank</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>In
Witness Whereof</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
the Parties have caused this Agreement to be executed as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>TRxADE
    Health, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Suren Ajjarapu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suren
    Ajjarapu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Foods
    Merger Sub, Inc. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Suren Ajjarapu</I></FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suren
    Ajjarapu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Superlatus,
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Timothy Alford</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    Alford</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercialization Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to Agreement and Plan of Merger</I>]</FONT></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="A picture containing text, font, logo, graphics&#10;&#10;Description automatically generated" STYLE="height: 61px; width: 155px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRxADE
HEALTH, Inc. Amends Definitive Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agreement
with Superlatus, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK, July 14, 2023 &mdash; TRxADE HEALTH, Inc. (NASDAQ: MEDS) (&ldquo;TRxADE&rdquo;), a pharmaceutical exchange platform provider, announced
today that it entered into an amended and restated merger agreement with Superlatus, Inc. (&ldquo;Superlatus&rdquo;), a U.S.-based holding
company of food products and distribution capabilities, which amends the terms of the original merger agreement entered into by the parties
on June 30, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
restated, upon closing of the merger, shareholders of Superlatus will receive an aggregate of 30,821,941 shares of MEDS stock at $7.30
per share, which will be comprised of (i) 136,441 shares of MEDS common stock, representing 19.99% of the total issued and outstanding
MEDS common stock at the closing of the merger, and (ii) 306,855 shares of a new class of MEDS non-voting convertible preferred stock
with a conversion ratio of 100 to one, multiplied by such shareholder&rsquo;s pro rata percentage ownership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the amended and restated merger agreement provides that, effective one (1) business day immediately prior to the closing date
(the &ldquo;MEDS Rights Record Date&rdquo;), TRxADE will issue to the shareholders of TRxADE as of the MEDS Rights Record Date, including
the independent directors who are entitled to certain amount of MEDS common stock in connection with their 2023 annual compensation and
regardless of whether the common stock has been issued or vest before the MEDS Rights Records Date (collectively, the &ldquo;MEDS Rights
Shareholders&rdquo;), a non-transferrable right to receive one share of MEDS common stock at no cost (the &ldquo;MEDS Rights&rdquo;),
with seven (7) MEDS Rights issued per share of common stock of TRxADE held as of the MEDS Rights Record Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a full description of the amended and restated merger agreement, please see TRxADE&rsquo;s Current Report on Form 8-K filed today with
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>About
Superlatus, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superlatus
is a diversified food technology company with distribution capabilities. We scale food innovation and transformational change to our
food systems to optimize food security and population health via innovative CPG products, agritech, foodtech, plant-based proteins and
alt-proteins. We provide industry-leading processing and forming technologies that create high nutrition, high taste, and textured foods.
Our management team consists of world-class food executives with an unparalleled understanding of technology and taste. For more information
on Superlatus, please visit Superlatus&rsquo; website at <U>https://www.superlatusfoods.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>About
TRxADE HEALTH, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRxADE
is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription
journey and patient engagement in the U.S. TRxADE operates the TRxADE drug procurement marketplace serving approximately 14,500+ members
nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information
on TRxADE please visit TRxADE&rsquo;s IR website at <U>investors.trxadegroup.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Forward-Looking
Statements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains certain statements that may be deemed to be &ldquo;forward-looking statements&rdquo; within the federal securities
laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the &ldquo;Securities Act&rdquo;) and
Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future
financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates
and projections about TRxADE and its industry, beliefs and assumptions. Such forward-looking statements include, but are not limited
to, statements regarding our or our management team&rsquo;s expectations, hopes, beliefs, intentions or strategies regarding the future.
In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including
any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following
words: &ldquo;<U>anticipate</U>,&rdquo; &ldquo;<U>believe</U>,&rdquo; &ldquo;<U>continue</U>,&rdquo; &ldquo;<U>could</U>,&rdquo; &ldquo;<U>estimate</U>,&rdquo;
&ldquo;<U>expect</U>,&rdquo; &ldquo;<U>intend</U>,&rdquo; &ldquo;<U>may</U>,&rdquo; &ldquo;<U>ongoing,</U>&rdquo; &ldquo;<U>plan</U>,&rdquo;
&ldquo;<U>potential</U>,&rdquo; &ldquo;<U>predict</U>,&rdquo; &ldquo;<U>project</U>,&rdquo; &ldquo;<U>should</U>,&rdquo; or the negative
of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking
statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or
performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should
not place undue reliance on any forward-looking statements. These risks include risks relating to the following: agreements with third
parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby;
our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others;
one or more conditions to closing of the proposed merger not being satisfied within the expected timeframe or at all or that the closing
of the proposed merger does not occur; the outcome of any current legal proceedings or future legal proceedings that may be instituted
against the parties or others, including proceedings related to the merger documents; the occurrence of any event, change or other circumstance
or condition that could give rise to the termination or abandonment of the proposed merger; unanticipated difficulties or expenditures
relating to the proposed merger; potential difficulties in employee retention as a result of the announcement and pendency of the proposed
merger; whether the combined business of TRxADE and Superlatus will be successful; and those areas detailed in TRxADE&rsquo;s most recent
Annual Report on Form 10-K and subsequent reports filed with the SEC. Forward-looking statements speak only as of the date they are made.
TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise that occur after that date, except as otherwise provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
Offer or Solicitation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities issued in connection with the proposed merger are being offered in a transaction not involving a public offering and have
not been registered under the Securities Act and may not be offered or sold in the United States except pursuant to an effective registration
statement or an applicable exemption from the Securities Act. This press release shall not constitute an offer to sell or a solicitation
of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state
or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skyline
Corporate Communications Group, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
Powell, President</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Rockefeller Plaza, 11th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office:
(646) 893-5835</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>info@skylineccg.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1"  ] )L# 2(  A$! Q$!_\0
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M4;VPN<7,?V*7S-OV<G?[>U:7]HI_S[W/_?DU5V2?W-1_[^C_ !I=DG]W4/\
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,ID%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>meds-20230714.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCJebP9z5Z8GekhvWBxbSmKPygliCKkpChY2nH2YYUL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:MEDS="http://trxadehealth.com/20230714" elementFormDefault="qualified" targetNamespace="http://trxadehealth.com/20230714">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://trxadehealth.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="meds-20230714_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="meds-20230714_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>meds-20230714_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>meds-20230714_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://trxadehealth.com/role/Cover" xlink:href="meds-20230714.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://trxadehealth.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140295628974128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 14,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TRxADE
HEALTH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001382574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3673928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2420
    Brunello Trace<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lutz<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">261-0281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEDS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meds-20230714.xsd" xlink:type="simple"/>
    <context id="AsOf2023-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
        </entity>
        <period>
            <startDate>2023-07-14</startDate>
            <endDate>2023-07-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-07-14">0001382574</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-07-14">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-07-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-07-14">2023-07-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-07-14">TRxADE HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-07-14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-07-14">001-39199</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-07-14">46-3673928</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-07-14">2420     Brunello Trace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-07-14">Lutz</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-07-14">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-07-14">33558</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-07-14">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-07-14">261-0281</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-07-14">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-07-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-07-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-07-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-07-14">Common     Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-07-14">MEDS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-07-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-07-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .F([E8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #IB.Y6%$@ J>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:95!Z'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1#JJKH'AZ2,(@43L @+D<G6:*$C*NKC&6_T@@^?L9MA1@-VZ-!3 EYR8'*:
M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N_ X>WI\65>M[ ^
MD?(:\Z]D!9T"KMEE\FOSL-EMF:RKNBFJ5<%O=S47U4KPN_?)]8??5=CUQN[M
M/S:^",H6?MV%_ )02P,$%     @ Z8CN5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #IB.Y6!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M .F([E842 "I[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( .F([E:97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Z8CN5MYS
M5YU6!   @A   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( .F([E:?H!OPL0(  .(,   -
M  "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ Z8CN5I>*NQS
M$P(   L              ( !=@\  %]R96QS+RYR96QS4$L! A0#%     @
MZ8CN5JK$(A8S 0  (@(   \              ( !7Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( .F([E8D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .F(
M[E9ED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trxadehealth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex2-1.htm</File>
    <File>ex99-1.htm</File>
    <File>meds-20230714.xsd</File>
    <File>meds-20230714_lab.xml</File>
    <File>meds-20230714_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "meds-20230714_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meds-20230714_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "meds-20230714.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MEDS",
   "nsuri": "http://trxadehealth.com/20230714",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-07-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://trxadehealth.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-07-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-23-024613-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-024613-xbrl.zip
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M$WM7@T"7I\<F@S?A NLJE;=?P)%'OMRZDY3?U3*\)EKD;Z#C4^Q?1L&;6$R
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ME,X>$G58GUBM6,-3W#A#G!L#77][G16.@]DLU6C3Y:8!9?,&&@>S/+F5-SX
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M<YBP3-1)ZR0 +<(HJ45 &@0^A]I3(DTP4(.B4D8E/XV"$BA.#<DIH$63M^
MLJ..N71:#CF/T'GPM@W T?X1G)(C.']&6PL2_5O9MMOJV5-JUZ=44>H'@QXY
M;L/AI61XVWDF,%=7\NWPR#=U[M.4[,:_/METOOVV>[D;O,ZRB,ZED[R<!>,(
M@7H-1!:P.V>^6$=(( @:E@^K(O/!P<Y/R:&#XTV$\)I=(40+(R($UE^.,[4
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MP01=A,YF$:FQ1YLUHTXQJ04<M)6F3K-4K$5@LTQRUP=CAXZJBF@.?;'3G&X
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MX0B"&^&(<U0 F P^3;K:6'4"T:U&*SL5"L@UY=?\)TOE!O[ D^(<-4F4!K@
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MJ9@C8@2GFK-R$=H5#XTFHD]F[YF,(R'R<-9.15P<5KBQ/;;'_WN/TRYEAMO
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MLH>G[.$'J<]_[E.?(I:/T)B,^&RD\R8'2#Q?1R/:KX^KHR\@P>Y 3-/%/>(
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MNJYNW1YV.R"_XY"Y;J'>;<.P!MKN7/82'I1ZG-IX9![OSR;EK@$#6\6G^ZC
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MTG++53'?^B2J94R-0C^&0S[NW85/!F-"JN"XJM$0'A=Y\_B6]]'NFO?:-CX
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MM]+8EV5A[#4RU$$TKA0=F7H+N]VV.'/G_!,6T=6JINX;?)9HJP9RO%T?*2*
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M/,D6L/792HCX4M$A!'%3C'J8. ,%LVMQ7I1()XU%_ >)^N$DPNG&?)SF<,C
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M)Q(T!3.4F%FY:I2#VG1A3BY&X4]M#P3-?=GL@6@MHFX.?T[,S9MN0>T-ZD&
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M);C>&E[3['0 4F@<F7)!'-%TL27Q\0,$7S 3XRV974>-W=HBZ\;,S>OT"US
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M.@N-O7B7KM9EWL2"9%6+> /G<=)DI0-:?EHZ6Q_X\7S.L?8$&)F43=A!LHH
MPP&>:;DN(0M0Q36/R;W^X,G,5S/%-"Y.%6"_%L>9K*< ;0)]?.7\);ZQ0NSJ
MA!LM#C,4SDAHN*I 6WSD%>!9'!HQ<<FS[@D[?WK^M+X@CL D?AJBXOL>47$
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M&PI%$J)>M.VED?">J$@\U$RG<D"-+(HYL D*45<#]3.K\N?&O#.W%4*/>K:
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M]^_X*1-(6TUQ,1M2H</&#F@9<^IQE3:":^DND]\0N\R'CL?'9R!NZGI\X]E
M%*=W% YK0^XIY?+>%WBC2V"5;I)Y,R?LMP3..J$$P=IZ9RLY]IN4)93K_4^Q
MZC$-![:,]A0SO4NOUL:6%,9&!P7#2P*QRAJQVNHBPX7U8Q5@ZS:7M&)2BUVB
MLD3"Q-;"OZ-<E4X9[9H ;/O]B,&#AD>J<>!G<]7V?O%^^6#I>PJ6+KU,[8YQ
MDTN!^@B\#Z .<<FV!5 M+^]1(BGC%]ERYM9(JB,Z$O*Q)I5?'PU]K:?F]Z?[
M*LF#Y2R9$#6&9H!Q^H/:!_N[.<42JWY=^W;C_%R5ZU32@B7P99;!$XN]S!)%
MY5DC=&MOW'$M!/7KFIV;"QM&:U';@6Z(](XX<YCX7H(;$L8@IHW@.E1<IO&<
MI Q]#+,6]/<RG /&*MPF)<'T4E;X$"VX"4&6Z3Y\@X0P;]ED#;SAE(@+,RNO
M1!0=;7>(:C?8,"NUQQB%K_)ULLS,:Y0>Y?JKW_EE;GF'JB*Y^25&^WV'W,UF
M7F*](?GDXXA0#Z)VF_!N(,I%;HXOH6L306)HD5$[LT5ES>]8:XB&E5Q=0;J$
MV\M/[D;"WE10E7CS$I'[,+S#,[+F\[NN=1*=\&]V6AK=K]#,2>UT$7S^Q%ZO
M0?Y"_/<3;OB>S*FX8"8PUK-=&ZNLNLU#=?H =G$*_:1MTPELP8DH\UXG(8VQ
MLDV-U5R'&&]>_",S,=N6_^>9K!U7NQG'#LN]\7,Q5P ?A8N]9;V2L%;)OHJB
M?Q@S[9 ,F]B4:-Q,"2'Y'PU"9.59-\'_LC;^DN4T!'YC5JY@!ZX8UVN]*:9[
M(L+!E+2*I)W!_D6N.QQT7=BEO.SI@CQ7N)Y'M#?'&_9F?0=U;TUK77?>FULW
M8]W3N\]>-.]'-F.R>3-&)]E*X-<4CU:KHF#AIYAF17>J62X&F\)+E*/0=3(-
M!W[V8GIQZZ7='R#9TF(FUB65%=/66\,K7(95ZI5&<\AGJ4.E=IT[JB^W8GVI
M='HL<*[- )/OSGJ R0$ 3%[T ),>8/*)4=^^4(X, J'N2T(*WZ1YXLIA76EW
M@8Z(<B72H^CE)&^E.[8SG]:ZK2;V;D$3QCB--EQ_? ?M0I>U#5VMP] LZ!?U
MKHMZ3P4 I[#1H*0DG\&U_@<9K^' <F14OB^1?3CG.)C%#8'5AB/>I\@.C$-G
M+\R!85<)\\NHOI+K+)U%;YAUQJPRZ9EOAK1T#6+"8PTCP<TH487 P?<=<%7T
M_2GUU<;XT!P)ZK^?,>VU69'TSQ?T3^\AHQT?0222QID4LIC?UMX^R^D<X.;X
M>H#1WA5A>W&:O34M7?W^,88#UQ]LK+>+?SBL6*4;$DHZN#V&M7OTVW O5%;A
M-M1=1+^CN6)=WD52 :8]8S?/<'!^>O[LV?,G%R>3$1.DG'[_\COSSVOT7117
MK,DM BN$C#7++B]6Z-$0;^+G=^_;UC;W=82]E9O&@J'X6X>I&1PQ1(A,\D[$
M-3U)6SK2CF'1'/WZWXLX'C7$4W?=^]MDZ=W?8YC&HU\1>Q'DTD<OTCPNF6W.
M\&.8RJ-?%7O1$'IO(0( 0OT]R<H<R>O?EEEN5@>)KQW!?![]TMB+D$ZW3]^3
M-1Y^UN39?K(FOQ;;JG:<3GF?P2.EJF1[R3-N8,0I$'4R>JJ.UW6G/E%W6$ON
M^7Z6G%T%OQAO]LD?RI=MR3_+=U1!K^+.1U'^L>7JKAQ=B]:O1[OUJ>)#7X%[
MTHII:Q7XM^ H7S.)06,I#@<;OMW("VZFD]V:6N[7X6&MP_TP);]/EAF:Q)+A
MX%\IF'6JZVP9_2Q$Z-%;(18+^$<(YCOU,-_FLJ)C%V"*E,DW%O[2EF/=<Y:Y
MVIPH=[HA1;^GD^O<S,7571S]\LOK.$JBG])Y<@M('.DCF\M[4C\61 [H"[E+
MAY#,L-=.2UE80FA37%&'&KXS+J8$!:,]$&X>VW^A&RZNLW+*^!;,L9 S<O6;
M]-JRQ7J^2G+($<_O%/$:YY+;:IRB28I.>K30$_3(?$R=:$QAG^5)#NK9(&N>
M<!DS)1+9X!]6KY@DAJVX&N6^'0Q<I*?%7P)C%3,[3E-SLXR96OVY%Y+)D;=%
M#]8D9$FDC4J(]9=KSZVX;TJ6WJ;L:E.^WXM->8O]G4'5^^\)B!FL$?%>UF>:
MDZ;IX.UE;QS1?6-CQB:GP\'GF8/H0:S!</#IYB!Z(&M )%&?9@ZBA[(&;%R/
MS!QL@<"=]Q"X X# ?==#X/IC\A./R3U1H,/+SKF?TYP(OS$#22\<^A4OE/.S
MO3A4MH8R'$@1A?VG?XLZ89I')^=GH^C'M?$DX"G\E-RY>-^K42D2V[NVW&DG
M6BU!7X8,H. !L+;F[]2"FH.W_1]EL5XJ4ML6)EL0>IACWAQ?@KL9F_]<KP@5
M/RE38E;?Q0LR/L2#!$5?O=]Q/-MF/SP[2(P9GYL@EFT)WK>E"0VRI5DXBO^C
M$OIAOP_( Z%&,'C@T>HVG9M/3\XO1M'"W)6EW/D^WCD.\#34YM8)J*GWAL4^
M.%@6U>K)1,!G=EL(U[E+&K<FEET/=[^L'Y6HX>4G$C6H]]\3-!QB<KF-H$%G
M*@Z-XJZ#F"&P,ST_PQ$=HR^_&#_#&[5.6)QH4R?T8Y(T<+KI<1K\-Y T0 !E
M8YOOXY T# =MC>#M) VLJ+ /A@:FO-ICS_JN+[#!3Q%'7XBA8>OZ>"R&!O-N
M'K(K_+,8&AHT%1V,2/=A:J#?[T+3T++\&W0SH^T;8$\<#</!_1?\'C@:VNV)
M)VA0PC;M7 TTRY]+U$#V1#,U;+SJ_E@:S'I]@/WY^2P-#>+SM@WY""P-U'^V
MP]FT(TM#I_SI9HJ&X6 #1T/T;5 T'(V#>[&?<K7O1*<U6VM%;SMSU"[]U(YT
MMNA966M-!]'-)_6FJV!MT:&DL*%)?3CHH8>'M]X?ITN]G6LA:%8?#GS\WS>K
M?X6="0?1K&Z<\-1UJ8ONN/7J8??R609'XNI^K>DO56OZ2VY-M^WH+Z4[/6Q'
MCUPW^C&\V:-?I'MIY;:)47,DF^<3OU0J-I5/I18L8J23IMQ[TIF$\-8NU+BW
M7ZJ#M&4;L%-L5;!]K O=7:07$$ZQ"A)W'"3$6"@_5?K9[I=]F]W!/<H!=&H?
M<9/=%A#>10_".P 0WO<]".\HJ^F/$0P]VYL6TZ:$8:WSM"-]M$OC:>M=AH.^
M[?2++C:L+/28_O&WM\F=\:BB7U(D;__?ZO_C-__S3*'\.WL3%%2ND0^?%$NI
M7E"XO.3;S.DVMJ1#.1ZKR,57IXP3E@PA[>B_INEX94%*(?1>D0&9ZU.VQZ+<
MD'Q&?C5?)AE*)+A(.B68(#*YYD@JBUMS_T61IZS+Y1)>MDU@EJ:5 ROI05"U
M1'1BE-Z,^5UZ V8D?-?<LC)S0AF#?I4?EDG=4VLKK9,?BZ2<8D7\9$.3S<R>
M%)Y?H28@_(AE=G7-Y9[ELLAR2EZ:A842B FK]*;,BX@:B:C,]]0L:=RY2A,T
M]*BZ'X^(*P'[ L?U0.O'6;G?[7'E;N($Z/@".E?G/2' EU][^X)UGI\1KO-W
M?]C1FGCH1^3_/?W.!,Q?X&F/V628%[@G>%Q]31@[$93=%@G!'[R>WG"P@2@:
MN("TUDG.1U8R+9;>RPIN$>(Z_UI6_UD7KZI:UVIL?$ Z)AT@=3@0S!G2D:FQ
M/Z.^0G-@V<&]5&C,<EFL5VL3A=HTN#1 !Q KM:*.87Z/?JGLI4X"8 &WLG,P
M689LRX&^J$M^# =:PM2#V,W%+M=79H:BIV=Q='%V\30Z46BF95%5&?IB"#E;
M21.7M']Y=)^O_44PZN:Y8RKR821_G4]A^O[[Q[^] 90"%9G__J\?__;7DCX>
MO<*/[05=T?#:Q+\W:<G_=J5'%WXXPUVWN@IDT1P3#4E0M[F(5=\DV5QKM=II
M+&1V,\%+04[>6W&/Z%?J2.9#DKNF.4X ZI!.I@GANRQH7WY@Y:[E19G?4V8J
MXLO*04-GD=GWKHQ%8^F\.U[L*ENM5X O1TBY6OR)GJ1CV&Y';SGV4H+::CF2
M%A'YX:"N(M^A'Z]R;R),GU ?*'>$FO Y62[3A'?;;RBZ$*Q5_6J5?$B9VH+A
MH+S.8_R1 +:$X'<Z\LL4^# SB#F0I]6J9!J1.$KS/PN&/EI@*77Z&!MSG8U9
MJIGN87N%.CI^CF%M'?TVV0N#LDW3F@W!H@SU[)@K)CC- [,X)1?;3K^LA1(R
M$1'/VO00HHO3EW)T)D!KS^:,3FRY)K+(JVB>)N;P_LO%Q?/X[.P,_W=Z=C8<
M "Z=R>!5I@WG$\/ )3F^D1?8G[S=?7% 0J 5W1Z@BMJ.,41FX MS*2Y]4^(\
M4>WADD:<13>9>3\2-$WY9#?WSI 1-Q8II7[Z9R/SI[MJ*W+X&-;[T6_=O=!<
M.\*J'8@-XE"]09CNU%9\>GIQ\>J+47_TR^E>RVDOU-CJ)("UL4TD'O=8:-QC
M]()ACT[EI[,_@@X/#D$8\%;,;SS^+#!_+\YZF_<5/DK[(KW:TR(-.LC72T3I
M*OSCWBS=[Q,[25;S?=O<0&E-WWP3-BS5<YLV@% -&.A1:[L9_F#OYK)9[J?#
M0:UY8YP:[RAU/9W26RMQ"W?#411\#T"RQ2/CKL&GC$RF[CB7$E"Z6 XIND(6
MV+9.V8DMZU]H::P*GGW30S;3((AWG/<E$1H[;^:C' _HFE@VONIHVYMN:TP)
MAC,<S(P+=AVD8VQ>Q+7>DLX77JU+D@2KPWVZI6T/N0]^FL8BXY5B1HG[(8AL
M788Q3T]K*YF\8<D>X1):,*HU:W3%62-4MV&GU_.5[Z%3'7I^3:@)69M'FG/?
M>5+.,P;6VX@B_;C,2N_(1T_/GA@[CZ@V*P!469AQ3ZC9#]M9<T1)@I@6+.2H
MR*>NT5Y8F$EMP:K!6::ES!*>;<RK;9@G*L3YB;):<BT&XB3 "(RBB0E=J+Q:
M ()=3IB/PSQXB=" PGII5J6XW^QK@KQ,UF4:/)A6;6S.4_0%IHG"P4WKJ;.7
M\X$7+O73VY7;UEK:^M!9."/MYIXWHC&3KG+&9EEAC\C*T7MQ\/O1,1SNGP9W
M?MK#G0\ [ORRASL?)]SY,?SWZ[WF+'9QW+TWY[N2[^6XUXI<.WGL'0A;=F)!
MYOV KOKWK:[Z]]I5CUH\=1=S?P%7G9^/LYU?R$5WA5/MJ4L$T>ZJMX%3[N.;
MU^(2Y9,'/M8U$=@\D$]SW7#&=W9IR!>7$M(>G/' R>0Z0*V>'*Q(RL_OPQD/
MY\GK.FO%Z8;3#4OR&5[W \Q'^+*$D/[!Y^-^3K=+"#S2"FTZW6J^R+#LZFY'
MRMLV-SF"T_CH'8MLG]EK(F167)%A[=$3GP2RU:V41>:PJ8K.Q9^-^!@B(UF'
M^#-,X'\Q FL/R*6W%+YOL9!!MAY=SLW'6-(W2IWD%?4#[8 34HS9V+_Z'L;L
M;+F+P#%_Z*C[<E>$JYUVVCI)<KIS-3!C:D2,+-HR)%?C12$T.GGF.<4!IKJC
MMJ-D>H,7*BS%=%D9U#2M)F4VQK1GN3;MTW252':*/ZTTGYX=KS%DMZEY\J2R
M!1!V9V!V*FFILBZ=3XQM>22M!H6K9MAHF7<U0?YM?@:#>5?38O>-6^3*P<NB
M=CXT-I7);$7-4KM-J^C%,-3$ME5YT);67U'T*CZWI65P+/%/C5T(:T7HA9A\
M"-TOBJZ6W3JUC9X+.89P9?BZTE->X>;NS9J^&HCE_>*A7.%\FR7FSL85Y/J1
MT&(GOD.-QK1>5:!S9_YVX5Y7N#L%,[OOZF6'G1HO<.^L8DB1N_4LFZZ-WP'G
MH3$Q2LKGE^3VB/OD#Q_2_3N@BH2!A$7)2O$@/]DE8W],,4'J']1*\"T[0G+.
M"1TXEO/QBM@]ZE;9VB3M*(DORK?GIV+4_9TU27S4T5I$$S'@9FJ PJU$+++Z
MNEDE)+$"U1X;5[OB-F385K'%O#D;IKAO*3JPWI2+_?2FO'$(QD:7RL_L-AF/
MAC%1=,;Y+TF.(R20"]'8M6UF4=CMM(KF:GD12<9 .N+0T$D#W([+EO0"R$I;
MMOB%^XWZ4(ZQVO%V?NZ1V697E3?8R+5GW\33BF-VD63YAN8^1,+CT8X7K1D
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MXM#$0UB#Q_^V-]*(6#'^B1!ES\.X JJ6.<#B9=A0;UEWUC^G>V5G9NG6>8.
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MR;$5C$)%R/%AD=-R1IQ41OPC)@3S6(HD,0A'I7R)EUNDH5>6P.=S_/4UK/9
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M]P8&L(AJ;C5[1R7IG.-P6"J-*W'4X8IBD<X8[2/^B8%W5(!\6%LJA7(8CR]
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M5MG8KW@342]G.[H.=9_M.Z$<"4\M+[BR>>-UM1C"FAO;>-:J9X:GR+UE,YV
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M&KJH*Z[V0:=-$Z+)/+[@M:/2D83#$E\-4<I-;$QXZ+S%&^N;=IAS1C*F8@.
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M6;'2;?K'2OR_7D+_R,D_ 5!+ P04    " #IB.Y652J4NOH?  !DX0  "P
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MOXL'FB_+39ZQYLQG'>3-"I(7@AJ)X0B,8.'IM+Q'1K'P&)=:&,B@C:EXYT:
MHD)KE]G<UR4^"Y^<G^\"_@C]P&H/U$/+P9@(-,R6+6>>4ZEUA'$+'-T1C/?
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MAKZ@5C U5>6&EY-8%">4!ZXCW=%8]H!XX]Z"L5&N.C !>.6).\N'#T'"<L?
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MM<E/"W1I /C0&EER)Y;5[=F6].G\"5()MZ$..:5*U0_PV*:=J)P*4^32$<Z
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MW$M?X/MT$-\\A*7G!O%MD<[$<.2;7:-GA_9@L/-"L=*Y"BYK?\/?4/<9A^"
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M:TI0]DC09?DS=/5,\$4]OGYI)(K4"Q'%JIS%6-@0ZA([_]41T'#KMT=:RB!
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M-O04OBD"%(?&!_6-0F ,%6$Z[Q[HNK$'W'MJBV_<+_<N5GOD?U!+ 0(4 Q0
M   ( .F([E97?8))G'4! #&Z"P )              "  0    !E>#(M,2YH
M=&U02P$"% ,4    " #IB.Y67@5.%=H/  #K1   "@              @ '#
M=0$ 97@Y.2TQ+FAT;5!+ 0(4 Q0    ( .F([E95*I2Z^A\  &3A   +
M          "  <6% 0!F;W)M."UK+FAT;5!+ 0(4 Q0    ( .F([E9.J^4E
M*P,  .\+   1              "  >BE 0!M961S+3(P,C,P-S$T+GAS9%!+
M 0(4 Q0    ( .F([E89TA87_0H  ("&   5              "  4*I 0!M
M961S+3(P,C,P-S$T7VQA8BYX;6Q02P$"% ,4    " #IB.Y6'_2;<5D'  #=
M5P  %0              @ %RM $ ;65D<RTR,#(S,#<Q-%]P<F4N>&UL4$L%
3!@     &  8 ;0$  /Z[ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
